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ABSTRACT
SOCIAL & LEGAL PERSPECTIVES ON UNDER-USE OF MEDICATION-ASSISTED
TREATMENT FOR OPIOID DEPENDENCE
Medication-assisted treatment (MAT) in combination with counseling is considered the
most effective treatment for opioid dependence by the World Health Organization, U.S.
Department of Health and Human Services, and American Society of Addiction Medicine. Two
MAT medications, buprenorphine and methadone, are considered essential medicines by the
World Health Organization. Despite MAT’s effectiveness, it is severely underused in U.S.
treatment settings, including physicians’ offices, hospitals, the Veterans Administration,
residential treatment centers, prisons, and drug courts. The dissertation examines social and legal
reasons for under-use of MAT in the U.S., including dominance of abstinence-only treatment
methods, separation of addiction treatment from mainstream medical treatment, insurance
barriers, statutory and regulatory barriers, under-education of physicians in addiction medicine,
under-education of mental health counselors in MAT, lack of physician involvement in the
criminal justice system, and public understanding of addiction as a spiritual disease rather than a
brain disease. The dissertation concludes with suggestions for expanding access to MAT,
including government funding incentives and integration of MAT into existing addiction
treatment centers and educational programs.
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INTRODUCTION
I. Dissertation Methodology and Organization
This dissertation examines the reasons for underuse of medication-assisted treatment (MAT)
from a social and legal perspective. MAT is the most effective treatment for opioid dependence,
especially in combination with counseling, yet it is severely underused within the U.S., including
in treatment settings and within the criminal justice system. MAT underuse stems from a
complex combination of factors: failure to understand addiction as a disease; historical
separation of addiction treatment from mainstream medication; statutory and regulatory barriers
to MAT access; the hegemonic 12-step movement, which emphasizes spirituality over
medication; and lack of education about MAT among physicians and counselors. I argue that
governmental policies for increasing MAT are unlikely to influence the addiction treatment field
and the criminal justice system unless the policies also address the barriers described above.
This dissertation is partially based on a comprehensive literature review and partially on
original research. The literature review includes health-related articles from medical journals,
health policy journals, and public health journals, as well as state and federal regulations and
statutes. Additionally, I examined literature from the fields of sociology, psychology,
communication and social work.
It is also based primarily on original research. I conducted 58 qualitative interviews in
person and over the telephone with professionals involved in substance use prevention, treatment
or research, including the following professionals: 17 drug and veterans court judges in the state
of Indiana (representing 20 drug and veterans courts), 1 judge who oversees a prison-based
treatment center, 21 physicians, 8 mental health counselors, 1 state-level criminal justice policy
maker, 1 probation officer, 3 CEOs of SUD treatment centers, 3 sociologists who study stigma
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and access to SUD treatment, 3 researchers in the field of pharmacological development for
mental health treatment, 3 public health researchers in the field of opioid dependence, 3
marketing representatives of MAT manufacturers, and 1 director of a city-wide needle-exchange
program. I have also observed two board certified addiction psychiatrists as they treat patients
suffering from SUD.
To recruit judges, I emailed adult drug court judges and veterans’ court judges listed in
the Indiana Problem-Solving Court Directory. Recruited judges included 11 drug court judges,
three veterans’ courts judges, and three judges who each oversaw a veterans’ court and a drug
court. Additionally, I interviewed one judge from a prison-based treatment program, the
successful completion of which results in reduced sentences. In total, the judges oversaw 20
problem-solving courts and one prison-based treatment program. Each of the veterans’ courts
required substance abuse treatment for participants. Generally speaking, the veterans’ courts
operate similarly to drug courts except that they only include veterans and require more
extensive treatment for co-occurring health conditions (e.g. post-traumatic stress disorder).
To recruit physicians, I emailed every physician listed in the Indiana University Medical
School directory who practiced or conducted research in the field of addiction medicine. I also
emailed every psychiatrist practicing in Bloomington, Indiana listed in the psychiatry directory at
www.healthgrades.com. To recruit counselors, I emailed every counselor who was listed on the
www.psychologytoday.com website as practicing in the field of addiction treatment in the
greater Bloomington area. I also emailed counselors listed as addiction treatment practitioners
for the largest local mental health/SUD treatment center. Counselors whom I interviewed
included psychologists with no bachelor’s degrees and graduate degrees, as well as licensed
social workers and licensed clinical social workers. In addition to these recruitment methods, I
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was contacted by counselors, physicians, SUD treatment facility administrators, the director of
the local needle exchange program, researchers, and an MAT pharmaceutical representative after
these individuals attended two talks that I gave at Indiana University about underuse of MAT.
Other individuals whom I interviewed were either recruited at public health conferences that I
had attended, or were individuals whom I knew personally prior to conducting the interview.
I obtained IRB approval for conducting these interviews from Indiana University in 2015,
and I received informed consent prior to beginning every interview. All interviews were semistructured and conducted during 2015 and the spring of 2016. Each interview lasted
approximately 45 minutes to one hour. Interview questions explored attitudes, beliefs, and
practices related to self-help groups, residential treatment, and MAT.1 The interviews were
coded using NVIVO and then analyzed for themes. I used Grounded Theory methodology due to
its suitability for studying under-explored research areas and identifying fundamental issues; a
research gap exists regarding reasons for underuse of MAT.2 Grounded theory methodology
involves multiple steps: analyzing data for themes, developing themes into codes, grouping
codes into categories, and using categories to develop theory.3
The introduction to this dissertation provides an overview of the current opioid addiction
and overdose epidemic, causes of opioid dependence, and different treatment methodologies for
opioid dependence, with a focus on MAT. Part I examines bias against MAT: in the context of
history and popular culture (Chapter 1) and law (Chapter 2). Part II investigates reasons for
underuse of MAT in two contexts: drug courts (Chapter 3) and physician offices (Chapter 4).
The dissertation concludes by discussing theories of innovation diffusion (to describe how MAT
can disseminate), and provides suggestions for increasing access to MAT in the U.S.
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II. The Opioid Addiction and Overdose Epidemic
A. The Opioid Crisis
Opioids are a category of addictive substances that activate an opioid receptor in the brain
called the mu receptor. Opioids include opium, morphine, heroin, and synthetic pain killers (such
as oxycodone, hydrocodone, and fentanyl). Currently, the U.S. is in the middle of an opioid use
epidemic. Approximately 21.5 million Americans had a substance use disorder (SUD) involving
illicit drugs or alcohol.4 Approximately 1.9 million Americans suffer from an SUD involving
opioid pain killers and 586,000 from an SUD involving heroin.5 Each day approximately 78
people in the U.S. die of an opioid overdose.6 The rate of opioid overdoses has skyrocketed in
the last decade, primarily due to the over-prescription of opioid pain killers7, which depress the
nervous system when used in large quantities or when combined with other central nervous
system depressants.8
Opioid overdoses are part of a growing national trend of drug overdoses, including those
from other addictive substances such as benzodiazepines and alcohol.9 The rate of drug
overdoses is a public health crisis, with more individuals dying annually from drug overdoses
than from car accidents.10 Overdose deaths from all opioids have quadrupled over the last
decade,11 with a 3.4-fold increase in overdose deaths from prescription pain killers and a six-fold
increase in overdose deaths from heroin.12 As prescription opioid pain killers have become less
widely available and more expensive, more individuals have turned to heroin.13 Four in five new
heroin users began by using prescription opioid pain killers.14 As a result, the rate of heroin
overdose quadrupled between 2000 and 2013. One reason for skyrocketing overdoses of heroin
is heroin’s addictive potential. It is estimated that approximately 23% of heroin users will
develop an opioid dependence.15
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Some states such as Kentucky have been hit especially hard by the opioid epidemic;
there, deaths from heroin overdoses increased by 500% from 2011 to 2012.16 The opioid
overdose rate varies significantly between states; states with high poverty rates tend to have
higher overdose rates. 17 Residents of rural areas, non-Hispanic whites, Alaskan Natives/Native
Americans, and Medicaid-eligible individuals also have disproportionately high rates of opioid
overdose.18 These demographic groups have the lowest rates of access to medical treatment
overall, compounding the problem, and are also particularly likely to live in poverty and have
low social mobility.19
According to the American Society of Addiction Medicine (ASAM), the increasing rate
of opioid dependence is driving the increase in overdoses.20 Opioid dependence has many
negative (sometimes tragic) consequences for the individuals dependent on opioids, their
families, and society,21 including productivity loss, increased medical costs (especially from
emergency room visits and hospitalization), mental distress, death,22 decreased economic
productivity, and drug-related crimes.23
B. What is Drug Dependence and Where Does It Come From?
While the Diagnostic and Statistical Manual of Mental Disorders now uses the phrase
“substance use disorder” (SUD) as a catch-all phrase to cover all spectrums of drug use (from
occasional use to physical and psychological dependence), throughout this dissertation I will
refer to SUD and dependence separately. I will refer to SUD as a spectrum of disorders24, with
dependence being one part of the spectrum. Drug dependence is a disorder (or disease)
characterized by the following symptoms: continued use of the substance despite recurrent
psychological, social, or physical problems caused by the drug; tolerance of the drug (marked by
needing increased amounts of the substance to feel the desired effect); and occurrence of
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withdrawal syndromes when the individual stops using the drug.25 In this dissertation, for
simplicity I will use the phrase drug dependence or opioid dependence as a synonym of
addiction, even some scholars prefer to describe physical dependence separately from addiction,
which they characterize as including both physical and psychological dependence. 26
Opioid dependence can arise in a number of ways. Opioid dependence may begin as a
result of repeated illicit behavior, such as purposely using opioids to “get high.” Some
individuals suffering from other mental health conditions such as depression, post-traumatic
stress disorder, or bi-polar disorder, use opioids illicitly in an attempt to “self-treat” their
condition.27 Opioid dependence can also result when patients take opioids that their physicians
prescribe for chronic or acute pain; in that case, opioid dependence is an iatrogenic disease,
meaning it is caused by the medical profession.28 Opioid dependence is particularly prevalent
among chronic pain patients. One study estimates that 5 to 24% of primary care patients taking
opioids for chronic pain improperly use opioids.29
Eventually, repeated voluntary use, whether illicit or licit, becomes compulsive and
involuntary, and individuals face psychologically and physically painful withdrawal symptoms
when they attempts to stop.30 Even if the individual is able to stop using opioids long enough for
withdrawal symptoms to cease, psychological and physical cravings will remain for months or
years, in part because the brain’s dopamine function is impaired31. Repeated drug use causes
physiological changes to the brain, disrupting “motivation, learning, judgement, insight, and
affect regulation.”32
Most individuals who use drugs do not become dependent.33 For those that do become
dependent, heredity is estimated to account for up to 50% of the reason behind dependence,
according to studies of twins.34 Humans, like all mammals, possess an opioid receptor in the
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brain, suggesting an evolutionary mammalian predisposition to opioid use and susceptibility to
opioid dependence.35 In addition, a confluence of other environmental, behavioral, social, and
psychological factors impact the likelihood of whether one will become drug dependent.
For example, in one well-known study, isolated rats were repeatedly given cocaine. A
significant minority of the rats became addicted to cocaine, choosing to forgo food and water in
order to obtain more of the drug.36 However, other rats that were repeatedly given cocaine while
living in a “rat park” (a pleasant space with opportunities for socialization, exercise and fun)
were significantly less likely to become dependent.37 Of course, it is impossible to ensure that all
humans live in the equivalent of a “rat park”; even those living in an ideal environment may still
become dependent. Nora Volkow, Director of the National Institute on Drug Abuse, argues that a
positive environment can serve as a “protective factor” against drug dependence but does not
guarantee that one will never become drug dependent.38
The influence of all these factors are summarized in the Ecological Framework.
According to that Framework, susceptibility to addiction may result from complex interaction
between four levels of factors: the individual level (e.g. heredity, other MHDs); personal
relationships (e.g. sexual abuse, unstable home life); community (e.g. availability of drugs in the
neighborhood or schools); and societal (e.g. cultural norms, national distribution of prevention
and treatment programs).39 According to the Framework, successful prevention and treatment
programs should address all four levels of factors.40
The fact that drug dependence likely results from several causes, including heredity,
voluntary and involuntary behavior, and one’s environment, suggests that in many ways it is very
similar to other chronic diseases.41 Drug dependence etiology is frequently compared to that of
diabetes because of the confluence of factors that influence both diseases’ progression.42 Despite
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drug dependence’s similarity to other chronic diseases, a popular cultural myth suggests that
drug dependence is not a disease but rather stems from immorality or lack of willpower to
conform to social norms.43 These misconceptions stigmatize individuals with drug dependence,
hinder their access to treatment, and prevent society from investing sufficient resources into
researching and developing more SUD treatment methods44.
C. Treatment for Opioid Dependence
In 2011, only 11% of individuals needing SUD treatment received it.45 Many reasons
exist for the under treatment of addiction, including a lack of treatment capacity within most
states46, a cultural stigma that discourages help-seeking behavior for drug dependence, and
attribution of addiction to immorality rather than disease47. Because a majority of individuals
with drug dependence who undergo treatment relapse48, a cultural misconception also exists that
SUD treatment is unsuccessful49.
However, evidence-based drug dependence treatment has comparable success rates to
diabetes treatment.50 A common problem among individuals with drug dependence is lack of
compliance, sometimes due to co-existing mental health conditions or living in an environment
that makes treatment difficult, such as homelessness.51 Those individuals that do comply with
evidence-based treatment guidelines tend to do well.52 As in diabetes treatment, lack of
compliance with addiction treatment is a major predictor of recurrence of distressing
symptoms.53 Finally, like diabetes, drug dependence has no “cure,” but can be managed
successfully through evidence-based treatment.54 As in diabetes treatment, over the long-run
relapse may sometimes occur; but as long as relapse becomes less frequent and less severe, then
treatment should be considered effective.55
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Multiple evidence-based treatment methods exist for opioid dependence (i.e. treatment
methods validated in scientific studies).56 They include medication-assisted treatment (MAT),
psychological counseling, contingency management, and support groups. MAT is the use of
FDA-approved pharmaceuticals for treating drug dependence. According to the World Health
Organization (WHO), the U.S. Department of Health and Human Services (DHHS), the
American Medical Association (AMA), the ASAM, and the American Association for the
Treatment of Opioid Dependence (AATOD), MAT is the most effective treatment for opioid
dependence. Despite MAT’s effectiveness, it is severely underused in U.S. treatment settings,
including physicians’ offices, hospitals, the Veterans Administration,57 residential treatment
centers, prisons,58 and drug courts.59
Access to MAT is limited in the U.S. Health policy scholars refer to two kinds of health
access: potential access and realized access.60 Potential access is the percentage of individuals
with the resources or ability to receive treatment, including health insurance, income, physician
availability (such as the number of specialists in a given city), available treatment slots per
capita, transportation to treatment, and knowledge about the treatment method.61 Simply by
examining the number of MAT providers in the U.S., it is clear that potential access is very low.
Less than 45% of SUD treatment centers in the U.S. provide even a single form of MAT.62 A
2012 study found that 80% of Opioid Treatment Programs (i.e. methadone clinics) were
operating at 80% capacity and 96% of states and the District of Columbia lacked sufficient
buprenorphine treatment capacity.63 Only 46% of counties have at least one physician certified
to provide buprenorphine treatment; and only 2% of all U.S. physicians have and 3% of primary
care physicians (the nation’s largest and most accessible group of physicians) are certified to
provide buprenorphine.64 In terms of insurance, only a few states’ Medicaid programs cover
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every form of MAT, some states have life-time limits (meaning maximum coverage periods) for
MAT, and many commercial insurance carriers create prior authorization and “fail first”
barriers.65 One study found that less than one-third of states had wide-spread MAT
implementation (meaning sufficient infrastructure, staff, and funding for MAT provision).66 The
most widespread implementation of MAT existed with respect to methadone.67
Realized access refers to the percentage of individuals who actually receive the
treatment.68 In 2012, of the 2.5 million Americans who needed treatment for opioid abuse or
dependence, fewer than one million received MAT.69 Even within SUD treatment centers that
offer at least one form of MAT, only approximately one-third of patients with opioid dependence
receive MAT prescriptions.
Scholars have reported several reasons for low potential and realized access to MAT:
cultural bias against MAT; bias from Narcotics Anonymous (NA) and other 12-step groups; bias
and lock of MAT education among mental health therapists; an undersupply of physicians
treating addiction; regulatory barriers; cost; and concerns over illicit diversion.70 In 2012 the
National Center on Addiction and Substance Abuse at Columbia University published a report
that the U.S. treatment system needed “significant overhaul” and suggested that the “low levels
of care that addiction patients usually do receive constitutes a form of medical malpractice.”71
D.

A Note on Prevention

This dissertation focuses on opioid dependence treatment rather than prevention,
although prevention is extremely important and deserves more scholarly attention. The
traditional preventative method of warning children that drugs are “bad” is insufficient for
preventing drug dependence and overdose72. Opioid addiction often stems from physicians
overprescribing painkillers for chronic or acute pain rather than from individuals who
10

consciously deciding to “get high.”73 The spike in opioid addiction and overdoses in the U.S.
over the last decade can be directly attributed to the over-prescription of prescription painkillers,
largely due to federal agencies encouraging the treatment of pain as a “fifth vital sign”74 as well
as unscrupulous marketing practices by Purdue Pharma, the maker of OxyContin.75 The number
of prescriptions for opioid pain killers in the U.S. nearly tripled between 1991 and 201376, with
the U.S. currently accounting for almost 100% of the hydrocodone and 80% of the oxycodone
market.77
Unfortunately, while MAT is over-regulated in the U.S., the prescription of opioids for
chronic pain is under-regulated.78 For example, 49 of 50 states have instituted Prescription Drug
Monitoring Programs (PDMP), allowing physicians to look up patients in a database to
determine whether they have already received opioid painkillers elsewhere; but only 22 states
mandate that physicians examine the database.79 As a result, only about 35% of physicians who
issue a controlled substance examine a PDMP. 80 Physicians also do not have patient limits or
special certification requirements for prescribing opioid painkillers, as they do for
buprenorphine. Methadone cannot be prescribed in physicians’ offices for addiction treatment;
although lower dosages can be prescribed in physicians’ offices for pain management.81 Thus,
regulations for accessing opioid painkillers (the source of much opioid addiction) are looser than
regulations for accessing pharmacological addiction treatment.
III. Evidence-Based Treatment Methods
The success rate for opioid dependence treatment with appropriate treatment is similar to
other chronic diseases.82 Not all treatments for opioid dependence are equally effective,
however, and many common misconceptions exist about what constitutes effective treatment.83
The four primary types of treatment for opioid dependence in America are 12-step groups and
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other support groups, counseling, contingency management, and MAT. This chapter describes
each treatment option in turn, including a discussion of residential treatment and detoxification
treatment. The chapter ends with a brief discussion of treatment integration.
A.

Narcotics Anonymous and Twelve-Step Groups

Support groups are the most common and accessible treatment for drug dependence in
the U.S. Twelve-step groups are the most popular drug dependence support groups, of which
Alcoholics Anonymous (AA) and Narcotics Anonymous (NA) are the most well-known and
widely attended. NA is the primary form of treatment in over 90 percent of inpatient
rehabilitation settings as well as within prisons and drug courts. NA is available in most major
U.S. cities and many smaller cities as well.
Active participation in NA consists of regular (sometimes daily) group meetings,
guidance from a sponsor within the group, and following the “twelve steps” of recovery84:
1. We admitted that we were powerless over our addiction, that our lives had become
unmanageable.
2. We came to believe that a Power greater than ourselves could restore us to sanity.
3. We made a decision to turn our will and our lives over to the care of God as we
understood Him.
4. We made a searching and fearless moral inventory of ourselves.
5. We admitted to God, to ourselves, and to another human being the exact nature of
our wrongs.
6. We were entirely ready to have God remove all these defects of character.
7. We humbly asked Him to remove our shortcomings.
8. We made a list of all persons we had harmed and became willing to make amends to
them all.
9. We made direct amends to such people wherever possible, except when to do so
would injure them or others.
10. We continued to take personal inventory and when we were wrong promptly
admitted it.
11. We sought through prayer and meditation to improve our conscious contact with
God as we understood Him, praying only for knowledge of His will for us and
the power to carry that out.
12. Having had a spiritual awakening as a result of these steps, we tried to carry this
message to addicts, and to practice these principles in all our affairs.85
12

The twelve steps of recovery illustrate a number of themes, including regular group
communication, dependence on a Higher Power, striving for moral purity, seeking forgiveness,
helping others stay drug-free, and admitting the nature of one’s problem.86 The steps are
followed chronologically, with individuals spending varying amounts of time on each step with a
sponsor’s assistance.
NA developed from Alcoholics Anonymous (AA) and is identical to AA in all respects
except for its target audience, which is individuals dependent on drugs, not alcohol. AA began
in the 1930s as part of the Oxford Group, an evangelical Protestant church.87 Bill W., a member
of the Oxford Group, formed AA in order to share the method he used to obtain sobriety: a
spiritual experience aided by the support of fellow sufferers.88 Based on his personal experience
of recovery, Bill W. believed that sobriety could be achieved by anyone who shifted his or her
dependence away from chemicals and towards a Higher Power.89
Even though NA is the most common drug dependence treatment in the U.S., studies
about its effectiveness at promoting abstinence have mixed results. Many studies purporting to
prove its effectiveness have failed to distinguish between causation and correlation.90 According
to the National Institute on Drug Abuse, fewer studies of NA exist than of AA, so studies of AA
may serve as a useful analog.91 The Journal of Addiction published the results of four rigorous,
experimental studies of AA; only two found that AA had a significant positive effect on
abstinence, one found a negative effect, and one found no effect.92 A comprehensive review of
studies from 1966 to 2005 regarding AA’s effectiveness at improving abstinence reports,
“experimental studies have on the whole failed to demonstrate their effectiveness in reducing
alcohol dependence or drinking problems when compared to other interventions."93 The
National Longitudinal Alcohol Epidemiologic Survey found that AA’s retention rate is
13

approximately 30%.94 Those members who remain tend to be highly motivated, and some of
them will be active members for life.

Some randomized control trials of AA have found that it

is efficacious in promoting abstinence and psychosocial health for those individuals who
continue to attend meetings (despite the large drop-out rate), but those studies have not
specifically examined the context of opioid dependence.
AA and NA may be a helpful supplement to mental health therapy and/or MAT, so long
as NA does not discourage individuals from using other treatment methods,95 but unfortunately
evidence exists that it may discourage attendees from utilizing MAT.96 Some twelve-step groups
restrict MAT patients’ ability to claim clean time, speak at meetings, or be a sponsor.97 One
study found that 25% of NA patients failed to disclose that they were undergoing MAT for fear
of incurring stigma from their group. Future studies should estimate the efficacy of NA and AA
in promoting abstinence while considering their discouragement of MAT, which has higher rates
of efficacy.
B.

Mental Health Therapy

U.S. treatment providers use multiple methods of mental health therapy or psychological
counseling for treating opioid dependence. Mental health therapy may be provided in group or
individual settings, with group therapy being more common for drug dependence treatment; it is
the primary form of treatment provided within the criminal justice system, inpatient
rehabilitation centers, hospitals, and outpatient settings. Even though group therapies for drug
dependence differ widely by content and context, goals typically include education about drug
dependence, providing motivation to stop drug use, overcoming denial, teaching recovery and
coping skills, and resolving life problems that may be contributing to drug use.98 A group
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typically includes six to 12 participants.99 A group leader serves as a discussion facilitator and is
less active than a therapist in an individualized session.100
Despite the widespread use of group therapy, a paucity of research exists on its
effectiveness, largely due to inherent research difficulties.101 Research suggests that group
therapy should be combined with individual therapy.102 Also, preliminary controlled studies
suggest that group therapy may increase adherence to medication.103 Therefore, for some
populations, MAT and group therapy should be combined.
Mental health therapy may also be provided in an individualized setting. Effective
individualized therapy for drug dependence typically includes a focus on problems caused by
drug dependence, enhancing motivation to change, developing coping skills, reinforcement,
managing pain, improving interpersonal skills, and forging an alliance between the therapist and
client.104 Motivational interviewing, supportive-expressive therapy, and cognitive behavioral
therapy are three evidence-based methods of providing individual mental health therapy.
Motivational interviewing increases client commitment to stop drug use and begin
recovery; it is collaborative, aims to respect the client’s autonomy and values, expresses
empathy, and identifies and elicits the client’s desire to change.105 The role of the therapist has
been described as “a good salesman, who keeps the client talking and thinking while moving the
client toward a decision to buy [recovery].”106 A variety of randomized controlled trials have
shown motivational interviewing to be effective for treating SUD. Evidence of motivational
interviewing’s success, however, is stronger for nicotine and alcohol abuse than for drug
abuse.107
Supportive-expressive therapy analyzes the client’s drug use in relation to his or her
interpersonal and cognitive world.108 The therapist helps the client express reasons for drug use
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and how it has proved problematic.109 The therapist assists the client in working through
interpersonal issues that may be related to drug abuse110 and explore the meanings he or she has
ascribed to drug abuse and form solutions to interpersonal problems.111 Supportive-expressive
therapy may be most effective when combined with additional treatment methods;112 controlled
trials demonstrate that it may increase the medication adherence of individuals suffering from
opioid dependence.113
Cognitive behavioral therapy is the most studied form of mental health therapy for drug
dependence; here, the therapist and client analyze and review the “sequence of thoughts,
feelings, behaviors, and circumstances that lead to substance abuse” in a structured and usually
time-limited sequence.114 Components of cognitive behavioral therapy include recognizing
triggers, avoiding risky situations, and using psychological approaches to manage cravings. 115
The therapist teaches the client specific skills, such as recognizing and counteracting painful
feelings without the use of drugs.116
C.

Contingency Management

Contingency management involves giving individuals tangible rewards for desired
behavior, such as abstaining from drug use.117 Rewards depend on the context. I observed one
drug court hearing where participants earned a raffle ticket if they attended counseling sessions
and tested negative for drugs during the previous week. At the end of the drug court hearing,
there was a prize drawing where participants could win gift cards to restaurants and movie
theaters. In methadone clinics, participants who successfully follow protocols for a long time
may eventually be given “take home” privileges allowing them to take home a few days of
medication so that they do not need to attend the clinic daily. Eventually, take home privileges
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may be extended to a few weeks (depending on state law and clinic policies), contingent on
participant adherence to clinic rules.118
Contingency management has been tested in numerous settings and with different types
of addiction, including drug and gambling addiction; studies have found it increases abstinent
time and treatment adherence when used with other treatments, such as counseling and/or
MAT.119 In particular, it can be used to reinforce participation in other treatment programs.
D.

Medication-Assisted Treatment (MAT)

MAT is the use of FDA-approved medications for treating drug dependence. According
to the DHHS120 and the WHO,121 MAT is the most effective opioid dependence treatment.
Professional medical associations such as the AMA, ASAM, CDC, SAMHSA, the Institute of
Medicine, the National Institute on Alcohol Abuse and Alcoholism, the National Institute on
Drug Abuse, and NADCP.122 According to SAMHSA, patients receiving MAT cut their risk of
death from overdose in half.123 The three medications most commonly used within MAT are
buprenorphine (commonly known by the brand name Suboxone®), Vivitrol® (extended-release
naltrexone), and methadone.124 Each has been proven significantly more effective at preventing
drug use relapse than a placebo in rigorous, double-blind experimental studies.125 Also, the
MAT retention rate is greater than that for either counseling or 12-step groups.126 Unfortunately,
all medications for treating opioid dependence are underutilized and under-prescribed, and rarely
available within inpatient rehabilitation centers,127 rarely used within prisons, and underused
within drug courts.128 Buprenorphine, methadone, and extended-release naltrexone are each
described in more detail below.
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1.

Methadone

Methadone is the oldest FDA-approved medication for treating opioid dependence.129 It
works by activating the brain’s opioid receptor, called the mu-receptor.130 Methadone is a
complete mu-agonist, meaning that it completely activates the mu-receptor.131 As a result, it
prevents cravings for opioids, while allowing individuals to stop using heroin and painkillers
without experiencing withdrawal.132 Because methadone has a higher selectivity for the mureceptor than heroin or painkillers, it methadone prevents euphoria or a “high” if a person abuses
substances while undergoing methadone treatment.133 A person taking methadone can function
normally and does not feel or appear “high.”134 Methadone treatment has been proven to
decrease death rates, relapse, drug-related crimes, HIV/AIDS from shared needles, medical costs,
and unemployment.135 According to the National Institute on Drug Abuse, every dollar invested
in methadone treatment saves society $38.136 Lower programmatic restrictions on methadone
provisions and higher dosages are predictors of positive outcomes.137
Methadone can be dangerous if diverted and improperly used, but most individuals who
obtain methadone use it for treatment and do not abuse it.138 Because methadone has a high
potential for physical and psychological dependence, it is a Schedule II narcotic under the
Controlled Substances Act (CSA), where Schedule I is the most legally restrictive and Schedule
V is the least restrictive.139 In order to prevent illicit diversion, methadone is only available at
certified methadone treatment centers, to which the patient must usually return daily to continue
treatment.140 These treatment centers are often heavily visible and stigmatized by city
governments and residents.141 Additionally, some cities and a handful of states lack a single
methadone clinic.
If an individual has commercial health insurance or Medicaid, the generic version of
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methadone can be quite affordable. In some states (such as Indiana, however, methadone is not
covered by state Medicaid, making it unaffordable for many individuals in need. Likewise, the
cost of daily transportation to a methadone clinic may be a financial barrier to low-income
individuals.
2.

Vivitrol (Extended-release naltrexone)

Vivitrol has been approved for treating both opioid dependence and alcoholism.142 Unlike
methadone or buprenorphine, it does not contain any opioid ingredient.143 Instead, it contains
extended-release naltrexone, which is a complete mu-receptor antagonist, meaning it completely
blocks the mu-receptor.144 Vivitrol prevents an individual from experiencing euphoria if he or
she abuses any opioid,145 making the medication very effective at preventing relapse.146 But a
patient must undergo complete detoxification before receiving Vivitrol; if opioids have not yet
been naturally flushed out of his or her system, the individual will experience immediate and
painful withdrawals.147
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Vivitrol is not a controlled substance, so it can be prescribed by any licensed physician.149
The medication is given as a monthly injection that lasts for 30 days.150 Unfortunately, it is very
expensive, costing around $1,000 per month for individuals without health insurance151 as many
individuals with dependency do.152 Some but not all Medicaid programs cover Vivitrol. Even if
an individual has commercial insurance, the copayment can be quite expensive and be a
treatment barrier.
There are some benefits of Vivitrol that are distinct from buprenorphine and methadone.
Some individuals who fear being stigmatized for taking an opioid medication may be more
comfortable taking Vivitrol. The lack of an opioid ingredient also makes it practically
impossible for patients to abuse or overdose on it, unlike buprenorphine and methadone.153. In
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addition, because Vivitrol is a monthly injection, patients may find it easier to adhere to
treatment. Some physicians say that patients on Vivitrol just need to make one good decision per
month. Buprenorphine patients could simply decide to stop taking the daily pill or sublingual
film on any day.154 Likewise, patients may fail to visit a methadone clinic daily.
3.

Buprenorphine

Buprenorphine is a partial mu-agonist.155 It prevents an individuals with opioid
dependence from going into withdrawal or experiencing cravings.156 An individual taking
buprenorphine can feel, act, and appear completely normal.157 Unlike methadone, the opioid in
buprenorphine is not very potent, so it is less likely to be abused or cause an overdose. Because
Buprenorphine has higher selectivity for the mu-receptor than any other opioid, including
methadone, it prevents a “high” if the individual takes another opioid158 and so, individuals who
take it daily have little incentive to abuse opioids.159 Moreover, unlike methadone,
buprenorphine has a “ceiling effect”; after a certain dosage, the patient feels no additional
physical sensations from additional buprenorphine, deterring them from taking too much. The
naloxone in the buprenorphine-naloxone serves as an abuse deterrent, because naloxone when
injected causes painful withdrawal symptoms.
Buprenorphine can be prescribed by any licensed physician in an office setting, as long as
the physician obeys DEA rules for Schedule III substances and has obtained a waiver from
SAMHSA as required under the Drug Addiction and Treatment Act of 2000.160 This waiver is
commonly referred to as a DATA Waiver or an “X number” because it appears as the
physician’s DEA number preceded by the letter “X.”
A patient undergoing buprenorphine treatment typically receives a monthly prescription,
which he or she fills at a local pharmacy. The patient then takes the medication at home daily in
20

the form of a pill or sublingual film.161 The DEA limits automatic refills on Schedule III
narcotics to five refills or six months (whichever comes first).162 However, physicians
commonly require patients on buprenorphine treatment to return monthly for an appointment to
obtain a new prescription.163
Numerous studies have documented buprenorphine’s effectiveness at preventing relapse,
euphoria, and drug cravings.164 Increased access to buprenorphine has been associated with a
decrease in mortality from opioid overdose.165 For example, in France, increased buprenorphine
treatment was associated with an 80% decrease in opioid overdoses.166 Increased access to
buprenorphine lowers medical costs by preventing the need for expensive in-patient treatment or
emergency room visits and is also associated with increased employment and fewer drug-related
crimes.167 As patients’ buprenorphine dose and length of time in treatment increases, their risk
of relapse decreases.168
Buprenorphine also increases compliance with mental health therapy regimens.169
Individuals treated with buprenorphine are more likely to participate regularly in out-patient
mental health counseling than non-users,170 perhaps because individuals can more easily focus
on behavioral and psychological changes if their physical cravings are controlled. Finally,
buprenorphine has been used effectively and safely in pregnant women171 and adolescents.172
In 2008, buprenorphine prescriptions cost about $120 to $570 per month (depending on
the dose) without health insurance.173 However, the FDA recently approved two generic
versions of Suboxone (buprenorphine-naloxone), potentially decreasing its cost.174 Commercial
health insurance carriers175 and all state Medicaid programs cover buprenorphine treatment,
although some Medicaid programs have coverage time limits.176 Some buprenorphine
manufacturers provide discount cards for low-income individuals, which may decrease cost.177
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In May 2016, the FDA approved Probuphine, a six month surgical buprenorphine implant
embedded in the arm.178 Probuphine is implanted in a minor surgical procedure performed in
physicians’ offices.179 The implant slowly releases buprenorphine and will likely eliminate the
potential for diversion. Physicians who prescribe and administer Probuphine must complete an
additional certification in Probuphine Risk Evaluation and Mitigation Strategy (REMS).180
Because Probuphine was only recently made available, long-term studies of its efficacy are not
yet available.181 However, preliminary studies look very promising. According to the FDA,
A response to MAT was measured by urine screening and self-reporting of illicit opioid
use during the six month treatment period. Sixty-three percent of Probuphine-treated
patients had no evidence of illicit opioid use throughout the six months of treatment –
similar to the 64 percent of those who responded to sublingual (under the tongue)
buprenorphine alone.”182 The National Institute on Drug Abuse calls Probuphine “a
game-changer” in opioid dependence treatment.183
4.

Comparing the Medications

As compared to methadone, buprenorphine and Vivitrol may carry less cultural stigma
because they can be prescribed in physician offices rather than a specialized clinic.184
Appointments for Vivitrol and buprenorphine may also offer patients more privacy than visiting
a methadone clinic.185 If a co-worker sees a patient on buprenorphine entering a primary care
physician’s office, that co-worker does not know the reason for patient’s visit; entering a
methadone clinic, however, is a sure sign an individual suffers from drug dependence.
Unlike Vivitrol, buprenorphine does not require complete detoxification prior to the first
dose.186 Rather, treatment begins when the patient is in mid-withdrawal.187 The complete
detoxification required prior to Vivitrol treatment may serve as a disincentive to some
individuals, because opioid withdrawals are very painful and commonly include multiple days or
weeks of diarrhea, muscle aches, excessive sweating, jerking or twitching muscles, fatigue, and
nausea.188 Complete detoxification from opioids without relapse is extremely difficult, often
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requiring multiple attempts. One study of patients treated with methadone, for example, found
that 25% had a phobia of detoxification.189 As a result, individuals sometimes enroll in in-patient
rehabilitation centers to detox, which cost approximately $31,500 for 30 days.190
Finally, both Vivitrol and buprenorphine are less time-consuming than methadone,
because patients can obtain a 30-day supply of buprenorphine from a local pharmacy and take
them at home daily and a Vivitrol injection is only needed once per month.191 But methadone
treatment generally requires daily travel to a methadone clinic;192 many individuals with
dependency are low-income193 and find it especially difficult to afford daily transportation to a
methadone clinic or take time off of work to attend.
In terms of effectiveness, no randomized controlled study has compared methadone,
buprenorphine, and naltrexone. However, studies have found that buprenorphine and methadone
are approximately equally effective194, with the exception that severely dependent individuals
may do better on methadone. No study has compared methadone to Vivitrol or buprenorphine to
Vivitrol.195 It appears that buprenorphine and methadone may be more effective at managing
cravings relating to opioid use as well as responses to stress.196 More cross-medication studies
are needed.
5.

How Physicians Choose One Medication Over Others

If a physician can prescribe either Vivitrol or buprenorphine or refer a patient to a
methadone clinic, she will need to choose which medication is most appropriate for a particular
patient. This is a highly individualized decision. Each of the medications has been proven
effective at preventing relapse, lowering the risk of mortality and morbidity, decreasing criminal
recidivism and decreasing unemployment. But not every medication is right for a particular
patient.
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During interviews with physicians, including primary care physicians and psychiatrists, I
discovered certain trends regarding Vivitrol prescription. Physicians were more likely to
recommend Vivitrol to individuals with opioid dependence for a shorter time or who had a lowlevel of dependence. Because full detoxification is required before starting Vivitrol, patients who
have used opioids for a long time or are severely dependent may not be able to complete full
detoxification, especially outside of a residential setting, hospital or prison. On the other hand,
some physicians mentioned that patients forced to detox through incarceration may be ideally
positioned to begin Vivitrol despite long-term use. Physicians are also more likely to recommend
Vivitrol for patients with financial resources to pay for the medication. Finally, patients who are
actively participating in the criminal justice system (e.g. in drug court or probation) may be
prohibited from taking any medication with an opioid ingredient, leaving only Vivitrol as a
viable option.
Other factors might lead physicians to recommend buprenorphine. It might be a good
option if a patient has successfully tried buprenorphine before or if a patient is unwilling to try
Vivitrol because of personal reasons such as a fear of commitment. Moreover, it might be
appropriate for patients who have been unable to abstain from opioids while on Vivitrol or those
who are unlikely to successfully complete full detoxification. Patients are likely to prescribe
buprenorphine to patients for whom it is affordable; the medication’s greater affordability is
particularly important in some states, like Indiana, where state Medicaid does not cover
methadone for addiction treatment and Vivitrol copayments remain cost-prohibitive for many.197
Finally, the medication may be better for patients suffering from depression, since there is some
evidence that buprenorphine effectively treats depression, even though it has not been FDAapproved for this purpose. Additionally, because buprenorphine contains an opioid ingredient, it
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may be more appropriate for individuals who suffer from acute pain. But this may not be so for
chronic pain patients; many medical studies do not support the efficacy of using opioids to treat
chronic pain.198
Physicians stated that they would be most likely to recommend methadone for patients
who have used opioids for a significant period of time or are severely dependent, those with
acute pain, and who did abstain from opioid abuse on Vivitrol or buprenorphine. Additionally,
multiple physicians mentioned that some patients need the accountability of a daily clinic visit to
obtain a prescription, such as patients with serious co-occurring mental health conditions like
schizophrenia or bi-polar disorder who may be unlikely to consistently take buprenorphine daily
at home. However, a few physicians mentioned that whether they referred patients to a
methadone clinic would partially depend on how well that clinic was managed. Some
methadone clinics have historically provided doses that are too low199, or have served as a central
point for illicit drug dealers to convene, targeting patients outside the clinic200. Additionally,
some physicians have complained of overpopulated methadone clinics with inadequate staff. For
example, physician 4 once worked at a methadone clinic in the North East with 400 patients, and
sufficient staffing. But she feels differently about the methadone clinic nearest to her office in the
Midwest, which has approximately 2,000 patients, many of whom are not carefully monitored
and do not receive enough counseling.
All physicians emphasized that they strongly consider their patients’ wishes and opinions
about the choice of medication. They agreed that patients were more likely to ask for
buprenorphine than Vivitrol because full detoxification is not required, they may have already
started buprenorphine after purchasing it on the streets if a doctor appointment was physically or
financially inaccessible, and they fear the long-term commitment Vivitrol requires. But
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physicians also agreed that few patients have heard of Vivitrol before speaking with a physician,
while almost all have heard of buprenorphine and methadone. Therefore, a lack of information
about Vivitrol may explain why fewer request it. Likewise, patients are more likely to ask for
buprenorphine than methadone because they do not want the hassle of travelling to a clinic daily,
feel that methadone is more stigmatizing, or do not want to take a full agonist.
D.

Detoxification Alone

Detoxification is sometimes considered “treatment,”201 but alone it is almost always
ineffective, especially for opioid dependence, because physical changes in the brain from opioiddependence persist post-detoxification.202 The social, psychological and occupational difficulties
associated with drug-dependence also do not immediately cease upon detoxification.203 In fact,
the chance of death from overdose is highest immediately following detoxification, because an
individual’s psychological and physical cravings persist, but physical tolerance for opioids is
low.204 Therefore, detoxification should always be combined with another form of treatment.
Additionally, detoxification tends to be more successful if completed in a controlled
environment, such as a residential treatment facility or under a relative’s watchful eye.
The false assumption that detoxification alone is sufficient may arise from the cultural
misunderstanding that addiction is an acute rather than a chronic disease.205 An acute disease,
such as a broken arm, may require only a short-term treatment to restore the body to its healthy
state. A chronic disease, however, requires long-term care, meaning that relapse is possible;
therefore, even an individual who is not actively abusing drugs may need to continue counseling,
MAT, or support groups.
E.

Residential Facilities
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Some individuals with opioid dependence choose to enter or are referred to a residential
treatment facility. Residential treatment can be short-term (such as for one month) or long-term
(six months to one year). Long-term residential treatment centers attempt to resocialize the
patient in a community where “other residents, staff, and the social context [are] active
components of treatment.”206
Residential treatment centers frequently provide a range of services, including mental
health counseling, self-help groups, and detoxification services. According to the National
Institute on Drug Abuse, short-term residential treatment centers typically use a 12-step recovery
model.207 Unfortunately, surveys have found that most residential treatment facilities do not
offer MAT. But there is no reason why residential facilities could not introduce patients to
buprenorphine or Vivitrol treatment assuming physicians at the facility have the appropriate
credentials and that the facility then connects patients with community providers after residential
treatment.
Scholars find it difficult to accurately assess residential treatment’s effectiveness
compared to community-based or outpatient treatment, because residential treatment center
programming differs dramatically. One study found that residential treatment participants
showed greater improvement on social factors and co-occurring mental health conditions,208 but
no benefits superior to community-based treatment in drug use.209 It is likely that participating
residential treatment facilities did not offer MAT; therefore, we do not know the success rate for
addiction treatment in those offering MAT. Another study found that 80% of individuals who
underwent residential treatment for opioid dependence relapsed within 2 years, regardless of
whether residential treatment was voluntary or compelled.210
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Policymakers and criminal justice administrators should know that residential treatment,
especially short-term, is rarely sufficient treatment for opioid addiction. Ongoing communitybased care after release is essential for full recovery. Gossop et al. examined abstinence rates of
242 heroin users from 23 U.S. residential centers; they found that 60% of heroin users relapsed
within 12 months of release from the residential center, with most relapsing shortly
afterwards.211 Smyth et al. studied 101 opioid-abusing individuals in Ireland and found a relapse
rate of 91%, with 59% of relapses occurring within one week of release.212 These studies
strongly imply that residential treatment should be followed by regular outpatient treatment.
A primary purpose of residential treatment is detoxification; patients may find it easier to
complete detoxify in a controlled environment rather than at home. As painful withdrawal
symptoms increase during detoxification, individuals benefit from community support and are
unlikely to access drugs. But if treatment does not continue following release, the individual is
at risk of relapse and death from overdose due to decreased physical tolerance.213 Prison or jail
may serve the same purposes as a residential detoxification facility, but overdose is the number
one cause of death following release, again attributed to low physical tolerance and a lack of
follow-up treatment.214
E.

Treatment Integration

Up to this point, I have discussed treatments for opioid dependence separation. However,
every physician whom I interviewed has mentioned the need for treatment combinations and
flexibility. Unfortunately, few studies have been done comparing treatment combinations.
Instead, one treatment is usually compared to a placebo. This fact reflects the problematic
segregation of treatment fields, including insufficient collaboration between psychiatry and
psychology, and between mental health and addiction treatment.
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Existing studies provide inconsistent results about the effectiveness of different treatment
combinations. Although they form the bulk of opioid addiction treatment in the U.S., behavioral
interventions (e.g. counseling and 12-step groups) have poor treatment in opioid treatment if
provided without MAT (one study estimates that 80% of those who receive behavioral
interventions only relapse).215 Therefore, behavioral interventions should be supplemented with
MAT, which has significantly lower relapse rates. Relatedly, some studies suggest that relapse
rates are lower for those who receive both MAT and behavioral interventions rather than
behavioral interventions alone. Therefore, DHHS, ASAM, and WHO all recommend
complementing MAT with behavioral interventions.216 However, a meta-analysis of 65 studies
found no improvement in treatment retention or abstinence when MAT was supplemented with
behavioral interventions, suggesting that more research on the topic is needed.217 The relatively
difficulty of designing behavioral intervention studies relative to medication intervention studies
may explain the greater heterogeneity of behavioral study results. For example, even though
cognitive behavioral therapy is a standard method of mental health counseling, it is not applied in
exactly the same way by every therapist; on the other hand, medication provision is more likely
to be uniform across physicians. Additionally, therapists’ empathy, interpersonal skills, and other
personal characteristics may have a strong effect on treatment efficacy; such factors likely
influence medication efficacy less. According to a study published in Psychiatric Services, “[The
field] psychosocial treatments is heterogeneous, and there is a lack of sufficient, high-quality
studies to assess which psychosocial interventions have the most success in various
populations.”218 The difficulty of assessing treatment combinations, such as the combination of
medication and behavioral treatment, increases in the context of dual-diagnosis patients.
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The correlation between SUD and other mental health disorders (MHDs) is very high,
with 17-40% of SUD patients also suffering from mood disorders, anxiety disorder,
posttraumatic stress disorder, severe mental illness, antisocial personality disorder, or borderline
personality disorder.219 Individuals suffering from SUD are twice as likely to suffer from anxiety
or mood disorders as the general population; and individuals suffering from anxiety or mood
disorders are twice as likely to suffer from an SUD.220 Some hypothesis for the high rate of cooccurrence of MHD and SUD have been proposed, including similar brain circuitry involved in
SUDs and many MHDs, self-medication of MHD using drugs, and (in some cases) symptoms of
MHDs caused by drug use.221
Obviously, health practitioners treating SUDs or MHDs should be aware of their cooccurrence and should attempt to treat both types of disorders together, especially if SUDs may
increase MHD symptoms or vice versa. Yet, addiction treatment centers rarely provide mental
health treatment; and mental health treatment centers rarely provide addiction treatment. 222 A
multi-state study published in 2009 found that 18% of addiction treatment centers and 9% of
mental health centers had dual-diagnosis treatment capability.223 Many SUD treatment centers
fail to assess patients for MHD, and many mental health centers fail to assess patients for SUDs.
Even if a treatment center only offers SUD or MHD, failure to assess a patient as a dualdiagnosis patient may result in ineffective treatment. Instead of inefficient segregation, SUD
treatment centers and MHD treatment centers should be integrated into dual-diagnosis treatment
centers. Infrastructure development for dual-diagnosis treatment is badly needed (e.g. for clinic
integration and cross-training of providers in SUD and MHD treatment).
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F.

Summary

Opioid addiction requires long-term treatment, often using a combination of treatment
methods. Behavioral interventions alone, such as counseling and 12-step groups, have poor
outcomes, with more than 80% of patients returning to drug use.224 Likewise, detoxification
alone results in poor outcomes. MAT is the most effective treatment for opioid dependence,
especially when provided in combination with counseling. The three forms of MAT for opioid
dependence (methadone, buprenorphine, and extended-release naltrexone) have each been
demonstrated to lower overdose rates, mortality, morbidity, and recidivism. Despite the
effectiveness of MAT for maintenance-treatment, it is highly stigmatized in the U.S.,
overshadowed by abstinence-only philosophy (formed around the hegemonic 12-step program),
and strictly regulated. The following chapter applies this background information by examining
the cultural bias against MAT.
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CHAPTER 1: CULTURAL BIAS AGAINST MAT
The U.S. has an unusual cultural bias against the use of FDA-approved medication for
treating drug dependence,225 especially given the fact that medication is commonly used to treat
other illnesses. Americans consider pharmaceuticals to be a normal part of life, as the frequency
of television advertisements for such products pharmaceuticals demonstrates. So why is
medication for treating drug dependence so heavily stigmatized?
The chapter begins with a brief history of addiction treatment in the U.S. It then discusses
misconceptions surrounding addiction in light of addiction treatment history. Specifically, two
misconceptions are examined: the idea that willpower and self-control should be sufficient to end
addiction;226 and the idea that addiction is related to immorality, requiring spiritual treatment.
The chapter ends by examining abstinence-only treatment (meaning treatment without the use of
MAT), which has been strongly influenced by misconceptions of opioid addiction treatment and
cultural biases against MAT.
I. A Brief History of Addiction Treatment in the U.S.
Perceptions of addiction treatment have changed over time in the U.S. However, some
addiction treatment practices that are common today can be traced back to attitudes that are
decades’ or even centuries’ old, such as the incorporation of religious practices into treatment
protocols. Other attitudes towards addiction are more modern, such as the understanding of
addiction as a chronic disease rather than an acute disease. Chronic diseases are long-lasting
complex diseases, often affecting many bodily systems; whereas, acute diseases are sudden,
severe, short-term diseases, often isolated to one part of the body.227 Due to their complexity,
chronic diseases are typically more difficult to treat than acute diseases.228
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Favored addiction treatment methods relate to societal and professional assumptions
about addiction’s etiology. For example, individuals who perceive addiction as a form or
symptom of spiritual deprivation likely support spiritual reformation as a form of addiction
treatment; those who perceive addiction stems from a lack of self-control likely support
treatments that teach self-control, such as psychotherapy; and those who understand addiction to
result from low dopamine levels are likely to support treatments that increase dopamine
production. Therefore, in order to understand modern addiction treatment, it is helpful to review
historical assumptions about addiction’s nature and related treatments.
A. Views of Substance Dependence in Early American History
In the U.S., self-control is both a practical ideal and a moral ideal that can be traced back
to America’s Protestant foundations. For the Puritans, self-control was a sign of morality.
Moderation in everything, including alcohol, was heavily emphasized in Biblical readings. For
example, Puritans were encouraged to forgo luxury, wear simple clothes, be abstemious in food
and drink, and live in simple houses. Churches had minimal décor. Lacking a conception of
addiction as a disease, excessive alcohol or drug use was perceived as sinful, gluttonous or selfcentered behavior. In the late 1700s, around the time of the American Revolution, self-control
was considered an essential component of citizenship. A citizen lacking self-control could not be
trusted to vote in an election; he might commit any number of acts including offenses, such as
voting for a politician whose platforms would benefit himself but harm others.
Alcohol use was common in the American colonies; it was used regularly in daily
cooking, as a home remedy for illnesses, in ceremonies, and as part of social events. However,
the overuse of alcohol was considered gluttonous and sinful, in violation of the Puritan ethic of
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self-control. Treatment for dependence was rare and largely consisted of attending religious
services.
In the late 1700s, arguments surfaced that substance-dependent individuals suffered from
a disease needing treatment. Benjamin Rush, a signer of the Declaration of Independence who is
often deemed “the father of psychiatry,” argued that alcoholism was a progressive medical
condition.229 His writings on this topic were reprinted thousands of times and widely distributed.
Rush also claimed that alcoholism had a genetic component, observing that it seemed to run in
families.230 Some of his writings were medically flawed, at least in light of today’s science. For
example, Rush argued that individuals suffering from alcohol dependence should be given
opioids as a replacement maintenance therapy, arguing that opioids were less addictive than
alcohol.231 But Rush’s recommendations demonstrate that maintenance treatment for substance
dependence treatment is not a new concept, even though the types of maintenance treatments
used have changed over time.
Rush observed that incarceration was ineffective for treating substance dependence, and
argued that Sober Houses should replace jails as residences for individuals with alcohol
dependence.232 Sober houses were necessary, because individuals with alcohol or drug
dependence were barred or discouraged from receiving treatment in public hospitals or
psychiatric institutions, as were others with diseases considered immoral (e.g. venereal diseases).
233

Interestingly, Rush suggested that these Sober Houses should be funded through a percentage

of alcohol sales.234
Even though Sober Houses developed during the 1700s and 1800s described addiction as
a disease, their daily programs centered on moral and religious education. 235 Daily religious
devotions, for example, were considered critical for rebuilding weak characters. Unfortunately,
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Rush’s understanding of addiction as a disease was not shared by many Americans. Some
religious groups continued to view addiction as a sin, and some clergy viewed the disease theory
of addiction as an excuse to engage in sinful behavior.236
In the 1800s, many treatment centers (e.g. Sober Houses) hired physicians to provide
“medications,” most of which would not be considered scientifically-valid today. Treatment
centers also provided recreation, rest, nutrition, massage, and other activities designed to
improve one’s physical and psychological health. Some treatment centers operated like luxurious
spas for wealthy individuals, while others resembled poorly-run hospitals and were called
“asylums.” Individuals were encouraged to reside at treatment centers for many months, and
sometimes years. Because alcohol and drug-dependence were perceived as being part of the
same disease (insobriety), individuals with both alcohol and drug dependencies attended
treatment centers.237 Aftercare consisted of church membership, involvement in fellowships,238
or other community associations for individuals with dependencies.
B. The Temperance Movement
In the early 1800s, the U.S. witnessed the beginning of the temperance movement239,
which ultimately influenced societal perceptions of individuals with dependency. Even though
alcohol use had been widespread and generally accepted in American society since colonial
times, by the early 1800s many Americans feared that alcohol use was increasing significantly,
especially on the Western frontier. Some saw alcohol use as part of an immoral tavern culture
common among single men and cowboys in the Wild West that threatened the fabric of civilized
community life.240 Originally the temperance movement sought to promote moderate alcohol
use, not to eliminate alcohol use altogether.241 By the 1850s, however, the temperance movement
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promoted complete abstinence from alcohol; and advocated legal prohibition as the best method
for accomplishing this goal.242
The temperance movement took a particularly cruel view of individuals with alcohol
dependence. Some leaders of the temperance movement suggested that individuals with alcohol
dependence should be left to die, so that heredity would stop being a cause of alcohol
dependence.243 Temperance movement leaders also assumed that individuals with alcohol
dependence would not need treatment, because legal prohibition would supposedly forever end
alcohol use, and thus dependence.244 Eventually, when state governments (and later the federal
government) criminalized alcohol-related activity, governments slashed funding for existing
treatment initiatives (e.g. asylums) in the expectation that treatment would no longer be
needed.245 The misunderstanding that complete abstinence from a substance is sufficient for
ending dependence continues today, as does the belief that simply criminalizing a substance will
end dependence.
Shortly after the nationwide prohibition of alcohol began, individuals with alcohol
dependence who continued to seek and use alcohol were relegated to prisons, because most
public and private treatment centers had closed.246 According to historian William White, the
collapse of private alcoholism treatment facilities “was mirrored by the progressive collapse of
the addiction treatment field as a professional area.”247 Although treatment centers in the early
1900s had few medically-valid treatments, their mere existence had suggested that drug
dependence was a disease requiring treatment. In contrast, the jailing of substance-dependent
individuals suggested that dependence was a sign of immorality. Moreover, although few
professional standards existed for addiction treatment,248 the decline in the numbers of practicing
addiction treatment professionals contributed to the perception that the new treatment field was
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unnecessary. But psychiatric institutions--which largely excluded individuals suffering from
addiction-- continued to receive government funding.249
Prohibition of alcohol led to calls for prohibition of other addictive substances, including
opioids and cocaine. Fear and bias against Chinese immigrants who were perceived as opioid
users encouraged Congressmen to limit opioid access. In 1915, the U.S. Congress passed the
Harrison Anti-Narcotics Tax Act (Harrison Act), which regulated the use, sale, manufacture, and
distribution of narcotics (including opioids and cocaine), effectively making them illegal for
most uses.
C. The Washingtonian Movement, Fraternities and Alcoholics Anonymous
In the late 1800s, fellowships for individuals recovering from alcohol dependency began
and spread quickly. The Washingtonian movement (a predecessor to AA) was the most popular
fellowship, until it fizzled out in the early 1900s. It focused on rebuilding character and
increasing self-control to abstain from alcohol.250 Washingtonian meetings required participants
to admit their addiction, promise to abstain from the addictive substance, share stories, and pray.
Members met regularly at each other’s homes. Other fellowships were called “fraternities” and
catered to wealthy individuals, involved numerous symbols and ceremonies, relied on
motivational speeches and prayer, and also required complete abstinence from the abused
substance. Members who were caught using substances were forced out of the organization. Like
the Washingtonian movement, fraternities decreased in popularity during the early 1900s.
After the temperance movement led to the closing of most SUD treatment facilities, a
new fellowship organization, AA, filled the void. AA evolved from the Oxford Group, an
evangelical spiritual organization. Member Bill W., a co-founder of AA, developed the famous
AA “12-steps” after experiencing what he called a “spiritual awakening,” which, in combination
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with sharing his experiences, allowed him to remain sober. He sought to share his sobriety
method with others suffering from alcoholic dependence in anonymous groups whose meetings
were modeled after the Washingtonian movement. After receiving positive media and movie
coverage,251 AA spread like wildfire and became the only source of widely-accessibly addiction
treatment. Eventually, other support groups modelled on AA developed, including NA. Even
today, most professional treatment centers design their programs around the philosophy of the
12-steps.252
D. Psychoanalysis and Psychological Therapy
During the early 20th century, the psychoanalysis movement also influenced perceptions
about the nature of addiction and addiction treatment. Psychoanalysis construes addiction not as
a primary disease in its own right but a symptom of neurosis or a disordered personality.
Addiction was also viewed as a maladaptive strategy for dealing with psychological problems,
including emotional immaturity. Some leading psychoanalysis practitioners perceived addiction
as a suicidal flight from an inner conflict. Therefore, according to psychoanalytic theory, the
only effective treatment for addiction was complete reconstruction of the personality253 with the
goal of enhancing emotional maturity through developing self-control.254 Interestingly,
psychoanalytic theory did not demand complete abstinence because a restructured personality
might allow for moderate alcohol use.255
Psychoanalysis was available to few individuals, namely wealthy urbanites, and became
discredited as a treatment modality in the latter half of the 20th century.256 But it continues to
influence addiction attitudes, including the common misunderstanding that individuals suffering
from addiction are emotionally and psychologically immature. Psychoanalytic theory also
contributed “a model of outpatient psychotherapy that focused on character reconstruction”257
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that remains influential in contemporary treatment practices. Sigmund Freud also popularized
the belief that lay individuals trained in psychoanalysis theory (as opposed to physicians) could
effectively provide therapy, increasing the involvement of non-physicians in addiction
treatment.258
By the 1960s, cognitive therapy had replaced psychoanalysis as the dominant
psychological treatment for addiction. Cognitive therapy was used to discover and correct
automatic negative thoughts, such as those related to drug use triggers or cravings. In the 1970s,
professionals combined cognitive therapy with behavioral therapy to form cognitive behavioral
therapy (CBT), creating what some describe as a revolution in psychological practice.
Counselors were (and continue to be) the primary health practitioners involved in CBT, while
physicians receive little training in its techniques.
E. Modern MAT
1. Aversion Therapy
One early use of medication in addiction was aversion therapy, primarily used for treating
alcohol dependence .Aversion therapy causes association of the substance of abuse with an
unpleasant sensation, such as nausea or an electric shock. Aversion therapy relies on the
Pavlovian principle that, after repeated exposure to a stimulus, an unconscious response will
occur. If individuals repeatedly experience alcohol in conjunction with nausea, for example, they
may experience aversion (e.g. nausea) at the mere sight or thought of alcohol. Thereby, one can
be trained to dislike a substance that one formerly used. As early as the 1800s, aversion therapies
using chemical tinctures and electric shots were used in some treatment centers. The first
medication to be widely used in aversion therapy was disulfiram (Antabuse), which was FDAapproved in 1951. Later aversion therapies for alcohol dependence included naltrexone259
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(approved in 1994) and acomprosate (approved in 2004). However, each of these prescription
medications is seriously underused for treating alcohol dependence, just as other medications are
under-prescribed for treating opioid dependence. For example, current estimates suggest that
Antabuse is used by only 120,000 individuals worldwide.260
2. Morphine Maintenance Therapy and Methadone
In the late 1800s and early 1900s, physicians prescribed morphine to individuals with
opioid dependence as a maintenance treatment. An estimated 200,000 to 4,000,000 individuals
received maintenance treatment, primarily in large cities.261 Physicians assumed that regularly
providing a small dosage of morphine would prevent dependent individuals from experiencing
withdrawal symptoms, prevent criminal activity, and prevent opioid overdoses from using higher
dosages. However, the Harrison Anti-Narcotics Tax Act (Harrison Act) effectively ended the
practice of morphine maintenance treatment. The Act also represented the first major federal
intrusion into medicine, formerly regulated entirely by states.262 Even though the Act did not
specifically state that maintenance treatment was illegal, the Narcotics Division of the
Prohibition Unit of the Department of the Treasury (the predecessor to the DEA) interpreted the
Harrison Act as barring maintenance therapy. The Commissioner of the Narcotics Division,
Henry Anslinger, was notorious for his belief that drug users were bad characters and insisted
that addiction was a criminal rather than a public health problem.263 The Treasury adopted
Anslinger’s view of individuals suffering from drug dependence and interpreted a part of the act
stating that physicians could prescribe opioids "in the course of his professional practice only” as
barring maintenance therapy.264 According to the Treasury, because drug dependence was not
considered a disease, treatment for drug dependence was not in the course of a physician’s
professional practice.265
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In 1919, in Webb v. United States, the U.S. Supreme Court further clarified that the
Harrison Act prohibited physicians from prescribing narcotics for maintenance treatment.266
Some physicians continued to prescribe morphine for maintenance treatment after the Harrison
Act. They were targeted by the Treasury, leading to the largest government raid on physician
offices in U.S. history. According to Richard Boldt, “In the decades that followed passage of the
Harrison Act, the moral meanings that attached to the use of narcotics in the United States
underwent a dramatic shift.” As a result of the raids, physicians largely existed the addiction
treatment field and the general public saw physicians prescribing maintenance treatment as bad
actors rather than healers.267 Like the general public, policy makers continued to view
maintenance treatment as immoral. While discussing maintenance treatment, a U.S. Senate
committee in the 1950s stated that "it would be absolutely immoral to give in to drug addiction"
and that the government "should not adopt any program to give the drug addict "sustaining' doses
of narcotics."268
The Harrison Act largely restricted research on maintenance treatment for several
decades. In the 1960s, two researchers working at the U.S. Public Health Hospital in Lexington,
Kentucky discovered that methadone was effective for easing withdrawal of individuals
suffering from opioid dependence (methadone had been discovered as a pain management
medication in Germany two decades earlier).269 Having learned of the research on methadone,
the AMA, ABA, and the Kennedy administration recommended prescribing methadone on an
experimental basis in clinics associated with hospitals. 270 During a study at Rockefeller
University, researchers (led by Vincent P. Dole) found that methadone could be used not only for
treating withdrawal symptoms but for long-term maintenance treatment. 271 Dole’s research team
experienced harassment from the Federal Bureau of Narcotics, but Dole argued that methadone
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maintenance treatment should be considered within the scope of physicians’ professional
practice; he did not face legal consequences. 272 By the late 1960, methadone maintenance
treatment was expanding to clinics affiliated with hospitals across the U.S. At proper dosages,
methadone blocked cravings, preventing individuals from attaining a “high” from other opioids,
and had minimal side effects. 273 Studies also demonstrated that methadone helped patients hold
jobs and rebuild relationships with family and friends who had become estranged. 274 However,
physicians generally continued to be uninterested in addiction treatment. In the late 1970s, the
U.S. House of Representatives recognized the fear the Harrison Act had instilled in physicians
when it said, “There are relatively few practicing physicians in the U.S. today who treat narcotic
addicts because of the uncertainty as to the extent to which they may prescribe narcotic drugs for
addicted patients."275
In the early, 1970s, methadone was approved by the FDA for treatment of opioid
dependence, and the federal government created a complex system of regulations for methadone
distribution in a closed network.276 For three decades, methadone was the only FDA-approved
medication for addiction treatment. Then in 2002, the FDA approved the U.S.’s second
pharmacological treatment for opioid dependence, known as buprenorphine (in the forms of
Subutex and Suboxone, which also contains naloxone as an abuse deterrent). Foreseeing
buprenorphine’s FDA approval, the DEA moved buprenorphine (previously approved as a
painkiller at a different dosage) from Schedule V to a more restrictive schedule III substance
under the Controlled Substances Act. Also foreseeing buprenorphine’s FDA approval, in 2000
Congress passed the Drug Addiction Treatment Act (DATA), requiring certification of
physicians and patient limits for office-based prescriptions.277
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In 2010, the FDA approved a third pharmacological treatment for opioid dependence:
extended-release naltrexone (Vivitrol), a monthly injection.278 Most recently, in May 2016, the
FDA approved a surgically implantable version of buprenorphine, Probuphine, which lasts up to
6 months at a time.279 Despite existence of these effective treatment methods, 12-step groups
continue to be the most common form of addiction treatment in the U.S., followed by mental
health therapy.280
In recent years, professional health organizations and U.S. government agencies have
encouraged the simultaneous use of multiple treatment modalities for addiction (a “multiple
paths approach”).281 For example, a health practitioner might encourage individuals with
dependencies to undergo buprenorphine treatment and cognitive behavioral therapy and to attend
a support group. In some treatment facilities, these different treatment models are even beginning
to overlap to the point of integration.282 For example, while support groups and MAT have rarely
overlapped historically, Methadone Anonymous, a support group for methadone treatment
patients using a 12-step program, spread in the 1990s. As a result, “recovery” from addiction
may now mean participation in any number of treatment modalities.283 Additionally, government
descriptions of addiction as a neurological disease and the re-characterization of addiction as a
chronic disease by the AMA may have somewhat improved public perceptions of MAT.284
D. The War on Drugs
In 1971, President Nixon declared a War on Drugs, largely in reaction to Vietnam
veterans returning to the U.S. using heroin.285 Nixon also created the DEA to coordinate antidrug efforts by federal agencies.286 However, Nixon believed that addiction treatment was as
important as prosecution of drug-related crimes. Under Nixon, more federal funds were allocated

43

to addiction treatment than had ever been before in U.S. history.287 Importantly, more funds were
devoted towards treatment than towards law enforcement.288
Nixon established a two-pronged approach to eradicating drugs: cutting supply and
decreasing demand.289 Cutting supply consisted of going after big-time drug dealers, primarily
those who brought drugs into the U.S. from abroad. Decreasing demand consisted of treating the
addiction that was driving so many drug purchases at home. Methadone treatment was
encouraged.290 During their tenure in the years following Nixon, Presidents Ford and Carter
largely followed the path Nixon had laid out for the War on Drugs.291
Reagan became president in an era when a subset of society viewed addiction as a
treatable disease but growing numbers feared and stigmatized drug addicts due to the supposed
“crack epidemic”. In the 1980s, media reports sensationalized crack-induced violence in innercities, further solidifying the public’s belief that drug use was always immoral. Federal agencies
and Congress enhanced criminal penalties.292 At the same time, Reagan slashed the federal funds
allocated to addiction treatment and significantly expanded the budget for drug-crime
prosecutions.293 The demand side of Nixon’s original War on Drugs policy was largely ignored.
State politicians followed suit, not wanting to be considered “soft on crime.”294 Many presumed
that severe criminal punishments would provide a strong disincentive, making addiction
treatment programs unnecessary, an attitude reflective of the Prohibition era.
Most infamously, in 1984 Congress passed the Anti-Drug Abuse Act, including
mandatory minimum sentencing guidelines.295 These guidelines bound judges to what many
contemporary scholars view as unjustly severe sentences for simple drug possession and lowlevel drug trafficking. Prior to mandatory minimums, judges were permitted to consider
circumstances of the crime when sentencing a defendant but no longer. Mandatory minimums
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led directly to exploding prison populations, such that the U.S. has more prisoners per capita than
any country in the world. In some cases, mandatory minimum sentences for drug trafficking
were higher than for murder.
In 1984, Nancy Reagan began her “Just Say No” campaign, which inadvertently
reinforced the idea that addiction is a matter of choice rather than a disease.296 The movement
focused on protecting white, middle-class children from drugs. However, once a child became
addicted to drugs, the “Just Say No” campaign offered no solutions. Even today, public schools
routinely invite speakers to talk to children about the dangers of drugs but rarely explain medical
options for treating addiction.
Under President George H. W. Bush, less than 1/3 of the Federal War on Drugs budget
was allocated for treatment297, in sharp contrast to the Nixon era’s funding priorities. Even
though funding for treatment slightly increased under President Clinton, the bulk of funding
continued to be directed towards law enforcement. However, cognizant of the racial
discrepancies in mandatory minimum sentencing guidelines, Clinton signed a law decreasing the
ratio of mandatory minimum sentences for crack (used predominantly by blacks) versus cocaine
(used predominantly by whites).
George W. Bush’s presidency continued to approach the War on Drugs through “tough
on crime” policies. Aware of rising overdoses from opioid painkillers, the federal government
took little action. Rather than focusing on treatment, the U.S. Drug Czar, the head of the Office
of National Drug Control Policy, targeted marijuana-related crimes and encouraged widespread
drug testing for disciplinary, not medical, reasons (as opposed to medical reasons). At the same
time, federal and state drug enforcement agencies underwent a significant militarization.
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President Obama’s presidency began to reorient the U.S. towards a public health
approach to the drug problem.298 The current Office of National Drug Control Policy describes
itself as pursuing “a public health approach,” sending a strong message that addiction is a
medical rather than a moral problem.299 The President’s 2016 Budget Submission to Congress
requested historic levels of funding for “health responses to illicit drug use.”300 The Obama
administration has heavily criticized mandatory minimums, but Congress has yet to completely
eradicate them, although it has persuaded Congress to repeal mandatory minimum sentences for
simple crack possession and to further diminish the discrepancy between other crack and cocaine
punishments.301 Significantly, the Department of Justice has told federal prosecutors to avoid
pursuing charges that would trigger mandatory minimums for low-level offenses, giving federal
prosecutors the official “go ahead” to circumnavigate them.302 President Obama has also
pardoned numerous incarcerated, non-violent drug offenders.303 Finally, the administration
created a Recovery Branch within the Office of National Drug Control Policy to focus on
expanding addiction treatment and decreasing addiction-related stigma.304 Though the tide is
finally turning towards prioritizing public health measures for addiction, the scars left by the War
on Drugs will take a long time to heal.
The War on Drugs has focused government resources on prosecuting drug offenders
rather than treating dependence, perpetuating the common misconception that drug dependence
is a personal choice and a personal failing.305 The U.S. has spent billions of dollars annually on
the War on Drugs and dedicates a tremendous amount of prison space to drug offenders.306
According to the Federal Bureau of Prisons, in December 2014, 48.7% of individuals in federal
prisons were incarcerated for drug offenses.307 Incarceration of drug offenders, especially nonviolent individuals, is one reason why the U.S. has the world’s highest incarceration rate.308
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II. Addiction, Self-Control and Willpower
A. American Values and Addiction
As described above, addiction has been stigmatized since the time of the Puritans, in part
because addiction appears to contradict the value of self-control. Addiction today continues to be
associated with immaturity, because control of one’s feelings and behavior is an important mark
of adulthood in American culture.309 Individuals are expected to “exercise invisible surveillance
of themselves and others” and to constrain their own desires, whether for food, drugs, or
money.310 Likewise, moderation continues to be a revered ideal in American culture. For
example, politicians still praise the American middle class more so than the lowest or highest
socioeconomic classes. Individuals with drug dependence, however, are unable to exert selfcontrol while using drugs due to their disease symptoms (e.g. severe psychological and physical
cravings, inhibited dopamine production). As a result, they are socially stigmatized by a public
who perceives lack of self-control as a character flaw.311
Individuals with drug dependence are also unfairly characterized as lacking willpower, or
the desire to stop using drugs.312 For example, a Gallup poll of individuals with an addicted
family member reported that most respondents believed that a lack of willpower was the main
cause of addiction, even though they also believed that addiction is a disease.313 Unfortunately,
those who hold this perception are less likely to recommend treatment to their family members,
perhaps because they assume that merely deciding to stop using drugs is effective. 314 Even
individuals who obtain treatment often do not understand addiction is a disease and feel guilty
for being unable to follow through on their desire to stop using drugs.315
Why is willpower insufficient for overcoming addiction? “Addiction” comes from the
Latin root “addicere,” which means “to surrender to a master.” According to modern science,
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this is exactly what happens to the brain: it is hijacked by the abused substance (the master).
Neural networks reform, physical tolerance builds, and natural dopamine production declines.
The individual becomes unable to feel average levels of euphoria without the drug, even from
activities that had previously produced euphoria naturally, such as spending time with lovedones or eating a favorite food. Regardless of how the addiction started (e.g. whether by choosing
to “get high” or by being prescribed an opioid painkiller for chronic pain), the individual
experiences a physical and psychological compulsion to take drugs. Eventually the drug use
stops being about “feeling good” and starts being about “not feeling bad.” When the individual
abstains from drugs, he or she feels psychologically and physically miserable, experiencing
painful withdrawal symptoms.
The combination of withdrawal symptoms, cravings, and low natural dopamine levels
leads the individual to desperately seek more drugs. Environmental stress or triggers may
increase the desperation. As a result, medical organizations rigorously oppose the idea that
addiction is a voluntary state. According to Thomas McLellan, Editor-in-Chief of The Journal of
Substance Abuse Treatment and a former U.S. Drug Czar, “At some point after continued
repetition of voluntary drug-taking, the drug ‘user’ loses the voluntary ability to control its use.
At that point, the ‘drug misuser’ becomes ‘drug addicted’ and there is a compulsive, often
overwhelming involuntary aspect to continuing drug use and to relapse after a period of
abstinence.”316 Nora Volkow, the Director of the National Institute on Drug Abuse, has most
succinctly described the relationship between addiction and choice:
Choices do not happen without a brain—it is the mechanism of choice. The
quality of a person’s choices depends on the health of that mechanism. However
much we may wish that a person’s choices were free in all instances, it is simply
a fact that an addicted person’s failures in the realm of choice are the product of
a brain that has become greatly compromised—it is readily apparent when we
scan their brains.317
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The common perception that addiction is a “choice” is psychologically harmful and stigmatizing.
Individuals with opioid dependence cannot merely exert self-control over their dependency.
They may have the willpower to stop using drugs but lack the physical and psychological ability
to accomplish this desire. The conception that addiction is a choice also leads to the general
public and policy makers being less willing to help those who are dependent on drugs.318
It is dangerous to encourage individuals with drug dependence to recover through
willpower alone. If individuals with drug dependence merely abstain from drug use (applying
willpower alone) their tolerance lowers, significantly increasing the risk of dying from an
overdose if they resume drug use. And studies show that individuals with opioid dependence
who apply willpower alone (without other evidence-based treatment) almost always relapse.
Even if they do not overdose as a result of relapse, they are likely to experience low self-esteem
and guilt for having failed. Low self-esteem is related to low self-efficacy319; and low selfefficacy may be related to lower rates of help-seeking behavior.320
B.

The Relationship between Pharmaceuticals and Willpower

Americans have a complex relationship with pharmaceuticals. Despite being relatively
healthy (especially compared to individuals in many developing nations), they take more
pharmaceuticals than citizens of any other nation and yet sometimes fiercely judge one other for
taking pharmaceuticals. Such social judgments depend largely on what condition the
pharmaceutical is meant to treat, including whether that condition is seen as “voluntary” or
“involuntary.” Americans assume that “voluntary” conditions do not need to be treated with a
pharmaceutical since a resolution to fixing this negative voluntary behavior should be sufficient.
For example, someone who created a problem through lack of self-control presumably should
develop the willpower to resolve the problem through self-control and then follow-through.
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Obesity is a classic example of a condition for which Americans have a negative opinion
of pharmaceutical usage. Culturally, obesity is constructed as a condition for which one is
personally to blame, even though it can result from medical conditions such as hypothyroidism
and genetic predisposition. Thus, it may be that any medicalized obesity treatment may attract
societal disapproval. For instance, Americans have negative views of gastric bypass surgery
despite the fact that gastric bypass surgery has been shown to extend the life-expectancy of
morbidly obese individuals and to prevent many harmful diseases.321 Instead, friends and
relatives may advise morbidly obese individuals to lose weight through behavioral change. One
study of patient behavior towards patients with asthma found that physicians were more likely to
recommend pharmaceutical treatment for asthma to patients with normal weight than to patients
with obesity (who were more likely to receive advice about losing weight).322 On the other hand,
Americans have few qualms about an individual taking pharmaceuticals to treat a genetic disease
such as cystic fibrosis, even if behavioral or dietary changes could alleviate symptoms.
Like obesity, Americans tend to misconstrue addiction as an individual’s fault that
originates solely from a lack of willpower or from misapplied will power; an individual with the
ability to choose not to be an addict in fact chose to do so.323 From this vantage point, addiction
treatment is not necessary; addicts simply need to make a different choice. Even some
Americans who claim to support addiction “treatment” assume that treatment means increasing
willpower—not an outlandish assumption, given the “12-steps” of AA and NA that stress taking
responsibility and abstinence. An Indiana prosecutor recently announced a new “treatment” for
incarcerated individuals with dependency consisting entirely of education about why drug use is
harmful. These treatment models presume that individuals are dependent because they are did
not know enough to make a right choice and so chose wrongly out of ignorance. This means, of
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course, that an individual’s tendency to make wrong choices can be easily corrected with
education.
If drug addiction is the result of poor choices, then counseling and support groups are
acceptable treatments because they teach skills that one can use to make a different choice to
avoid drugs. But pharmaceutical treatments are an ill fit for this paradigm of increasing
willpower because they do not incorporate education and skill building. Following this logic,
pharmaceuticals may even prevent individuals from learning to make the right choice by simply
eliminating their drug cravings! Essentially pharmaceuticals are perceived as too easy a solution
to a problem that a person must “work” to overcome. The idea of taking a pharmaceutical (e.g.
buprenorphine) indefinitely without doing the real “work” to overcome addiction is perceived as
especially problematic. For example, some individuals describe methadone as merely a
“crutch.”324
In summary, even Americans who view addiction as a disease may also assume that
addiction originates from misapplied willpower, implying that education and willpower building
is the best or only appropriate treatment. Many Americans also view pharmaceuticals as a “cop
out,” preventing the individual from learning how to choose to properly apply willpower. But
every element of this American is false. First, addiction is not a disease of misapplied willpower;
even though drug abuse may start voluntarily through misapplied willpower, eventually cravings
and behaviors become compulsive, illustrating that willpower is actually minimally involved). 325
Second, there is no scientific basis for believing individuals with drug dependence must be
forced to work harder to overcome the disease rather than taking the supposedly “easy way out”
through pharmaceuticals. The amount of effort an individual puts into overcoming addiction is
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irrelevant if the disease is compulsive since by definition compulsion is an irresistible urge which
effort cannot overcome.
Rather than a disease of misapplied willpower, addiction is a disease of lack of control
regarding drug use, primarily due to severe physical and psychological cravings and withdrawal
symptoms.326 Even if an individual possesses willpower, she may lack self-control around drugs.
Interestingly, MAT can actually be seen as a way of increasing self-control as it blocks
compulsive cravings, allowing individuals to focus on other activities and to more easily acquire
and apply skills learned through counseling.
III. Immorality and Drug Addiction
Today, professional medical organizations and the U.S. government call addiction a
disease, but much of the public continues to perceive it as a moral failing—a perception that is
shockingly held by many health practitioners and criminal justice administrators. The link
between addiction and morality persists today in addiction treatment facilities and providers who
center treatment on the twelve-step philosophy, in which MAT is often perceived as irrelevant or
harmful.
A.

Legacies of the War on Drugs

The War on Drugs also delays help-seeking behavior for addiction in at least three ways:
stigmatizing individuals with drug dependence, causing them to hide their illness; causing
treatment delays out of fear of being caught; and minimizing ability to pay for treatment.
Because drugs are illegal, many Americans believe that drug dependence and individuals with
drug dependence are immoral.327 This conception causes society to stigmatize the individuals
with drug dependence, and individuals with drug dependence may internalize this stigma,
possibly resulting in self-isolation and depression.

52

Individuals with stigmatized medical problems are particularly likely to hide these
diseases and not seek medical treatment,328 as with HIV/AIDS.329 Persons with dependence
problems do not want their friends, family, and physicians to think of them as criminals or moral
failures.330 Those who do not understand privacy laws may be afraid to admitting drug
dependence to a doctor or a counselor. Individuals convicted of drug possession, including
marijuana, are ineligible for food stamps, public cash assistance, student educational loans, and
(in some states) a driver’s license, so the stakes may be very high.331 Additionally, individuals
convicted of drug possession have a criminal record, making it difficult to find employment,
especially with health insurance. And in most states at least one form of MAT is not covered by
Medicaid, requiring individuals to pay out of pocket. Ironically, some individuals unable to
obtain jobs due to criminal records may feel that they have no other option than to sell drugs
illicitly. Some physicians whom I have interviewed describe knowing patients who sell drugs in
order to afford treatment for drug addiction.
B.

Treatment and Morality

AA and NA fit comfortably within the idea of morality-related abstinence and perpetuate
the assumption that, unlike other diseases, addiction is related to morality.332 Even though AA
and NA officially call addiction a disease, these groups encourage their members to seek
forgiveness, strive for moral purity, and forge a relationship with a Higher Power.333 Several
tenets of NA have strong moral undertones:
4. We made a searching and fearless moral inventory of ourselves.
5. We admitted to God, to ourselves, and to another human being the exact
nature of our wrongs.
6. We were entirely ready to have God remove all these defects of character.
7. We humbly asked Him to remove our shortcomings.
8. We made a list of all persons we had harmed and became willing to make
amends to them all.
9. We made direct amends to such people wherever possible, except when to do
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so would injure them or others.
10. We continued to take personal inventory and when we were wrong promptly
admitted it.334
AA describes its treatment as based on a “spiritual awakening” (e.g. in step 12). Members
appear to concur. A study of over 500 AA members found that the most common perception of
AA’s purpose was “to help alcoholics develop a spiritual way of life” (80.2% of respondents),
while the second reason was “to help alcoholics not to drink” (64.4%). Furthermore, over 90%
believed that developing a relationship with a higher power was necessary to be sober. Members
most often described the “higher power” in AA discourse as a Judeo-Christian god, but nonreligious understandings of this term also exist. Given AA’s clear emphasis on spirituality, it is
interesting that over 90% of respondents described alcoholism as a progressive disease.335
Relationships are also important to recovery in AA and NA, implicating the moral
dimensions. Just as sin is separation from God in Christianity, separation from a Higher Power in
AA both causes disease and further separation.336 Recovery involves repairing this relationship
through improving personal character, including reforming relationships. It is insufficient to
merely abstain from the abused substance. According to AA tenets, an alcoholic who continues
to exhibit character defects such as self-centeredness is not truly sober but merely not
drinking.337 Other character defects that might preclude real sobriety include self-pity, anger, and
resentment, which suggest that members have not turned their lives over to a Higher Power.338
Recovery also requires service to others (see Step 12). Within AA and NA, resuming substance
use is a moral action because it may harm relationships with others, the fellowship between
members, and the relationships between members and a Higher Power.339 AA literature includes
the following statement: “So our troubles, we think, are basically of our own making. They arise
out of ourselves, and the alcoholic is an extreme example of self-will run riot”—meaning
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following one’s own desires rather than relying on a Higher Power. According to historian
Ernest Kurtz, “AA does not treat alcoholism, it treats the alcoholic.”340 AA’s and NA’s focus on
morality makes it particularly attractive to criminal justice administrators who are trying to
transform “criminals” into moral citizens.
Some studies have shown that NA and AA may help individuals to avoid drug use,
especially those who are highly motivated. However, one study found that psychological wellbeing and decreased craving is correlated with regular attendance in the support group, not with
following the spiritual steps.341 Therefore, a support group that was not centered on morality
might also help increase abstinence. Other support groups do exist, but they are few and far
between. Unfortunately, the morality-focused principles of NA and AA reinforce the notion that,
even if addiction is a disease, it is somehow very different from other chronic diseases.
Addiction is the only disease called a “disease” but treated with morality-based principles.
Imagine, for example, if individuals with STDs were encouraged to attend morality-based
support groups. In the 21st century, most Americans would be outraged! However, treating
addiction as a morality-based disease does not seem strange.
C.

MAT and Morality

Many Americans continue to assume that drug dependence is a sin and dependent
individuals are immoral.342 Even many Americans who regard substance dependence as a
disease believe that it is also a moral condition.343 Therefore, treating drug dependence appears
to require treatment reforming morality, not medication. Obtaining a prescription from a
physician does not require seeking forgiveness, making amends, or developing relationships or
improving spirituality. If one understands addiction primarily as immorality, then prescriptions
are superfluous at best or harmful at worst if they prevent the person from reforming her morals.
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In NA philosophy, for example, an individual should replace her dependence on drugs with
dependence on a Higher Power; therefore, some NA members may fear that accepting MAT is
equivalent to replacing one drug dependence with another, preventing individuals from forming
an ideal relationship with a Higher Power.
Thus, individuals who perceive drug use as immoral and MAT as “just another drug” are
also likely to regard MAT as immoral. Despite methadone’s proven benefits, in the 1990s in
New York City, then-Mayor Rudy Giuliani called methadone treatment an “immoral solution” to
opiate dependence.344 But MAT is not “just another drug.” One reason for this misconception is
the perception that patients undergoing MAT are “drugged” and that they will appear sluggish
and non-functional. This image of methadone patients may be spread by movies. Studies show,
however, that patients properly maintained on methadone do not appear drugged and that their
motor skills and reflexes are not impaired, so that they can drive and operate heavy machinery. 345
Additionally, some methadone clinics have gained notoriety in the public eye for being badly
managed, with participants receiving insufficient doses (allowing them to “get high” from
another drug only a few hours later) or attracting drug dealers just outside the front door.
Because methadone clinics are isolated from the general practice of medicine, most Americans
have had no experience seeing methadone patients, creating fertile ground for misconceptions to
spread.
Conflation of addiction with immorality may negatively affect treatment professionals as
well as patients. Physicians who primarily treat individuals with drug dependence are sometimes
stigmatized as if they aided and abetted criminal activity. Such stigmatization discourages
physicians from entering the addiction treatment field. Studies also show that some physicians
harbor biases against their own patients who suffer from SUD since they presume that these
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patients are making an immoral choice to remain addicted rather than to improve their health.346
When physicians harbor such biases, they may be unlikely to pursue addiction treatment-related
education, such as training required for buprenorphine certification, and may unconsciously
discourage patients from asking about MAT or being honest regarding relapses.
D.

Eliminating the Link between Addiction and Immorality
1.

Reforming Criminal Law

The federal government must change its battle tactics in the War on Drugs, focusing
instead on public health initiatives rather than law enforcement. In fact, the government should
stop referring to a “war” at all. Even though drugs are the supposed enemy in the war, by
association individuals with drug dependence become considered the enemy as well, rather than
individuals suffering from a disease. Little empirical evidence exists that the War on Drugs has
been effective at lowering drug use, while significant evidence suggests it has increased the
stigma of drug dependence.347 Currently, addiction treatment is severely underfunded within
every criminal justice institution, including drug courts, prisons and jails. Money saved from
slashing War on Drugs law enforcement funding could be used to expand quality treatment
programs in the federal criminal justice system as well as to provide grants to states for
developing their own treatment initiatives. Financial savings could also be used to develop
incentives for private sector and academic development of drug dependence treatments, such as
grants to pharmaceutical developers and universities. Currently only three FDA-approved
treatments for opioid dependence exist, and no treatments exist for cocaine, marijuana, or
methamphetamine dependence; significantly more research and development in addiction
treatment is needed. Finally, funds could be used to educate the general public about evidencebased treatment, including public service announcements.
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Prosecutors should also stop targeting low-level drug offenders. Throughout the War on
Drugs, the DEA has targeted low-level drug offenders in the hopes that they will reveal the
names of higher-level traffickers through plea bargains. This strategy, however, has
overwhelmingly failed because individuals at these lower levels of simple drug possession are
unlikely to have information about higher-level dealers. Instead, these low-level offenders obtain
a criminal record, hampering their ability to obtain treatment if they are unable to obtain a job
with health insurance or to afford treatment. Furthermore, targeting low-level drug offenders
reinforces the public perception that drug dependents are immoral. Multiple judges whom I
interviewed stated that low-level drug traffickers commonly sell drugs to fund their own drug
habits, suggesting that many of these individuals need treatment more than prison time.
2.

Changing How We Talk About Addiction

Over centuries, references to describe dependent individuals have been morality-laden. In
the mid-1890s, the term “dope fiend” became common, with “fiend” being a German derivative
meaning “wicked” or “hated person.”348 Historically, individuals who recovered from drug
dependence were described as “redeemed”, “repentant”, “straight”, and “reformed,” and many
treatment centers were referred to as “reformatories.”349 Today, Americans routinely perceive
individuals with drug dependence as immoral.
The idea that individuals with dependence are immoral is reinforced through various
means, including discourse. According to William White, “The language of addiction is a coded
language. Each word emerges as a means of signaling nuances of one’s personal, professional
and political values and affiliations. The rhetoric chosen…rationalizes particular types of
interventions into their lives.”350
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In the past and present, the words “clean” and “dirty” have been used to refer to
individuals with drug dependence. Cleanliness has been synonymous with moral purity and
dirtiness with moral impurity. Even today, treatment professionals and criminal justice
administrators’’ sometimes refer to drug screens as “clean” (meaning drug-free) or “dirty”
(meaning suggesting drug use). In the medical context, such language is improperly used to refer
to drug use. For example, a diabetic whose urine is screened for sugar does not have her urine
referred to as “clean” or “dirty.”
Some addiction terms, however, have had a disease connotation, such as “cured,”
“recovered,” and “recovering”. Today the preferred language is “recovered” or “recovering,” in
keeping with the medical understanding of addiction as a chronic disease that is rarely cured but
can be effectively managed.351 Professional health organizations and the government should
strongly encourage treatment professionals and criminal justice administrators to use medical
rather than moral terms when discussing drug dependence instead of “clean” and “dirty” in
reference to drug screenings.
3.

Decreasing Stigma

Mental health disease are usually more stigmatized than physical diseases, possibly
because the root MHDs is more difficult for the public to see or understand; and among MHDs,
addiction is one of the most stigmatized diseases.352 Even persons who believe that addiction is a
disease continue to stigmatize individuals with drug dependence by, for example, not wanting to
marry them out of fear of passing a genetic predisposition onto children.353 Changing cultural
biases takes time, but steps can be taken to begin the process of destigmatizing drug dependence
and MAT.
Three primary modes for fighting stigma exist: advocacy, public and professional
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education, and increasing inter-personal contact between stigmatized and non-stigmatized
groups. Public service announcements efficiently provide information to the public and may
influence public attitudes. The federal government has funded numerous public service
announcements for preventing drug use (most famously Nancy Reagan’s “Just Say No
Campaign”). These announcements uniformly provide information about prevention only; they
do not provide information about treatment. The model is wrong, especially while we are in the
midst of the opioid overdose crisis. Public service announcements should provide information
about prevention and treatment. For example, the announcement could direct individuals to a
website with a range of evidence-based treatment methods. Ideally, the website should also
include a searchable database of treatment providers for each zip code or city.
Increasing inter-personal contact between stigmatized and non-stigmatized groups is
important for decreasing stigma for the stigmatized group. The contact often encourages the nonstigmatized group to humanize the stigmatized group. Unfortunately, open inter-personal contact
is particularly difficult in the context of addiction. Unlike members of some other stigmatized
groups (e.g. individuals with darker skin), individuals with drug dependence are not easily
recognizable. They can easily hide the source of their stigma from co-workers, friends, and
family.
Additionally, exposing the general public to individuals with drug dependence in “active
addiction” (meaning currently using drugs) is not sufficient; the public should also be exposed to
individuals with drug dependence who are undergoing treatment or are in long-term recovery. If
the public is only aware of individuals in active addiction, then the public is unlikely to
appreciate the benefits of treatment. The public is also more likely to see someone in the midst of
cravings or engaging in actions not considered socially acceptable (e.g. prostitution or theft in
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order to purchase more drugs). Such exposure could further increase stigma of individuals with
drug dependence rather than decreasing it. Unfortunately, unless addiction is quickly destigmatized (unlikely), most individuals suffering from drug dependency will continue to hide
their status and contact between the stigmatized group and non-stigmatized group will remain
minimal. Fortunately, celebrities who voluntarily “come out” as being individuals with drug
dependence undergoing treatment or being in long-term recovery can form a source of exposure
between the stigmatized and non-stigmatized groups. If the celebrities’ stories are discussed in
the mass media, then information can be quickly diffused to the general public. Ideally, such
stories would include information about prevention and treatment. In other words, such stories
could serve as “public service announcements” as well.
IV. Abstinence-Only Treatment
Today abstinence-only treatment is the norm in the U.S and is deeply entrenched in U.S.
culture.354 While studies suggest that abstinence-only treatment may be effective for 30-50% of
long-term dependent cocaine users, studies suggest that it is significantly less effective for
individuals with opioid dependence.355 In general, studies estimate that behavioral treatment
without medication prevents relapse in only 20% of individuals with drug dependence.356
Abstinence-only treatment goes hand-in-hand with sociocultural and individual biases against
MAT. Abstinence-only treatment can refer to treatment without any form of MAT, or treatment
without agonist MAT (in which buprenorphine and methadone are prohibited, but Vivitrol is
allowed). Abstinence-only treatment facilities typically provide mental health therapy and
support group participation but not MAT. Such facilities may also prohibit patients from starting
MAT elsewhere or refuse to accept patients currently undergoing MAT. Individual practitioners
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such as counselors often have an abstinence-only treatment philosophy, and will not recommend
any form of MAT or agonist MAT to patients.
This section begins by discussing why abstinence-only treatment is the dominant
treatment in the U.S., and examines the discourse associated with this philosophy. It then argues
that the conflict between abstinence-only treatment and MAT stems from differing notions of
sobriety and recovery, and fears about MAT grounded in inaccurate information. Finally, the
chapter examines how abstinence-only treatment stigmatizes MAT patients.
A.

Comparing the Frequency of MAT versus Abstinence-Only Treatment

Abstinence-only treatment is the norm in SUD treatment in the U.S.; less than 45% of all
treatment programs (private and public) offer any form of MAT.357 Even among treatment
centers that offer MAT, its actual implementation remains very low. Knudsen et al. found that
only 34% of opioid-dependence patients in programs that offer MAT actually receive MAT.
Naltrexone treatment is particularly limited.358
Treatment program administrators and staff have widespread distrust of MAT,
contributing to its under-provision.359 Counselors form the majority of professional SUD
treatment providers, but a large minority also philosophically oppose MAT. One study found that
approximately 50% of SUD counselors either have not heard of MAT or are philosophically
opposed to it. In another study of all U.S. state agencies responsible for funding SUD treatment,
one state agency director explained, “[Barriers to MAT adoption] are mostly cultural with some
of the substance abuse providers …saying clients should just quit and shouldn’t have to be on
naltrexone…or people should just quit and not be on methadone and buprenorphine.”360
Over 90% of treatment organizations programs are centered on the 12-steps of AA and
NA, known as the Minnesota Model of treatment organization. Unfortunately, 12-step centered
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programs tend to prohibit MAT. The hegemony of abstinence-only and 12-step discourse (in
SUD treatment centers throttles any chances for MAT discourse. Treatment programs provide
limited or no information about MAT to patients. One study found that patients tended to learn
about MAT from other patients for whom abstinence-only treatment had failed, rather than from
practitioners or treatment programs.361 Information patients learned about MAT from 12-step
groups is often inaccurate, such as the idea that MAT is just a “crutch” rather than a treatment.362
Some patients know that abstinence-only treatment is not working, but continue to participate
due to ignorance of or lack of access to MAT.363 In one study where individuals with opioid
dependence were interviewed about their treatment pasts, the researcher concluded:
[Dominance] of the discourse was evidenced throughout the subject’s [sic]
treatment histories by the preponderance of references to NA, AA, or other 12step recovery groups. In nearly every case, whenever the possibility of attending
“treatment” became an option it was inevitably 12-Step based, and those who
were seeking alternative treatment models were consistently faced with a lack of
access and information.364
B.

Differing Conceptions of Sobriety and Recovery

Understandings of sobriety and recovery differ between abstinence-only philosophy and
medical (MAT-accepting) treatment philosophy differ. Although “sobriety” is a commonly used
term, it lacks a standard definition.365 Abstinence-only proponents view sobriety as complete
abstinence from any mind-affecting substances, including MAT or agonist MAT. In contrast,
medical view proponents understand sobriety as “control, balance, and moderation” (which is
similar to the dictionary definition of sobriety).366 The medical treatment philosophy regards
MAT as an appropriate treatment because it improves individuals’ functionality so that they can
express control, balance, and moderation.
The meaning of “being in recovery” is likewise disputed. According to the abstinenceonly philosophy, being in recovery means abstaining from any mind-affecting substance,
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including opioids in agonist MAT. Therefore, one cannot be in recovery while using agonist
MAT. At most, one could be making a step towards recovery. 367 Interestingly, many abstinenceonly treatment centers do permit pharmacological treatments for other MHDs, such as SSRIs for
depression. On the other hand, within the medical view, recovery more commonly means “not
abusing substances.” Therefore, MAT is permitted so long as it is taken as prescribed and no
substances are abused. Given that addiction is a disease, taking a medication for addiction as
prescribed falls within the colloquial definition of recovery.
“Recovery” can also be understood as a broader concept than just abstinence from mindaltering substances or drug abuse. It sometimes takes on a more holistic definition, meaning that
a recovering individual is no longer abusing substances, has improved overall health, and is
reintegrating into the community.368 Many organizations and practitioners accept this broader
understanding of recovery, whether or not they adhere to an abstinence-only philosophy. In AA
and NA, recovery includes an additional component--spirituality, defined as being in a
relationship with a Higher Power). Treatment organizations and practitioners whose treatment is
centered on AA/NA likely include spirituality in their definition of recovery as well.
In another semantic complication, treatment facilities and practitioners sometimes
distinguish between “remission” and “recovery.” Remission is the decline in pathological
symptoms, here, drug abuse. Recovery, on the other hand, is the addition of positive health and
integration into community life, as well as the decline in pathological symptoms.369 Practitioners
who believe that remission and recovery are different concepts may believe that MAT can cause
remission but not recovery, perhaps unless support groups and/or counseling are used as well.370
Obviously, if spirituality is a necessary component of recovery, as understood within NA and
AA, then MAT alone is insufficient. But MAT alone could be understood to improve community
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integration and overall health by decreasing drug abuse and recidivism.
C.

MAT and “Recovery”

Many organizations and practitioners who provide MAT encourage counseling and/or
support group involvement, assuming that MAT alone is insufficient for complete recovery.
They are probably correct in many, but not all, cases. For example, a patient whose drug
dependence is related to his PTSD is more likely to completely recover when MAT and
counseling for PTSD are provided together. Otherwise, without counseling for PTSD, the patient
may try to self-medicate with other drugs like cocaine, methamphetamines, or other drugs whose
effects are not blocked by MAT for opioid addiction.
However, interviews with health practitioners and administrators, I have often heard
about policies that coerce MAT patients into other treatments under the guise that recovery is
impossible without them. For example, treatment centers tell patients that they can only receive
MAT if they also attend counseling and/or support group treatment. Patients who disagree with
the policy are not provided with MAT. Such policies take the ideal of recovery to an extreme. It
is contrary to harm-reduction principles and patient-centered care, both of which suggest that
practitioners should meet a patient “where he or she is.” Such policies also unfairly imply that
counseling/support groups are more important for recovery than MAT; because patients are not
required to undergo MAT in order to participate in them.
Three physicians whom I interviewed in Indiana stated that the treatment facility in
which they work required patients to attend counseling and support groups to access MAT. If
patients failed to attend sessions, they cannot access MAT. The policy applies even if urine
screenings indicate abstinence from drug abuse, suggesting that MAT is working. Each of the
three physicians expressed discomfort with the policy, because when they cancel MAT
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appointments they worry that the patient is at greater risk of relapse and overdose.
In light of MAT’s validated effectiveness, providers and facilities should encourage
rather than coerce patients into using additional treatment modalities. Multiple arguments against
coercion in counseling and support groups exist. First, coercion into multiple treatment
modalities is rare (or non-existent) for other chronic diseases. For example, diabetes patients are
not told that their insulin treatment will cease if they fail to see a nutritionist and exercise
regularly. Primary care physicians do not withhold antidepressants from patients who fail to
attend counseling. Second, studies show that MAT may improve patients’ ability to partake in
counseling and support groups at a later date by stabilizing physical cravings and preventing
euphoria from drug use. Therefore, patients may be better off in the long-run if they begins MAT
and then later add additional treatment modalities. Third, even without supplementary
treatments, MAT is effective. In fact, as compared to counseling alone, MAT by itself is more
effective at promoting abstinence from drug abuse. But if treatment organizations only allow
MAT for patients in counseling and support groups, then patients who resist these methods will
be left with no treatment at all, . Finally, I have never heard of requirements that patients
attending counseling or support groups must also participate in MAT. Therefore, MAT as a
treatment modality is singled out unfairly.
DATA requires buprenorphine providers to have the capacity to refer patients for
counseling, but it does not require patients to attend counseling in order to access treatment. It is
possible that some health practitioners are confused and assume that MAT provision is illegal
without counseling. Clarification of this point in widely-read professional literature and MAT
trainings help dispel misconceptions.
D.

Other Misconceptions about MAT
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In addition to the misconception that MAT hinders sobriety, I have encountered other
common misconceptions about MAT among practitioners, treatment organizations, criminal
justice administrators, and policy makers. These common misconceptions are assumptions that
MAT prevents autonomy, concern about long-term use of MAT, and fear of illicit activities
related to MAT (i.e. diversion or abuse of MAT).
1.

MAT and Autonomy

According to Gomart, conventional addiction discourse frequently positions the drug user
as a slave of the drug in contrast to an abstinent “autonomous liberal agent.”371 Practitioners who
adhere to abstinence-only philosophy may assume that individuals cannot make autonomous
decisions and are “slaves” unless they are abstinent from all opioids, including agonist MAT.
The notion of “freedom” (without opioids) versus “slavery” (with opioids) obscures the
complicated way in which medications and individuals interact to encourage agency and
autonomy.372 Because MAT reduces cravings and eliminates rewards from opioid abuse by
activating the opioid receptor and preventing a “high”, one could say that MAT encourages
freedom rather than slavery; MAT ends physical cravings, a source of compulsion or “slavery.”
The individual has greater agency because he can focus on non-drug-seeking tasks.
Some journalists and scholars have called methadone “liquid handcuffs,” because once
the individual ceases taking methadone for addiction, cravings and the ability to “get high”
return. This argument is unfair, because many (if not most) medications for chronic diseases
could be interpreted as “handcuffs.” Schizophrenia medication could be described as “handcuffs”
for schizophrenia patients, because when they stop taking the medication negative symptoms
recur, or one could describe insulin as “handcuffs” for diabetes patients, because when they stop
taking insulin, negative symptoms will recur. However, our culture seems far more concerned
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about medication for addiction treatment. Why?
The Protestant work ethic has been improperly applied to chronic diseases, especially
addiction. It suggests that one should overcome addiction by “working harder,” not by taking
medication, which can be seen as laziness and inauthentic sobriety. If a dependent individual
takes a medication indefinitely, the misconception goes, then when will they ever do the “real
work” of overcoming addiction? Many counselors whom I interviewed implied that the “real
work” of overcoming addiction was going to counseling and support groups rather than taking
medication. I have also routinely heard this sentiment in interviews with criminal justice
administrators.
The American public seems to project the Protestant work ethic onto addiction even more
so than other chronic diseases, assuming that addiction stems from a lack of willpower373,
correlated with laziness. They assume that if addicted individuals “willed” themselves to stop
using drugs, they would be able to stop; when addicted individuals cannot stop using drugs, they
are thought too lazy to apply willpower.374 MAT is perceived as a crutch, allowing addicted
individuals to remain lazy and not do the real work of recovery. The longer the individual
remains on MAT, the lazier he or she appears.
2.

Concerns Regarding Long-Term Use of MAT

One of the most common questions I receive about my research is, “Will people who take
MAT need to be on it for their entire lives?” People usually ask me this question with profound
concern, as if the thought of someone being on medication for life is extremely distressing, even
though it is common for other diseases. The short answer to this question is that it depends on
the person. Some patients will need medication for a long-time; others will not. A consensus
exists in the medical literature that long-term use of MAT agonists is better than short-term use
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(few studies regarding long-term use of Vivitrol exist yet due to its recent FDA approval). Even
though buprenorphine and methadone significantly reduce illicit opioid use, 90% of patients
relapse after tapering from buprenorphine375, and 80% of patients relapse within one year after
tapering from methadone.376
According to interviews I conducted, physicians are not typically worried about longterm use of MAT; if they are, it is typically a question of whether MAT has long-term
physiological side effects of the medication (e.g. liver damage). On the other hand, criminal
justice administrators (e.g. drug court judges) and counselors routinely worry about long-term
use of MAT due to concern that it delays “real” recovery or sobriety. When I ask drug court
judges whether participants can graduate from drug court while under treatment with agonist
MAT, a large minority say “no,” because they believe that the participant is not yet “sober.”
3.

Concerns of Diversion and Abuse of MAT

This section will discuss how patients, professionals and criminal justice systems address the
problem of diversion of buprenorphine and methadone.
i.

Buprenorphine

Like any medication with an opioid ingredient, buprenorphine can be abused and cause
overdoses. As buprenorphine use has increased in recent years, so has the risk of accidental
overdose or accidental ingestion by children.377 However, buprenorphine overdoses are rare
relative to heroin, oxycodone, or methadone overdoses,378 and the majority of persons prescribed
buprenorphine do not abuse or divert it. There are two reasons for this. First, the partial muantagonist nature of buprenorphine prevents the patient from experiencing euphoria from taking
any additional opiate, including extra buprenorphine).379 Second, buprenorphine is far less
potent than heroin, oxycodone, methadone, and other common opiates.380 Unfortunately,
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negative media articles that have “overstated the medication’s risk and overhyped the tendency
of it to be sold on the black market” have caused some policy makers to become suspicious of
expanding access to buprenorphine.381
Policy makers are particularly concerned that individuals who illicitly access
buprenorphine, such as by purchasing it on the street, are at greater risk for overdose for many
reasons, including not knowing what ingredients it has been mixed with and what dose is safe.
They are also concerned that individuals who purchase buprenorphine on the street may be using
buprenorphine to “get high” in contrast to individuals seeking buprenorphine treatment through
legal channels. Some major newspapers have published articles regarding buprenorphine’s
diversion and abuse, possibly discouraging physicians from prescribing it and policymakers from
making it more widely available.382
Law enforcement agencies across the nation have encountered increasing amounts of
diverted buprenorphine being sold on the streets. Like policymakers, law enforcement may
assume that such buprenorphine is purchased primarily for the purpose of “getting high.” But
recent studies have found that black market purchasers are more likely to buy to help themselves
become sober, seeking treatment rather than to a “high”383; epidemiologic evidence suggests that
injection drug users and heroin users are more likely to illicitly purchase buprenorphine as selftreatment.384 These individuals may find it easier to purchase buprenorphine illicitly than to
obtain a doctor’s appointment.385 The bizarre fact that a black market has developed for
treatment medication points to the high demand for treatment relative to the number of available
providers.386
Health practitioners’ attitudes about buprenorphine diversion are nuanced. One survey of
physicians in 2003 found that 44% believed patients purchased buprenorphine illicitly to manage
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withdrawal, 34% for maintenance until treatment, 17% to try it out, and 7% to “get high.”387 A
2009 survey of 339 health practitioners working in addiction treatment programs, half of whom
were physicians, found that the median response to questions of diversion concern was “neutral”;
participants neither agreed nor disagreed that buprenorphine-naloxone diversion was a dangerous
problem.388 Nearly two-thirds of clinicians believed that diverted buprenorphine-naloxone was
used to prevent withdrawal or when people cannot obtain their drug of choice.389 Clinicians who
worked with patients treated with buprenorphine-naloxone were significantly more likely to
believe that diversion occurred primarily from limited treatment access390 and were less likely to
perceive diversion as dangerous.391 Their largest concern was that it could lead to overdose. The
study authors point out that “if use of illicit buprenorphine-naloxone occurs mainly a) among
treatment-seekers with history of injection drug use or with substantial physiological
dependence, and b) because of inadequate access to treatment or withdrawal prevention, then
diversion may ironically decrease community opioid overdoses.”392
Indeed, other recent studies have found that illicit buprenorphine purchases occur
primarily among treatment seekers and injection drug users393 and that treatment access is
limited.394 A 2010 survey of illicit buprenorphine purchasers concluded, “[T]he results of this
study suggest that demand for illicit buprenorphine is driven by people trying to avoid
withdrawal and to reduce cravings; these results do not support the position that buprenorphine
users are trying to attain euphoric effects.”395 Another 2015 survey of legal buprenorphine
patients found that 84% perceived buprenorphine diversion as mostly positive and 77%
perceived it as a morally right, altruistic behavior to help others without access to treatment.396
Proposals for decreasing barriers to buprenorphine treatment are commonly countered
with the argument that decreasing barriers will increase diversion. However, assuming that
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increased diversion occurs, policy makers should ask whether diverted buprenorphine is
primarily harmful or whether it serves as a stepping stone towards more legal buprenorphine
treatment. A recent study found that individuals who had prior experience with non-prescribed
buprenorphine were more likely to enter legal buprenorphine treatment and to remain in
treatment after six months than individuals who began buprenorphine treatment while
buprenorphine-naïve.397
ii.

Methadone

As early as 1972, news articles were warning the public of methadone diversion. The
tone of these articles was frequently negative, without a balanced discussion of the benefits of
widely-available methadone maintenance treatment. Popular headlines from that year included
“Study finds black market developing in methadone” (New York Times), “Curse or cure?
Controversy balloons over use of methadone as a heroin substitute” (Wall Street Journal), and
“Methadone: Will it spread addiction?” (National Observer).”398
As early as the 1970s, researchers were finding that individuals most often purchased
methadone illicitly was for “self-treatment.”399 Diversion of methadone may also allow
marginalized persons to help one another. A study of methadone diversion in England found that
such diversion to others was both altruistic and self-protective; a patient helped those who could
not enter an OTP in case he was one day kicked out.400 The authors saw diverted methadone in
the U.K. as “potentially having more value as a personal safeguard and social resource than a
commodity on the black market.”401 A 2015 study by Johnson and Richert found similar attitudes
in the U.S.402
Since the late 1990s, methadone diversion has significantly increased. But diverted
methadone has typically been prescribed for pain treatment, not addiction treatment.403
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Methadone pain prescriptions grew nearly eight-fold between 1998 and 2006.404 Methadone for
pain treatment is typically in pill or film form, unlike methadone for addiction treatment, which
is typically liquid.405 Diverting liquid methadone provided under supervision is more difficult
than diverting methadone in pill form dispensed from a local pharmacy; some methadone
patients in OTPs divert methadone by storing the liquid in their cheeks and then spitting it into a
hidden container.
All government agencies can be expected to be concerned with buprenorphine and
methadone diversion, but state law enforcement and the DEA have been particularly vocal about
its dangers. In 1989, the DEA told Congress that “Methadone is an addictive, euphoriaproducing drug with a high street value, and we believe it obvious that the dispensing of such a
drug to an addict population, which by definition has shown itself to be more likely to abuse
drugs than the general population, should be done only within a tightly regulated framework."406
The DEA has also been concerned with the possibility that poly-drug users sell methadone to
fund purchases of other drugs, so that methadone programs could be indirectly subsidizing other
drug abuse.407 When the DEA considered expanding take-home privileges in the late 1980s,
Eugene Haislip, Deputy Assistant Administrator for Diversion Control, stated it “can only be
expected to exacerbate the problem.”408 Likewise, the DEA dismissed medical organizations’
proposals you categorize buprenorphine in a less restrictive schedule of the Controlled
Substances Act, largely due to fears of diversion.
Policy makers should acknowledge potential dangerous of buprenorphine and methadone
diversion, including overdose from self-treatment with wrong doses. However, the concern
should be balanced with the need for expanding legal treatment without stigmatizing or singling
out addiction treatment patients from other medical patients.
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E.

Stigma of MAT-Patients in Abstinence-Only Treatment

The culture of abstinence-only treatment promotes stigma against individuals treated with
MAT. Unfortunately, society places persons treated with MAT in a “uniquely marginal social
location,” seeing them as neither “the sober addict” nor the “the fantasy outlaw heroin user.”409
Persons undergoing MAT sometimes do not have “the full status of patient” or are denied the
ability to call themselves “in recovery.”410 In mainstream culture they are ostracized as addicts;
in recovery culture they are stigmatized because they undergo MAT.411 Another study found that
some patients avoid MAT out of shame, preferring abstinence-only treatment.412
Unfortunately, stigmatization of MAT patients appears in the most popular form of
addiction treatment in the U.S.: 12-step groups. NA has not officially taken a position against
MAT 413 and is thus not officially an abstinence-only treatment. However, according to NA’s
main website, individual NA groups can decide to ban participants using MAT from meetings.414
It appears that a significant percentage of groups or members adhere to an abstinence-only
philosophy. Published studies report that up to 25% of members of NA and similar 12-step
groups feel stigmatized if they undergo MAT.415 One 2011 article states an invisible moral
hierarchy of SUD treatments exists within AA and NA meeting discourse: abstinence-only
treatment is better than MAT, and MAT is only marginally better than active drug abuse. 416
Members report not telling their sponsors about their medical treatment because sponsors might
misunderstand it as substituting one chemical addiction for another.417 A 2000 study by
Rychtarik et al. found that only 53% of AA members believed MAT was or might be a good
idea.418 NA and similar groups are also unlikely to educate members about MAT.419
Some MAT-prescribing physicians recognize its stigma and try to help patients navigate
it. At an annual ASAM conference I attended, two speakers in two different sessions discussed
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encouraging patients not to tell their NA sponsors that they were on MAT. Both believed that
support groups were an important recovery tool but recognized that few non-12-step support
groups exist.
Given that AA and NA is the most accessible form of addiction treatment today, their
organizational headquarters have a moral obligation to prevent groups from excluding or
discriminating against MAT patients. AA and NA have previously released publications
explaining that one can be sober while taking mental health medication (e.g. for depression), but
they have yet to do so regarding MAT. In the meantime, rumors that MAT is just another drug
which one must get off of quickly continue to spread within AA and NA.
One study of methadone patients found wide-spread internalization of the idea that MAT
was just another drug. Some patients planned how to get off of it before they even began and
participated in methadone treatment half-heartedly, with some requesting low dosages contrary
to best-practices because they perceived lower doses to be less immoral. Patients tended to view
addiction as a coping strategy for a spiritual problem (a view encouraged by AA and NA) and
perceived methadone as an ineffective treatment that was unrelated to spirituality).420 Patients
believed that true happiness and recovery were impossible with MAT, even though their drug
use had decreased or ceased since beginning it. The study found that, even among MAT patients,
the cultural dominance of abstinence-only philosophy created cognitive dissonance and selfdoubt. The mono-discourse of abstinence-only treatment strangles discourses supportive of
MAT.
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V. Summary
Since the time of American Puritans, the general public has interpreted drug and alcohol
dependence as a sign of immorality and lack of willpower.421 In this chapter, I have argued that
Alcoholics Anonymous and the War on Drugs reinforce such inaccurate views of addiction. At
the same time, some Americans have viewed addiction as a neurological disease. However, even
among those Americans who call addiction a disease, many recommend treatments for
increasing spirituality (e.g. 12-step groups) and willpower (e.g. motivational interviewing), while
discouraging medication. As a result, addiction has become a medical anomaly: a concept
recognized as a disease but treated as something other than a disease, with medication
discouraged and spirituality encouraged. No other disease in America is overwhelmingly treated
this way. SUD treatment centers who discourage MAT while encouraging abstinence-only
treatment methods are actively preventing their patients for receiving the best-standard of care, a
tragedy in light of the deadliness of opioid dependence. Additionally, some SUD treatment
centers and support groups stigmatize MAT patients, claiming that they are not really in
recovery.
Bias against MAT is not only culturally ingrained but due to lack of education about
evidence-based treatment methods among counselors, physicians and the general public. Lack of
education is compounded by inaccurate widely-held beliefs. For example, many abstinence-only
treatment providers assume that MAT is just another drug (e.g. thus it cannot help one recover),
or that the risk of diversion/abuse outweighs the benefits.
As the next chapter demonstrates, cultural bias, lack of education, and misunderstandings
about MAT affect government regulations. In turn, government regulations minimize access to
MAT and decrease the likelihood of interactions between the general public and patients who
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have recovered through MAT. Even though MAT has transformed many lives, MAT patients’
isolation from mainstream medical care, as well as the stigma of addiction (compelling them to
be silent), prevents the general public from hearing success stories.422 Therefore, I argue that
decreasing regulatory barriers will encourage integration of MAT into mainstream medicine and
will improve Americans perceptions of MAT.
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CHAPTER 2: REGULATORY BARRIERS TO MAT
I. Introduction
Buprenorphine and methadone are both “controlled substances” under the Controlled
Substance Act. The federal government more stringently regulates medications that are
controlled substances than other prescription medications. Many commonly prescribed
medications in the U.S. are controlled substances, including anabolic steroids, Xanax, and opioid
painkillers. Physicians who prescribe controlled substances must register with the Drug
Enforcement Agency (DEA), keep detailed records of their prescriptions, and provide DEA
agents access to records for monitoring purposes. Similarly, pharmacies that dispense controlled
substances must maintain detailed records, store the medications under specific conditions, and
report prescription-dispensing rates to state and federal authorities.
Buprenorphine and methadone, however, are unique relative to other controlled
substances because they are subject to additional prescription limitations. Separating the
regulation of opioid addiction maintenance treatment from the regulation of other medical
treatments can be traced back to the Harrison Act of 1915.423 In 1919, the U.S. Supreme Court
interpreted the Harrison Act as prohibiting health practitioners from prescribing opioids to
known abusers, essentially preventing practitioners from legally prescribing maintenance
treatment with an opioid ingredient.424
Even though the Harrison Act has been repealed, statutory and regulatory restrictions are
greater for buprenorphine and methadone than for other schedule II and schedule III controlled
substances, contributing to the underuse of MAT in the U.S. An article published in the Journal
of the American Medical Association in 2008 estimated that less than 10% of patients currently
suffering from opioid dependance are receiving agonist treatment (meaning buprenorphine or
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methadone).425 Having seen the negative effects (e.g. waitlists for buprenorphine) of onerous
legal barriers, numerous health organizations have called for reforming how buprenorphine and
methadone are regulated. This chapter begins by examining regulatory barriers to buprenorphine
and methadone and concludes with suggestions for reforming existing regulations.
II. Regulatory Barriers to Buprenorphine
This section begins with a general overview of the Controlled Substances Act. It then
examines the history of classifying buprenorphine as a Schedule III substance, despite opposition
from health organizations advocating for a less restrictive schedule. The section then discusses
recent regulatory and statutory changes affecting buprenorphine and then concludes with
suggestions for furthering access to buprenorphine.
A. DEA Scheduling
Under the Controlled Substances Act (CSA), Congress delegates authority to the
Attorney General to classify substances or drugs within five schedules of control, with Schedule
V being the least restrictive and Schedule I being the most restrictive.426 For example, heroin is
in Schedule I and oxycodone is in Schedule II.427 The Attorney General’s decision must be
based on the substance’s abuse or dependency potential, medical value, and safety.428 The
Attorney General’s findings about abuse potential must consider several factors, including actual
or relative potential for abuse; scientific evidence of its pharmacological effect; current scientific
knowledge; history and current pattern of abuse; scope, duration, and significance of abuse; risks
to public health; psychic or physiological dependence liability; and whether it is an immediate
precursor of a substance already scheduled under the CSA.429 The Attorney General must also
consult with the Secretary of Health and Human Services before scheduling the substance; if the
Secretary recommends against controlling the drug, then the Attorney General must honor that
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decision. Finally, rules must be made “on the record,” meaning the rule-making process must
adhere to certain formal requirements, including notice to the public of the proposed rule and
time for public comment before the final rule is published in the Code of Federal Regulations. 430
The more restrictive the scheduling, the less accessible the medication becomes. All
physicians who prescribe controlled substances must register with the DEA, obtain a DEA
number, and meet DEA reporting requirements.431 However, under the CSA physicians may
only prescribe automatic refills for Schedule III narcotics for up to six months, or five
prescriptions (whichever is first).432 But there are no automatic prescription limitations for
prescribing Schedule V substances.433 Also, the more restrictive the scheduling, the less likely
physicians may be to prescribe the medication out of fear of losing their medical license for
wrong-doing.434
In 1981, the FDA approved the first version of buprenorphine as an injectable, hospitalbased pain killer.435 In 1985, the DEA scheduled that version of buprenorphine as a Schedule V
narcotic under the CSA.436 Schedule V controlled substances have a lower potential for abuse
than substances in Schedule IV; a currently accepted medical use in treatment in the U.S.; and
limited potential for physical dependence or psychological dependence relative to substances in
Schedule IV.437
In 2002, after other countries (especially France) had successful experiences with
buprenorphine for treating opiate dependence,438 the FDA approved buprenorphine for treating
this condition under the brand names Suboxone and Subutex.439 The Suboxone version contains
an abuse-deterrent ingredient, naloxone, which causes individuals who abuse the medication
through intravenous injection to experience immediate withdrawals.440 Therefore, Suboxone is
even less likely to be abused than Subutex, which contains only buprenorphine.441
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In 2002, the DEA rescheduled buprenorphine from Schedule V to Schedule III after it
became aware that the FDA would shortly approve buprenorphine for addiction treatment and
after it received a recommendation to reclassify the substance from the DHHS.442 Under the
CSA, substances in Schedule III have a lower potential for abuse than substances in Schedules I
and II; a currently accepted medical use in treatment in the U.S.; and the potential for moderate
or low physical dependence or high psychological dependence.443 The American Academy of
Addiction Psychiatry and the American Association of Addiction Medicine both recommended
less restrictive scheduling for Suboxone.444 The organizations believed that scheduling
Suboxone (which contains the abuse-deterrent naloxone) was more consistent with international
data suggesting low rates of buprenorphine abuse. Also by making buprenorphine combined with
naloxone less restricted then buprenorphine alone, the federal government would incentivize
physicians to prescribe the abuse-deterrent version of the medication.445
In determining buprenorphine’s abuse potential, the DEA considered that buprenorphine
would be prescribed to “known drug abusers.”446 The DEA’s response to comments on the Final
Rule addressing rescheduling noted, “Simply stated, providing an abusable substance to known
drug abusers imparts enhanced risks [sic].”447 The DEA feared that opiate naïve (new users) or
“non-dependent, opioid-experienced subjects” would obtain buprenorphine illicitly.448 It found
that such individuals may feel “good drug effects”449 if they try to abuse buprenorphine.
Ironically, however, opiate-dependent individuals rarely feel any “good drug effects” from
buprenorphine450—instead, they simply feel normal.451
In rescheduling buprenorphine, the DEA appeared to be more concerned with
buprenorphine’s potential to harm opiate naïve and non-opiate-dependent individuals than with
its potential benefits for treating opiate-addicted individuals.452 In its response to comments on
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the Final Rule, the DEA stated that “buprenorphine has abuse potential in a wide spectrum of
individuals. Vulnerable populations include drug naïve individuals (new drug abusers), opiate
experienced individuals and opiate dependent individuals.”453 Later, however, the DEA noted
that, “The extent to which buprenorphine is able to produce euphoria and “good drug” effects
limits its use by opiate tolerant abusers.”454
Unfortunately, the DEA’s findings did not consider how rescheduling buprenorphine
would impact access to treatment.455 In response to a comment that rescheduling buprenorphine
would make it less accessible for treating dependent individuals, the DEA remarked, “The
proposed placement of buprenorphine in Schedule III was not made on the basis of making
buprenorphine products available for office-based narcotic treatment. . . . The DEA did not
consider the need to expand narcotic treatment as a specific factor in determining the placement
of buprenorphine under the CSA.”456 However, currently accepted medical use is a factor that
the DEA is required to weigh in its scheduling determination, suggesting that the DEA should
consider how its decision may impede access to medical use of the treatment.
B. Drug Addiction and Treatment Act of 2000
In 2000, Congress passed the Drug Addiction and Treatment Act (DATA), Foreseeing
the likely FDA approval of buprenorphine, DATA modified the CSA,457 permitting physicians
to prescribe Schedule III, IV, and V substances for addiction treatment, while trying to prevent
their diversion and abuse.458
DATA’s passed was not marked with controversy. The initial version of the Act, DATA
of 1999, was introduced by Senator Hatch (R) in the Senate but was never brought to a vote.459
Representative Biley (R) then re-introduced DATA in the House of Representatives with
Republican and Democratic co-sponsors as DATA of 2000.460 It easily passed in the House with
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412 “yea” votes and only one “nay” vote.461 The Senate then added DATA of 2000 as an
amendment to the Children’s Health Act of 2000,462 which it then unanimously approved it. The
amended Children’s Health Act returned to the House for a final vote, where it was passed by a
large majority.463
DATA became law two years before the DEA rescheduled buprenorphine from Schedule
V to Schedule III. Although the DEA was aware of DATA and its purpose, in its Final Rule it
stated that that it was not considering how rescheduling buprenorphine would impact DATA
objectives, claiming that “The Drug Addiction Treatment Act (DATA) does not have an impact
on DEA’s scheduling responsibilities under the CSA.”464
DATA eliminated the DEA registration requirement for physicians who dispense a
Schedule III to V narcotic for purposes of detoxification or maintenance treatment.465 Instead, it
requires physicians to obtain a waiver (colloquially called a DATA waiver or SAHMSA waiver)
from the Secretary of Health and Human Services. 466 To obtain a waiver, a physician must
submit a notification of intent to the Secretary to begin prescribing such medications. This
notification must demonstrate that the physician meets several requirements under DATA: 1) the
physician is “qualified” to prescribe medication for opiate dependence treatment; 2) the
physician will adhere to the patient limits in DATA; and 3) the physician has the capacity to
refer patients for ancillary mental health services.467
DATA also defines “qualified physician” and imposes patient limits. A physician
becomes “qualified” by meeting the requirements in section 2(a)(5)(G) of DATA. First, the
physician must have a valid medical license under state law.468 Second, the physician must
prove that he or she has the necessary education or experience to treat opiate-dependent
individuals with buprenorphine (and similar medicines). The physician may demonstrate the
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education/experience requirement in several ways: through board certification as an addiction
specialist (by a major medical authority listed in the statute); by completing an addiction
medicine educational course at least eight hours in length (provided by a medical authority listed
in the statute); by participating as a principal investigator in a drug trial for buprenorphine or a
similar medication; or otherwise convincing the state’s medical board or the U.S. Secretary of
Health that the physician has valid experience/education for treating opiate-dependent
patients.469 Under DATA, physician assistants and nurse practitioners cannot become qualified
or obtain a waiver, even if they are licensed in a state that permits physician assistants and nurse
practitioners to prescribe Schedule III, IV, or V medications.470
In addition to defining “qualified physician” for purposes of obtaining a DATA waiver,
DATA also restricts how many patients a qualified physician may treat at one time.471 These
patient restrictions have been widely criticized within the medical community.472 Since the
passage of DATA, Congress has twice amended the patient restriction to expand the number of
patients a physician may treat.473 The original DATA Act prohibited any physician or physician
practice from treating more than 30 patients with buprenorphine at any time. 474
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Thus, if

three physicians owned a group practice and one was treating thirty patients with buprenorphine,
then the other two physicians could not treat any patients with buprenorphine.
In 2005, Congress passed the Drug Addiction Treatment Expansion Act, which
eliminated the 30-patient limit on group practices, but left it in place for each individual qualified
physician.476 Under this law, in a three-physician group practice, each physician within the
group could now treat up to 30 patients at any time with buprenorphine.477 The legislative
history of the Drug Addiction Treatment Expansion Act demonstrates that Congress was
concerned with how the group practice prescription limit restricted patient access. Rep. Mark
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Souder (R-Ind.) advocated for the Drug Addiction Treatment Expansion Act, stating:
“According to the American Medical Association, the current 30-patient cap has limited access
to effective substance abuse treatment services. . . . Lifting the cap would enable group practices
to treat more patients with this highly effective drug.”478
By 2006, the growing demand for buprenorphine was stymied by access barriers in the
form of long wait times to see qualified physicians. In response, Congress passed the Office of
National Drug Control Policy Reauthorization Act,479 which established the patient limits that
are currently in effect. Title XI of the Act permits physicians who have had a DATA waiver for
at least one year to treat up to 100 patients beginning in the second year, after notifying the
Health Secretary of their intent to do so.480 When the Act passed, Senator Hatch gave a
congratulatory speech:
It is clear this [30 patient] cap needs to be raised. To make an analogy, a doctor
[] would not turn away a broken arm because he or she had already fixed 30
arms that month! The doctor would not stand for it, and neither would society.
The same should be true for physicians treating drug addiction. Given that the
destructive effects of drug addiction are so much greater than a broken arm, we
should strive to ensure that the healing hands of doctors are not bound by
unintended mandates.481
Nonetheless, access remains scarce. In 2012, only 46.6% of U.S. counties had at least
one physician with a DATA waiver.482 Only 2% of all U.S. physicians have a DATA waiver,
and only 3% of primary care physicians, the largest group of physicians in the nation, have
obtained a DATA waiver.483
The AMA and the ASAM have repeatedly criticized the patient limits in DATA484 as
being arbitrary and causing unnecessary waitlists for patients.485 Such patient limits do not exist
for other Schedule III narcotics.486 They do not even exist for oxycodone, a Schedule II narcotic
and drug of choice for many opiate-dependent individuals.487 In cities with buprenorphine-
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prescribing physicians, patient limits may cause long waitlists that sometimes include hundreds
of patients.488 Buprenorphine is an effective maintenance treatment that can be used indefinitely,
and so once patients begin buprenorphine treatment, they are likely to have regularly scheduled
appointments for a long time. As a result, persons on waitlists may need to wait many months
until someone else stops treatment.489
C. Regulatory and Statutory Changes in 2016
1. Buprenorphine Patient Limit Regulation Change: July 2016
According to the Controlled Substances Act (which was modified by DATA), the
Secretary of Health may change patient limits for buprenorphine.490 In July 2016, DHHS
released a final rule (which I will refer to as the DHHS Final Rule) allowing “eligible
practitioners” to treat up to 275 patients under the Controlled Substance Act.491 In the Final Rule,
the DHHS justified patient limit changes by stating: “Given the evidence supporting
buprenorphine-based MAT as an effective treatment for opioid use disorder and the magnitude
of the opioid crisis, this rule is intended to increase access to buprenorphine-based MAT, prevent
diversion, and ensure quality services are provided.”
Practitioners may be eligible by virtue of having special credentials (e.g. board
certification in addiction medicine).492 Practitioners may also be eligible if they work in a
“qualified practice setting” (described in the next paragraph).493 Regardless of whether the
practitioner is board certified in addiction medicine or practices in a qualified practice setting,
the practitioner must have already obtained DHHS permission for at least one year to treat 100
patients, the practitioner cannot have had Medicare enrollment billing privileges revoked, or
have been found to have violated CSA.494 All practitioners must apply for renewal of the 275
patient limit every three years.
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A “qualified practice setting” is narrowly defined. It is a setting that includes the
following features: professional coverage for patient emergencies when the practice is closed
(e.g. at night); provides access to case management services, including referral and follow-up for
medical, behavioral, social housing, employment, or educational services or related services;
uses health IT systems; is registered for their states’ prescription drug program (there are slightly
different rules for contractors of Federal agencies); accepts third party payment or Federal
benefits.495
Interestingly, the rule allows for practitioners who are otherwise ineligible for the 275
patient limit to apply for temporary (6-month) emergency permission to treat up to 275
patients.496 The application requires the practitioner to describe the public health emergency in
detail, as well as the practitioners’’ proposed method for addressing the health emergency. In
some situations, DHHS may provide an extension beyond 6 months.497 Although the regulation
does not provide examples of emergency situations, one could imagine that a natural disaster
destroying other treatment centers might qualify as an emergency.
In the Final Rule, DHHS responded to comments received from practitioners and
interested individuals.498 In comments supporting the proposed rule, practitioners had cited
buprenorphine’s lifesaving potential, as well as the need for parity between addiction treatment
and treatment of other conditions. In comments opposing the rule, practitioners claimed that
increases in buprenorphine limits were worthless without increases in specialty practitioners.
Practitioners also argued that the definition of a qualified health setting is too vague and that
reimbursement levels for addiction treatment must increase.
2. Comprehensive Addiction Recovery Act of 2016
As of the writing of this dissertation, both houses of Congress have passed the
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Comprehensive Addiction Recovery Act (CARA).499 President Obama is expected to sign
CARA, having been a key supporter since the beginning, although the President has called for
greater funding for addiction treatment.500 CARA addresses many topics, including grants for
education and prevention, access to naloxone for opioid overdose reversal and improving access
to MAT. Section 303 amends CSA to allow for nurse practitioners (NPs) or physicians assistants
(PAs) to be “eligible practitioners” for provision of buprenorphine. Under DATA, NPs and PAs
were prohibited from prescribing buprenorphine, despite the fact that many states allow NPs and
PAs to prescribe schedule III medications. As a result, CARA may significantly increase access
to buprenorphine. Under CARA, NPs and PAs are considered “qualified practitioners” if they
meet the following criteria.501 First, they must complete at least 24 hours of specialized training
in addiction treatment (in contrast to physicians, who typically need 8 hours). Second, NAs and
PAs must be licensed under State law to prescribe Schedule III medication. Third, they must be
supervised by or work in collaboration with a qualifying physicians.502
In my interviews with physicians, I have heard overwhelming support for allowing NAs
and PAs to prescribe buprenorphine. Physicians routinely state that they encounter NAs and PAs
better educated about addiction than physicians. One physician effectively summarized the
sentiment shared by many other physicians whom I interviewed by saying, “95% of the time,
NAs and PAs would do a great job prescribing buprenorphine; 5% of the time the patients’
situation would be complicated, making NAs and PAs feel out of their depth.” (physician 19)
But so long as a supervising physician is available, those more complicated situations would be
well-managed.
D. Probuphine: A New Buprenorphine Treatment
In May 2016, the FDA announced its approval of Probuphine, a surgical implant that
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slowly releases buprenorphine into the arm and lasts six months.503 Probuphine administration is
a minor, office-based surgical procedure. Therefore, the FDA has required physicians who
administer Probuphine to become “certified implanters” by completing a program in Probuphine
Risk Evaluation and Mitigation Strategy (REMS), which teaches how to implant and remove the
rods containing buprenorphine. Patients must be seen at least once per month by a physician after
receiving the implant. REMS has been required by the FDA for a few other medications,
including a seizure medication and a diabetes medication.504 For Probuphine, the REMS
requirement is unique in so far that it is necessary in addition to the other buprenorphine
certification requirements under DATA.
A few days after the FDA announcement, I contacted Titan Pharmaceuticals (the makers
of Probuphine) to request information on the distribution of physicians certified in the REMS
program. I was told that 5000 physicians had already signed up. Physicians who prescribe
Probuphine must conform to DATA requirements (i.e. buprenorphine certification, patient
limits) or work within an OTP. But prescribers need not be the ones who actually implant
Probuphine. For example, in educational material about Probuphine, the FDA describes a
scenario in which a DATA-waivered psychiatrist prescribes Probuphine but a different physician
who is a certified Probuphine implanter visits the office to implant the rods in the patient.505
According to Titan Pharmaceuticals, Probuphine is intended for patients who have
already achieved stability on low to moderate doses of oral buprenorphine.506 Such stability may
be necessary to ensure that individuals do not attempt to remove the implant from their arm,
which could cause nerve damage and other serious medical problems. Additionally, some
individuals may require high doses of buprenorphine before they are stabilized, which the
implant does not provide.
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Probuphine will also be subject to a “closed distribution system,” meaning that Titan
Pharmaceuticals will ship Probuphine directly to physicians who have received REMS
certification. The physician will then store the REMS in the office, rather than requiring patients
to pick up the product from a pharmacy. The closed distribution system is likely meant to
prevent patients from trying to implant Probuphine into themselves. The closed distribution
system will benefit patients by eliminating the step of a visit to a pharmacy. However, the
additional paperwork and storage requirements required for physicians to maintain the
medication in the office may serve as a deterrent to physicians prescribing Probuphine.
III. Regulatory Barriers to Methadone Treatment
A. Opioid Treatment Programs
Methadone was FDA-approved for pain treatment in 1947. In the 1960s, it was found to
be effective for treating opioid withdrawal symptoms and as a long-term maintenance treatment.
Methadone’s regulatory history is significant for the numerous barriers to access put in place by
three agencies: the DEA, the FDA, and the DHHSA (and their precursors). Since the early 20th
century, regulatory decisions relating to pharmaceuticals were made by a law enforcement
division of federal government. During that time, the federal law enforcement agency interpreted
the Harrison Act as banning opioid-based maintenance treatment, creating hurdles for
researchers of maintenance treatments.
In 1970, Congress passed the Comprehensive Drug Abuse Prevention and Control Act
(CDAPCA), which moved treatment decisions away from law enforcement to the Department of
Health, Education and Welfare (the precursor of DHHS).507 The Act also consolidated the
Controlled Substances Act and the Controlled Substances Export and Import Act, which became
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Titles II and III, respectively, of CDPCA.508 In 1970, Methadone was classified as a Schedule II
narcotic, the second most restricted category of controlled substances.509
In 1972, the FDA-approved methadone for treating opioid dependence.510 The FDA
established a framework for distributing methadone at dedicated sites now known as methadone
treatment medication units (MTMUs).511 Medical treatment programs (which would provide
counseling and other social services) were required to oversee MTMUs; but MTMUs were
required to be located separately from medical treatment programs.512 The physical separation of
medical treatment programs (which were often part of hospitals) from MTMUs (which
administered the methadone) began the current separation of methadone treatment from
mainstream medical practice. Interestingly, while methadone for pain management initially fell
within the same segregated regulatory scheme, starting in 1976 the FDA allowed regular
pharmacies to prescribe methadone for pain management.513 The change followed a lawsuit
initiated by the pharmaceutical industry, which wanted to be involved in methadone
distribution.514 Methadone for addiction treatment, on the other hand, continues to be prescribed
and distributed in a closed network.515
In 1974, Congress passed the Narcotic Addict Treatment Act, in which the federal
government explicitly recognized methadone maintenance treatment (MMT) as effective. 516 But
rather than allowing all physicians to prescribe MMT, Congress restricted this ability to
physicians registered with the DEA.517 Because the 1972 FDA regulations remained in effect,
physicians still could only prescribe in federally regulated-treatment centers rather than in
general office-based practices.518 By that point, methadone was regulated by the DHHS, the
FDA, and the DEA, causing administrative hurdles to opening new methadone clinics.
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According to Adam Yarmolinsky and Richard Rettig, experts on the history of
methadone regulation, the Congressional restrictions in the Narcotic Addict Treatment Act
existed because of fears that users would divert prescribed methadone—so much so that the
Senate Bill was originally titled The Methadone Diversion Control Act of 1973.519 In the early
1970s, the New York Times and other print news media published articles warning the public of
the dangers of methadone diversion.520 Then, during Congressional hearings for the Narcotic
Addict Treatment Act, the DEA presented evidence of widespread methadone illicit
purchasing.521 However, the DEA did not clarify that, according to a contemporary study,
individuals who purchased methadone illicitly primarily did so for self-treatment rather than to
“get high.”522 Additionally, the DEA presented emergency room data related to methadone
overdoses and stories of opportunistic physicians who were overprescribing methadone for
financial gain.523 As a result, Congress had little reason to simplify the FDA’s regulatory
structure.
Access to methadone treatment for addiction is more heavily restricted in the US than in
any other developed nation.524 Methadone treatment for addiction (as opposed to pain) is also
one of the most heavily regulated medical treatments within the U.S.525 It is regulated by the
Substance Abuse and Mental Health Services Administration (SAMHSA), the DEA, and
individual states. With few exceptions, MMT may only occur within certified opioid treatment
programs, which are almost always isolated from other medical practices. An Opioid Treatment
Program (OTP) is defined as “a program or practitioner engaged in opioid treatment of
individuals with an opioid agonist medication.” All OTPs must be certified by SAMHSA. OTPs
must also be licensed in their states, and registered with the DEA.526 To become certified by
SAMHSA, the OTP must meet regulations within 42 CFR § 8. Since 2001, certified OTPs must
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also become accredited by a SAMHSA-approved accrediting body, such as the Joint
Commission (one of the largest health care accreditation organizations in the U.S.).527 Today,
IOPs represent 8% of all SUD treatment centers.528 They are separated from mainstream medical
treatment. The ASAM says, “Addiction treatment is often criticized as being a separate “silo”
from medical care, but OTPs are like silos within silos.”529
Individuals undergoing methadone treatment must travel to an OTP daily where they
receive methadone while supervised by OTP staff. OTPs are also required to provide mental
health counseling and to conduct urine screenings. Daily travel to an OTP may be difficult for
many individuals, especially those without transportation and low-income individuals who
cannot afford to miss work. The National Institute on Drug Abuse recommends that individuals
receive at least one year of methadone treatment,530 so travel to OTPs may constitute an ongoing,
sometimes onerous, time commitment. According to SAMHSA, in 2009 there were
approximately 1,200 OTPs operating in the U.S.531 However, Montana, Wyoming, North
Dakota, and South Dakota did not have any OTPs.532 Patients in those states must cross state
borders daily if they hope to legally obtain MMT.
Sometimes OTPs permit take-home doses. Whether a patient is eligible for take-home
doses depends on whether individual patients have certain characteristics and state law. For
example, in West Virginia, whether a patient may obtain a take-home dosage depends on the
length of time the patient has participated in treatment at the OTP; the patient’s absence of
criminal activity, serious behavioral problems, and drug abuse; the capacity to safely store
medication at home; the stability of home and environmental relationships; the patient’s work,
school and other daily activities; and the patient’s hardship travelling to the OTP.533 In West
Virginia, the allowable take-home dosage increases gradually over time, resulting in a maximum
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one month supply after two years of continuous treatment.534 In contrast, in Kentucky, the
maximum take-home allowance is 3 doses per week.535 Therefore, OTP patients in Kentucky
must still return weekly under the maximum take-home allowance.
The isolation of OTPs from other medical practices causes problems for methadone
patients and local communities. OTPs force methadone patients to congregate in a single area
where they are easily recognized as opioid addicts, making it easy for local communities to
stigmatize them. In addition, they are more visible to drug dealers; numerous law enforcement
personnel, judges, and physicians whom I interviewed stated that drug dealers target methadone
clinics, especially those known to provide such low dosages that patients are craving opioids by
midday. For decades, academics have expressed concern over this failure to integrate methadone
patients into mainstream medicine,536 yet it is rarely discussed as a pressing issue in public
discourse.
E. Methadone Treatment for Addiction versus for Pain
Between 1972 and the late 1990s, methadone was primarily used to treat opioid
dependence. In the late 1990s, however, more physicians began prescribing it for pain
management,537 encouraged in part by new guidelines from national pain-related organizations
and pain treatment standards implemented by the Joint Commissions. Many physicians chose to
prescribe methadone over other opioids for pain because it is relatively inexpensive and available
in a variety of doses and formats.538
Methadone is less efficient as a pain management aid than as an addiction treatment
medication. When prescribed for pain, methadone suppresses pain for only approximately four
hour, and patients sometimes need a minimum of five days to achieve full pain relief. But when
prescribed at appropriate dosages for addiction treatment, methadone suppresses opioid
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withdrawal symptoms for a day or more. Although it appears logical to assume that patients
would have more difficulty accessing methadone for pain than addiction treatment, but the
opposite is true. MMT regulations are significantly more stringent than for prescribing
methadone for pain management. Yet methadone overdoses overwhelmingly occur using
methadone prescribed for pain, not addiction treatment.539
Under federal law, when methadone is prescribed for pain treatment, the health
practitioner must follow general regulations for Schedule II controlled substances. Schedule II
controlled substances may be prescribed by any physician registered with the Attorney General
in accordance with state law. The physician must re-register with the Attorney General every
three years.540 In practice, this is referred to as obtaining a “DEA number.” Some states allow
nurse practitioners or physician assistants to prescribe methadone (and other schedule II
controlled substances) for pain relief when supervised by a licensed physician. Physicians may
legally prescribing Schedule II controlled substances in an office setting. But methadone
prescribed for addiction treatment must be prescribed and dispensed within a certified and
accredited Opioid Treatment Program (OTP). In other words, even if a physician is legally able
to prescribe methadone for pain treatment in an office setting, he or she cannot legally prescribe
methadone for addiction treatment in that same environment. Furthermore, methadone may not
be dispensed by a local pharmacy for addiction treatment, even if that pharmacy may legally
dispense methadone for pain management.
Clearly, methadone for addiction treatment is singled out as a “special case” that must be
heavily regulated. On the other hand, methadone for pain treatment is treated comparably or
identically to other Schedule II controlled substances.541 Methadone has the same ingredients
whether it is prescribed for addiction treatment or pain treatment. Dosages for addiction and pain
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treatment are different, but they may also dramatically differ within pain treatment. Therefore,
the only true difference between the two treatment contexts is the patient population: addicted
patients versus pain patients.
Even though the government treats both patient populations as unique, they may in fact
significantly overlap. One widely-cited study estimates that 4 to 25% of patients receiving opioid
pain management treatment in primary care settings are addicted to opioids. Although some
physicians continue to ignore the overlap between the two populations, in recent years many are
realizing that their pain patients are actually suffering from opioid dependence as well.
The treatment of pain and addiction patients contributes differently to the stigma of
addiction. The general public may misinterpret the reasons why addiction patients are
segregated from other patient populations and assume that they are dangerous, difficult to
manage, or somehow abnormal. Because the general public does not see methadone maintenance
treatment in general practice settings, the public may assume methadone is ineffective.
Additionally, other patients have no opportunity to see and interact with methadone treatment
patients. Separating MMT patients from other patients also reinforces stigma and
misinformation among health practitioners. Most physicians have never prescribed MMT or
personally witnessed another practitioner administer MMT. A physician may feel uncomfortable
referring a patient to an OTP which she has never visited or knows little about. Perhaps most
importantly, physicians with little experience of MMT may fail to provide information about
MMT to patients in need, possibly indicating failure of informed consent.
IV. Reforming Buprenorphine Regulations
A. Going Further than CARA and the DHHS Final Rule
Utilization of buprenorphine is very low in the U.S.,542 partly due to restrictions placed
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on prescribers under DATA.543 Today many cities do not have a single physician with a DATA
waiver,544 and many physicians with DATA waivers have very long waitlists. The Huffington
Post recently stated that one Ohio county clinic has a waitlist of over 500 patients.545 In theory,
Americans should be deeply concerned about the waitlists that many opiate-dependent
individuals must face when seeking treatment. After all, the popular media criticizes waitlists in
other countries, even when those waitlists are for elective procedures.546 Buprenorphine, on the
other hand, is life-saving, essential medicine.547 Furthermore, buprenorphine treatment has been
found to reduce drug-related crime,548 health care costs (particularly for emergency room visits),
and unemployment.549
Patient limits can result in tragedy. The point at which an opiate-dependent individual
recognizes that he or she has a problem and seeks help is an absolutely critical window that can
quickly disappear.550 The cravings for opiates and the withdrawal symptoms a person
experiences when they try to become sober may quickly overcome the desire to seek treatment if
an appointment with a physician cannot be obtained, potentially leading to overdose (especially
if the individual has lowered tolerance following detoxification). The tragedy does not affect the
patients alone; families frequently bear the financial and emotional burden of having to support
individuals struggling with drug dependence.
The passage of CARA and the new DHHS Final Rule should be applauded for their
potential to increase access to this life saving treatment by decreasing waitlists and increasing the
number of eligible practitioners. Not surprisingly, CARA and the DHHS Final Rule were
strongly supported by the American Medical Association and the American Society for
Addiction Medicine. Despite the passage of CARA and the Final Rule, more changes should be
made to increase access to buprenorphine.
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First, given that DATA patient limits were created with the primary purpose of
preventing diversion of buprenorphine, Congress or the DHHS should, at the minimum eliminate
patient limits for Probuphine, because Probuphine has a low risk of diversion. Additionally,
elimination of the patient limit could serve as an incentive for physicians to switch patients to
Probuphine after they have achieved stability on oral buprenorphine. Given that Probuphine has
a lower likelihood of diversion and a higher likelihood of compliance relative to oral
buprenorphine, physicians should be incentivized to switch eligible patients from oral
buprenorphine to Probuphine. Eliminating the patient limits for Probuphine would also allow
physicians to accept new buprenorphine patients without the need to discharge stable patients (a
situation which currently creates long wait lists).551
Second, oral buprenorphine-naloxone and future buprenorphine formulations with
deterrent-formulations should not be included in patient limits. Naloxone prevents a “high” if
buprenorphine is injected. By leaving the patient limit in place for pure buprenorphine but not for
buprenorphine-naloxone, physicians will be incentivized to prescribe the latter. Third, and
perhaps most importantly, the Federal government should actively work towards a lack of
limitations on buprenorphine in order to reach true parity between buprenorphine and other
treatments. No other medication has a patient limit and special educational certification is not
even required for prescribing prescription pain medication. While the idea of eliminating these
restrictions remains controversial, Congress initially enacted them almost fifteen years ago, when
U.S. office-based physicians had no experience with buprenorphine for addiction. Fifteen years
later, education and experience remains low but buprenorphine can no longer be treated like an
experimental medical treatment.
Congress should immediately, significantly increase funding for addiction education in
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medical schools and residency programs or provide funding incentives for schools to include
comprehensive addiction diagnosis and treatment education. Once the nation reaches the
threshold (whatever that may be) when physicians generally have good education about
addiction treatment, then the restrictions on buprenorphine should disappear, as they continue to
perpetuate the myth that addiction treatment is significantly different from treatment of other
chronic diseases.
B. Reforming Medicaid Life-Time Limits
According to SAMHSA, eleven states’ Medicaid programs set lifetime limits on
buprenorphine treatment.552 Medicaid programs rarely set lifetime limits on medications for
other chronic diseases, suggesting institutional bias against individuals with drug dependence.553
In the case of buprenorphine, lifetime limits negatively affect patient safety.554 According to a
study published in Health Affairs, “mortality rates were… more than twice as high among those
receiving no treatment, compared to those receiving buprenorphine [through Medicaid].”555
Medical studies show that drug abuse relapse is most effectively prevented by long-term
buprenorphine maintenance treatment, not short-term treatment.556 For example, a randomized
study found that 90% of patients relapse if buprenorphine treatment stops after 12 weeks.557
Therefore, individuals who lose Medicaid coverage for buprenorphine treatment have a high risk
of relapse.558
Not only is relapse harmful to the individual, it is bad for the state budget. When
individuals relapse, they are more likely to need expensive emergency room treatment, in-patient
rehabilitation, and/or hospital treatment due to opiate overdose. 559 According to the CDC, every
day approximately 7,000 individuals seek emergency room treatment for substance abuse-related
medical emergencies.560 Additionally, individuals who relapse are more likely to become
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unemployed than those who do not relapse,561 causing a loss in economic productivity. Finally,
individuals who relapse are more likely to commit drug-related crimes,562 draining state law
enforcement resources.
The federal government should encourage Medicaid programs to cover buprenorphine
indefinitely for Medicaid eligible individuals who have a formal medical diagnosis of opiate
dependence. For example, the federal government could agree to bear part of the cost of
Medicaid beneficiaries’ generic buprenorphine prescriptions, while prohibiting the state from
placing lifetime limits on buprenorphine maintenance treatment. Such limitations would actually
benefit state budgets. According to the National Institute on Drug Abuse (NIDA), approximately
12% of Medicaid beneficiaries over the age of eighteen have a substance abuse disorder.563
When Medicaid beneficiaries with substance abuse problems receive MAT, including
buprenorphine, Medicaid spends 33% less on their health care costs over the first three years,
and costs continue to decline thereafter.564 Medicaid is a block-grant program between the
federal government and state governments, so costs savings would be shared between the federal
government and state governments. Medicaid accounts for the single largest expenditure of
states’ revenues, so increasing access to MAT could significantly decrease total state Medicaid
costs, pleasing both cultural liberals and fiscal conservatives.
V. Reforming Methadone Treatment Regulations
One often voiced criticism for stringent government regulation of methadone is that
regulations fail to keep up with best medical practices, which can change more quickly than
regulations. As a result, in 2001 SAMHSA changed its requirements for opening an OTP. To
begin operating as an OTP, a facility must first obtain government certification. Then within one
year of certification, the OTP must obtain accreditation from a government approved third-party
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accreditation organization.565 Accreditation standards can change more quickly than government
regulations, so the shift to accreditation may better allow OTPs to keep up with best-practice
standards.
Unfortunately, the accreditation requirement does nothing to remedy the fact that OTPs
are outside of “mainstream” medicine, both literally (in that few doctors or patients have
experience with OTPs) and figuratively (in that the general public views OTPs more negatively
than other medical facilities). One way to integrate methadone into mainstream medicine would
be to allow physicians to prescribe methadone in regular offices (e.g. similarly to how
buprenorphine is currently prescribed). Other nations already allow general practitioners to
initiate and prescribe methadone treatment for addiction with good results and greater patient
access.566 For example, after Canada made methadone treatment available form general
practitioners, access increased by a factor of 5 in British Columbia and a factor of 30 in
Ontario.567 Only a few feasibility of methadone treatment for addiction in office settings have
been conducted in the U.S. (partly due to the difficulty of obtaining a federal exemption to
conduct such studies).568 These studies demonstrate potential efficacy of allowing physicians to
prescribe methadone for addiction treatment in regular offices.
A study by Merill et al. (2005) suggests that methadone treatment in general practice
settings could be an effective option for expanding access to methadone, especially for patients
without other severe mental health conditions who have already achieved stability in OTPs. The
study recruited patients from methadone clinics who had negative urine results for at least one
year, reliable methadone treatment attendance, no outstanding legal issues, or major psychiatric
problems. The study found high satisfaction rates among physicians and patients, as well as high
rates of abstinence from opioids among patients. Because patients received methadone treatment
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in primary care settings, they also benefited from treatment of other health conditions provided
in the same setting. For example, patients were also treated by primary care physicians for (or
referred to specialists for treatment of) Hepatitis C, tobacco use, hypertension, and psychiatric
disorders.569 Physicians’ attitudes towards methadone for addiction treatment were measured at
the beginning and end of the study; every physician viewed methadone treatment more favorably
at the end of the study than at the beginning and supported expansion of methadone treatment to
primary care settings.570 Interestingly, physicians in the study were general internists with an
average of ten years of practice in medicine and no prior addiction medicine training. The study
provided only 6 hours of training in methadone treatment, suggesting that even minimal
education about methadone treatment may be sufficient for treating stable patients suffering from
opioid addiction.
Physicians’ main complaint during the study was dislike of segregating records relating
to methadone treatment from other primary care records (as required by federal authorities who
granted permission for the study). Physicians also stated that those patients who did not do well
in office-based methadone treatment overwhelmingly suffered from co-existing severe mental
health conditions, for which the physicians had little training. Note, there is no evidence to
support that such patients would fare better in OTPs. Physicians overwhelmingly reported good
rapport with physicians, in contrast to widely held views among physicians that addiction
patients are “difficult.” According to the study authors, “Comparing them to other patients in
their public hospital practices, physicians generally viewed the methadone medical maintenance
patients as equally or more compliant, equally or less in need of emotional support, and the same
or lower on acuity of psychosocial stressors. Physicians were gratified to witness how patients
benefited from the program, and all indicated willingness to care for additional methadone
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medical maintenance patients.”571
A study by Harris et al. (2006) of methadone patients with diverse socioeconomic
backgrounds treated in office-based settings found illicit opioids in less than 1% of patients
during the three year program and retention of over 98% of patients for the length of the
program.572 Eligible study participants were required to have been enrolled in OTPs prior to
beginning the study with at least three years of stability (i.e. no urine screenings indicating
opioid use, no recent criminal activity, and regular attendance at OTPs), making study results
only generalizable to very stable patients. In another study, King et al. segregated 92 patients into
three groups: OTP methadone treatment, office-based methadone treatment, and routine officebased treatment (i.e. physicians see patients but no MAT is prescribed). Eligible participants had
at least 1 year of abstinence from opioids. The study found significantly higher rates of retention
in the office-based methadone treatment group (91% retention at twelve months) compared to
the other groups. The study also found significantly lower rates of positive urine drug screens in
the office-based methadone treatment group (where only 1.3% tested positive) compared to the
other groups.573 Other studies of office-based methadone treatment show similar positive results.
But currently all such studies occur as a result of researchers or legislators seeking FDAexemptions; therefore, office-based methadone treatment is still rare.574
ASAM has issued a policy statement recommending that methadone be made available to
stable patients in office-based practices, with the option of moving less stable patients or those
needing more structure to OTPs.575 Specifically, the ASAM recommends that all patients in
OTPs be given the option of “graduating” into office-based methadone treatment. ASAM also
recommends that OTPs and office-based providers create collaborative relationships (currently
rare), so that back and forth referrals become the norm.576
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However, physicians need increased levels of medical school and residency education in
in addiction medicine in order to become interested in office-based prescribing of methadone.
Even though buprenorphine may be prescribed in office-based settings in the U.S., most
physicians feel under-qualified or express low self-efficacy as a barrier to initiative
buprenorphine treatment. Physicians who did not obtain some medical school or residency
training in addiction medicine are unlikely to self-select into voluntary MAT training programs
(such as the 8-hour course required for buprenorphine certification). The same problem would
exist if methadone treatment for addiction were legal within office settings.577
VI. Summary
Statutes and regulations limit access to buprenorphine and methadone for addiction
treatment and are more stringent than those applied to the most widely abused prescription
opioids, such as oxycodone. Substance dependent individuals are a stigmatized group;
individuals suffering for pain are less stigmatized and commonly include a large voting block—
senior citizens. Therefore, for example, it is unsurprising that methadone for addiction is
relegated to OTPs, while methadone for pain management may be prescribed in general
physicians’ offices. Similarly, patient limits have been applied to buprenorphine but no other
FDA-approved medication.
Patient limits, take-home limits, and methadone patient relegation to OTPs all reflect
misinformation about MAT, especially overblown fears of divergence and abuse. Yet multiple
studies and physicians whom I have interviewed suggest that difficulty of accessing MAT from
physicians contributes to divergence; and MAT abuse is far more likely by non-dependent
individuals than by dependent individuals.
Law affects culture, reinforcing biases held by the general public. For example, laws that
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separate methadone patients from mainstream medical treatment reinforce the conception of
addiction as different from other diseases.578 Culture affects law, because policy makers bring
biases with them to the drafting table. Policy makers in the criminal justice system are likewise
influenced by cultural misunderstandings surrounding MAT.
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CHAPTER 3: THE UNDERUSE OF MAT IN THE CRIMINAL JUSTICE SYSTEM
I. Introduction
There is a well-known connection between drug use and criminal behavior. According to
the National Institute on Drug Abuse, drug use is implicated in at least five common criminal
offenses: drug possession or distribution, offenses related to obtaining drugs (such as stealing),
offenses related to associating with other individuals involved in drug-related crimes (such as
gang membership), abusive and violent behaviors related to drug-use (such as domestic violence
while “high”), and offenses related to driving under the influence.579
Just as opioid addiction has become more prevalent among the general U.S. population,
however, it has become more prevalent among the criminal justice population.580 A 2004
survey found that 53% of state and 45% of federal prisoners suffered from substance abuse
disorder.581 Approximately 24 to 36% of all heroin addicts enter the criminal justice system each
year582 and 20% of prison inmates have a history of injecting drugs.583 A 2009 study of arrestees
in Cook County, Illinois found that 82% tested positive for one illegal addictive substance at
time of arrest; the rate in North Carolina at time of arrest was 56%.584 During the last year, only
1-10% of the arrestees who reported drug use had received any outpatient treatment. 585 Among
pre-trial detainees suffering from opioid dependence, psychological and physical trauma from
forced acute withdrawal may increase the risk of self-incrimination.586
Individuals convicted for drug-related crimes may be diverted along a number of
different paths through the criminal justice system, including incarceration, probation, or drug
court. The prevalence of addiction and treatment methods available vary among these various
options. The chapter opens with a brief description of MAT underuse in prison. The chapter then
focuses on underuse of MAT in drug courts and veterans courts, because these courts’ explicit
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purpose is to treat SUD and MHD. Unfortunately, the arm of the criminal justice system that
should be most actively pursuing evidence-based treatment methods is failing to provide them.
The chapter ends with suggestions for improving addiction treatment in drug and veterans courts.
II. Opioid Dependence Treatment in Prison
Relapse rates of substance dependent individuals upon release are very high, which
indicates that substance abuse treatment in prison has been largely ineffective or under-provided.
One-third of individuals incarcerated for drug-related crimes relapse within two months of
release, 80% relapse within one year; and 95% relapse within three years.587
Failure to treat drug addiction in prison or to provide referral for treatment post-release
can have deadly consequences. Prisoners face a high risk of overdose following release,
especially within the first few weeks, because tolerance has declined but physical cravings and
environmental triggers may still remain.588 A study found that the general overdose risk for
recently-released Washington state prisoners was 12 times higher than the overdose risk for the
general public; in particular, the overdose risk in the first week following release was 127-times
higher than the overdose risk for the general public.589 Overall, 25% of post-release deaths occur
due to accidental drug overdoses.590
According to multiple studies, MAT treatment in prison prevents relapse, reincarceration, and HIV/AIDS.591 Gordon et al. (2008) and Kinlock et al. (2009) demonstrated
that methadone initiated in prison or post-release when inmates have integrated back into the
community was superior to counseling alone with respect to heroin use and treatment retention;
moreover, health outcomes were better for inmates whose methadone use was initiated in prison
than those whose use began post-release.592 Some MAT therapies may also be more effective
than others; a study of New York City heroin-dependent inmates found that inmates treated with
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buprenorphine were more likely to enter community treatment post-release than inmates treated
with methadone.593 However, inmates treated with buprenorphine were also more likely to divert
their medication than those treated with methadone.594 Thus, it should come as no surprise that
the WHO (which views addiction as an international public health issue) recommends that all
nations make methadone and buprenorphine widely available within prisons. Recently, the
National Commission on Correctional Health Care also recommended that methadone and
buprenorphine treatment increase in prisons.595
Yet, MAT is underused within U.S. prisons.596 In a 2009 study, Nunn et al. surveyed 50
departments of corrections (one in each state and the District of Columbia except North Dakota)
regarding their use of methadone and buprenorphine to treat opioid addiction. The authors found
that only 14% of prisons offered buprenorphine; 55% of prisons offered methadone under some
conditions, but primarily for special circumstances like pregnancy or pain relief. The authors
estimated that only 2,000 prisoners in the entire U.S. receive ongoing methadone or
buprenorphine treatment while incarcerated. Prisons in Southern states were significantly less
likely to offer the medications. Buprenorphine therapy was only common in the Northeast,
where one-third of prisons offered it. In general, 45% of systems referred inmates for methadone
treatment after release, and 29% referred them for buprenorphine. As compared to previous
years, more departments of corrections were permitting inmates to take methadone and
buprenorphine and providing referrals post-release.
A lack of knowledge about MAT’s effectiveness, however, remains widespread within
departments of corrections. The 2009 Nunn et al. study found that 49% of respondents were
unsure whether buprenorphine was an effective treatment, and 27% were unsure whether
methadone was an effective treatment. Among those departments of corrections that do not
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provide inmates with access to buprenorphine or methadone, 57% said it was due to a preference
for detoxification followed by abstinence-only treatment, and 20% cited security concerns about
having opioids available within prisons.
III. Opioid Dependence Treatment in Drug Courts
A.

What are Drug Courts?

Due to high relapse rates and overcrowded prisons in the late 1980s and early 1990s,
legislatures around the country established drug courts as an alternative to incarceration for
individuals convicted of drug-related crimes. Drug courts serve both punitive and rehabilitative
purposes. In June 2010, there were 1,372 adult drug courts in the U.S, along with 365 hybrid
courts for DUI and drug offenses.597 Fifty-five percent of U.S. drug courts are in rural regions,
18% are in suburban regions, and 27% are in urban regions.598 According to the U.S.
Department of Criminal Justice’s Drug Court’s Program Office, “[d]rug courts leverage the
coercive power of the criminal justice system to achieve abstinence and alter criminal behavior
through the combination of judicial supervision, treatment, drug testing, incentives, sanctions,
and case management.”599
Two primary drug court models exist: pre-plea and post-plea. In pre-plea drug court, the
arrestee enters drug court before pleading guilty to the charge. In post-plea drug court, the
arrestee must first plead guilty to the charge before entering drug court; the sentence is then
deferred while the defendant participates in the drug court program. In post-plea drug court, if
the defendant graduates from drug court, then his or her criminal record is expunged or the
sentence is waived. If the defendant fails to graduate from drug court, however, then the
defendant is incarcerated. Fifty-eight percent of adult drug courts are post-plea drug courts.600

109

Drug courts vary tremendously from jurisdiction to jurisdiction in terms of eligibility criteria,
program requirements, and treatment methods. In many jurisdictions, to be eligible for drug
court the participant must have been charged with drug possession, have no record of dealing
drugs or violent crime, and no history of violent behavior. As a result, repeat offenders and those
charged with the most serious offenses cannot opt to participate in drug court as an alternative to
incarceration. Typically, a drug court judge decides whether or not to accept a potential
participant into the drug court program based on an array of factors, including the number of
spaces available, an entry interview with the judge, the criminal record, an assessment of a
potential participant’s motivation, and need for treatment.601 If approved for drug court
participation, the participant, sometimes referred to as a client or customer, participates in a
program that typically lasts at least one year.602
Drug court programs usually consist of regular drug testing, court appearances, treatment
(most often in the form of mandatory counseling and support groups), and short-term punishment
for failure to meet program requirements. In my study of Indiana drug courts from 2015 to 2016,
19 of 20 courts required counseling and the same number required support group attendance.
Although participants are not required to attend 12-step groups due to First Amendment
concerns, most participants choose to participate in 12-step groups rather than other support
groups. I found that two reasons account for this fact: other support groups’ have limited
availability and drug court participants’ generally accept 12-step groups. In my study, no court
required participants to undergo any form of MAT.
In drug courts, the defense attorneys, prosecuting attorneys, and judges work together to
determine the best course of treatment for the defendant.603 Judges use a “hands on approach,”
forging personal relationships with clients that may lead them judge to be more empathetic
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towards some than others.604 Drug court staff consists of treatment staff (e.g. therapists and case
managers) and court officials (e.g. attorneys and the judge). However, drug court judges hold a
unique and significant power in the drug court, and may override physician-recommended
treatment plans whether or not the judge has medical experience.605
If defendants do not comply with any part of the drug court program, then graduated
sanctions are used, including more frequent probation officer meetings, status hearings, and/or
drug testing. Participants who commit severe violations have their participation terminated and
their original sentences re-imposed.606 Participants who successful complete the drug court
program can participate in a graduation ceremony.607
B.

The Prevalence of Opioid Dependence in Drug Courts

A 2008 study found that 19 percent of drug court participants primarily abused opiates, a
sharp increase from six percent in 2005.608 Between 2015 and 2016, I interviewed 17 judges
serving in 20 Indiana drug and veterans courts to understand how their institutions treat opioid
dependence. 59% of judges stated that opioid addiction was either very prevalent or the most
prevalent type of drug addiction in their courts; only five judges stated that opioid addiction was
not common. However, two of those five judges believe that opioid addiction is prevalent in their
geographic areas, but noted that few individuals suffering from opioid addiction are admitted
into their courts.
In my study, 53% of judges stated that heroin has become more common than
prescription pain pills among program participants, primarily because heroin costs less and is
more widely available. Judge 7 stated that a DEA raid on a local pain clinic has led to an
explosion of heroin use in the community:
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We have had some difficulties with the over prescription of opioids in our
community; they can’t get the opioids anymore because the specific doctor’s
clinic has been closed down by the feds, so those folks turn to the street, and
they turn to street Opana or Fentanyl and then they end up on heroin, and it’s
the worst heroin of all that they’re ending up on.
However, one judge perceived that heroin use was more prevalent than prescription pain pill
abuse among program participants; this judge also believed that law enforcement targets heroin
abusers more than prescription pain pill abusers. My Indiana-based study differs from results in a
national study by Matusow et al., which found that prescription pain pills are used by individuals
with opioid dependence in drug courts 66% of the time, whereas heroin was used 22% of the
time.609 The higher rate of heroin use in Indiana drug courts may reflect the relatively recent shift
from prescription pain pills to heroin as heroin has become more accessible.
C.

The Effectiveness of Drug Courts

Studies of drug courts’ effectiveness at preventing recidivism and drug use have been
generally positive, but some criticisms exist.610 Marlowe reviewed five meta-analyses of drug
courts and concluded “drug courts significantly reduce crime by an average of approximately 8%
to 26%, with most estimates falling around 14%.”611 Similarly, the Sentencing Project found that
drug courts reduce recidivism by 8% on the low end to 13% on the high end.612 In 2005, the
Government Accountability Office (GAO) conducted a meta-analysis of methodologically sound
drug court studies, pursuant to a Congressional mandate.613 The GAO reported that most studies
of drug court effectiveness carried out prior to 2002 lacked methodological rigor614 due to
selection bias, lack of randomized samples, lack of a control group, and failure to account for
socioeconomic factors.615 The GAO study concluded that the evidence of drug court success at
reducing recidivism was “limited and mixed.”616
GAO authors found a wide variation in drug court graduation rates, ranging from 27% to
66%, with graduates demonstrating lower recidivism rates than dropouts.617 The factor most
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correlated with program completion was compliance with drug court procedures. Interestingly,
the severity of sanctions for failure to comply with drug court procedures did not predict
completion rates.618 However, participants with “relatively fewer prior involvements in the
criminal system and who were older were more likely to graduate than were other
participants.”619 The GAO authors said that “those participants who were better able to
recognize their problems, recognize external problems, and were ready for treatment, were more
likely to complete the drug court program.”620This is consistent with other literature that suggests
participants should be matched to treatments based on their level of risk, responsibility, ability
and learning style.621 Dropouts had a recidivism rate comparable to persons who were not in drug
court.622
Drug courts are highly selective in determining which offenders are permitted to enter the
program, and frequently indirectly exclude the most severely-dependent individuals who often
have multiple prior convictions. As a result, studies of drug courts’ effectiveness are likely
skewed to reflect the success of less-dependent individuals.623 In general, different techniques
work for the two populations; while drug testing and drug treatment appear to be most effective
at reducing drug use among severely dependent drug court participants, judicial hearings are
most effective at reducing drug use among less dependent participants.624
D.

Frequency of MAT and Attitudes towards MAT in Problem Solving Courts

Few studies have examined use of MAT and attitudes towards MAT in problem solving
courts. However, existing studies have found widespread policies limiting MAT access, such as
policies forbidding participants from starting MAT while in the court program, requiring patients
to quit MAT in order to graduate, and barring patients utilizing MAT from entering the court
program. On the other hand, mental health counseling and twelve-step groups are almost always
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required for participants, with sanctions in place for participants who fail to participate in those
treatment methodologies.
1.

Matusow et al., A National Study of MAT in Drug Courts (2013)

The most comprehensive study to date was conducted by Matusow et al. in 2013 using
online surveys. 625 Respondents included administrators working within 93 drug courts in 47
states, plus Washington D.C. and Puerto Rico.626 Matusow found that half of drug courts did not
provide agonist medications (methadone or buprenorphine) to participants suffering from opioid
dependence under any circumstances,627 and that only 34% of drug courts allowed such
participants to use agonist medications.628 Drug courts provided buprenorphine treatment (40%)
more often than methadone (26%) or naltrexone treatment (18%).629 Only 40% of drug courts
allow participants already using agonist therapy prior to entering drug court to continue this
usage as a maintenance treatment; all other courts required clients to quit agonist therapy before
entering these programs.630 Moreover, although MAT is the medical standard of care for treating
pregnant women with opiate dependence, only 26% of drug courts provide these women with
MAT.631
Matusow et al. found that even among those drug courts open to MAT, practical barriers
sometimes prevented courts from referring patients to MAT. Urban courts that allowed MAT but
failed to refer patients to buprenorphine treatment cited cost as the primary barrier 43% of the
time. Rural courts that allowed MAT but failed to refer patients to buprenorphine treatment cited
lack of local buprenorphine-prescribing physicians as the primary barrier 74% of the time.
Surprisingly, 21% of respondents did not know why their drug court prohibited methadone.632
Similarly, when asked their opinions about MAT’s efficacy, the most common answer for was
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“uncertain” (58% of respondents), signaling drug court professionals’ lack of education about
MAT.633
Shockingly, more than 10 percent of respondents said that methadone or buprenorphine
“rewards criminals for being drug users.”634 Predictably, negative attitudes towards MAT and
misinformation about its effectiveness were most pronounced in those drug courts that banned
MAT.635 Interestingly, no significant associations were found between a) professionals’
knowledge of and attitude towards MAT and b) the professional’s discipline, role in the drug
court, education, or years of experience. Rather, “[t]he most significant differences in
knowledge and attitudes about MAT were between courts that permit MAT and those that do
not.”636 Furthermore, professionals’ attitudes towards MAT did not depend on the type of
medication that the drug court used, but rather were related to respondents’ attitudes towards
MAT in general.637 In that vein, the survey asked professionals in drug courts that prohibited
MAT whether they might introduce agonist medication “if evidence were available that
methadone or buprenorphine improved outcomes for drug court participants.” Almost half of the
respondents answered “yes” (49%).
2.

Andraka-Christou, A Study of Indiana Drug and Veterans Courts (2016)

According to my study of 20 Indiana drug and veterans courts, serious discrepancies exist
between drug courts’ adoption of MAT and the medical standard of care. Policies towards MAT
vary widely between courts in my sample. Some courts did not explicitly permit any form of
MAT; some courts explicitly permitted one or two medications but not three; and a few courts
permitted all three medications. While all judges were very familiar with mental health
counseling and self-help groups as treatment methods (including their methodologies and
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purposes), one judge expressed lack of familiarity with buprenorphine and four expressed lack of
familiarity with Vivitrol.
Every court in the study allowed participants to enter the program while undergoing
MAT. However, courts differed significantly in whether they allowed participants to continue
MAT upon entry. Such policies were usually medication-specific; for example, a court might
forbid participants from continuing methadone while in court but might permit them to continue
Vivitrol.
On a related note, courts also differed significantly in terms of whether they permitted
participants to begin MAT after entry. Again, relevant policies were often medication-specific.
Almost all courts (17 of 20) explicitly permitted participants to begin Vivitrol while in the
program, but one court did not permit participants to graduate from the program while on that
medication. Two judges who had never heard of Vivitrol prior to the interview assumed that
participants would be able to begin it while in the program because Vivitrol lacks an opiate
ingredient. Almost all courts (16 of 20) explicitly permitted participants to begin buprenorphine
while in the program; but seven courts only permitted participants to use buprenorphine for a
short period of time ranging from two weeks to 30 days). Half of the courts (10) permitted
participants to begin methadone while in the program. Interestingly, every court that allowed
participants to begin methadone also permitted them to begin buprenorphine and Vivitrol,
suggesting that courts open to methadone are more open to MAT in general. On the other hand,
some courts that permitted participants to use Vivitrol or buprenorphine did not permit them to
use methadone, reflecting the fact that judges are generally most ambivalent about methadone.
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Table 1: Can participants enter court while using MAT? If participants enter court while using MAT, can
they continue it?
Can use
Enter while

methadone

Can use

Enter

Can use Viv.

Court

Type of

on

in court

Enter while on

bupr. in court

while on

in court

#

Court

methadone?

program?

buprenorphine?

program?

Vivitrol?

program?

1

Drug

Yes

Yes

Yes

Yes

Yes

Yes

2

Veterans

Yes

Yes

Yes

Yes

Yes

Yes

3

Drug

Yes

No

Yes

Probably

Yes

Probably

4

Veterans

Yes

Yes

Yes

Yes

Yes

Yes

5

Drug

Yes

No

Yes

Yes

Yes

Yes

Prison-based

N/A

N/A

N/A

N/A

N/A

N/A

6

Drug

Yes

No

Yes

Yes

Yes

Yes

7

Drug

Yes

No

Yes

Yes

Yes

Yes

8

Drug

Yes

Yes

Yes

Yes

Yes

Yes

9

Drug

Yes

Yes

Yes

Yes

Yes

Yes

10

Veterans

Yes

Yes

Yes

Yes

Yes

Yes

11

Veterans

Yes

No

Yes

Yes

Yes

Yes

12

Drug

Yes

No

Yes

No

Probably

Probably

13

Drug

No

No

Yes

Yes

Yes

Yes

14

Veterans

Yes

Yes

Yes

Yes

Yes

Yes

15

Drug

Yes

Yes

Yes

Yes

Yes

Yes

16

Drug

No

Yes

No

Yes

No

Yes

17

Veterans

Unsure

Unsure

Unsure

Unsure

Unsure

Unsure

18

Drug

Yes

Yes

Yes

Yes

Yes

Yes

19

Drug

No

No

Yes

Yes

Yes

Probably

20

Drug

Yes

No

Yes

No

Yes

Yes

% Yes

84.2%

52.6%

94.7%

88.9%

94.4%

100%

N/A

Overall
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Table 2: Can participants begin MAT after starting the court program?
Court

Type of

Can start Methadone in

Can start bup. In

Can start Vivitrol in

#

Court

court?

court?

court?

1

Drug

Yes

Yes

Yes

2

Veterans

Yes

Yes

Yes

3

Drug

No

Probably

Probably

4

Veterans

Yes

Yes

Yes

5

Drug

No

Yes

Yes

Prison-based

No

No

No

6

Drug

No

Yes

Yes

7

Drug

No

Yes

Yes

8

Drug

Yes

Yes

Yes

9

Drug

Yes

Yes

Yes

10

Veterans

Yes

Yes

Yes

11

Veterans

No

Yes

Yes

12

Drug

No

No

Probably

13

Drug

No

Yes

Yes

14

Veterans

Yes

Yes

Yes

15

Drug

Yes

Yes

Yes

16

Drug

Yes

Yes

Yes

17

Veterans

Unsure

Unsure

Unsure

18

Drug

Yes

Yes

Yes

19

Drug

No

Yes

Yes

20

Drug

No

No

Yes

% Yes

50%

84.2%

94.4%

N/A

Overall
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Even though all judges expressed positive views of counseling and support groups, their
overall opinions about MAT (as opposed to a specific medication) ranged from distrust to
ambivalence to excitement. While many judges primarily discussed MAT in negative terms,
focusing on the risks of abuse or diversion, other judges discussed MAT’s usefulness. Judges
most commonly displayed ambivalence towards MAT in general, especially in courts where they
had approved use of one MAT medication while banning other medications. Examples of
ambivalence towards MAT include the following:
I would just say we’re guarded when it comes to medication-assisted
treatment. (Judge 8)
The other drug-assisted therapies [buprenorphine and Vivitrol] … I
wouldn’t say that we would be totally against it, but it would be something
that would be limited use, because . . . my feeling is, you’re trading one
addiction for the other, and yeah it’s legal and so forth, but our push is more
away from [MAT] rather than towards it. (Judge 6)
We don’t emphasize [MAT], but … there’s some individuals for whom
medication-assisted treatment is appropriate. Now I’m willing, personally,
as a judge, to have pretty, pretty much an open mind about, if I can find a
provider who will give me good, evidence-based reasons for using a
particular drug-assisted or medicine-assisted kind of intervention, I’m
willing to consider it. That’s fine. (Judge 2)
a. Attitudes Towards Methadone
Judicial attitudes towards methadone were either neutral (in courts that permitted
participants to begin methadone after entry) or overwhelmingly negative (in those courts that
banned methadone.) Of the three medications, methadone inspired the most negativity from
judges. For example, one judge who allowed buprenorphine and Vivitrol (but only for shortterm use) stated, “The methadone I find to just be a hideous, awful thing.” (Judge 7) While
judges generally did not explain their negativity towards methadone, their attitudes likely reflect
American society’s negativity towards methadone.
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In light of these negative judicial attitudes towards methadone, it is unsurprising that only
half of courts permitted participants to begin methadone while in the program. Three of twenty
courts prohibited participants from entering the program while undergoing methadone treatment.
Sixteen courts permit participants using methadone to enter the program, but six of those courts
required participants to stop the methadone treatment once in the program.
Judges’ most common criticisms of methadone treatment were related to its addictive
nature, distrust of methadone clinics, claims of methadone’s ineffectiveness at promoting
abstinence, the possibility of overdose, the likelihood of diversion, and cost (methadone is not
covered by Indiana’s Medicaid program). One judge was aware of research indicating that
methadone was effective in reducing recidivism and illicit drug use, but believed that research
was outdated on methadone’s efficacy as compared to abstinence-only treatment in drug court.
He believed that researchers are not comparing apples to apples but rather apples to oranges,
especially in light of emphasis on evidence-based counseling. Because of ambivalence towards
methadone, that judge neither banned nor encourage its use, choosing to approach methadone
use on a case by case basis. Even though the judge’s desire to learn more about MAT is
impressive, the fact that the judge is relying on self-education rather than deferring to a physician
is disconcerting.
Multiple judges expressed concern with management of methadone clinics. Even one
judge who stated that “methadone is shown to be very effective” by research believed it to be
only “marginally effective” when provided through poorly managed methadone clinics. This
judge described poorly managed methadone clinics as those that met only minimum federal
requirements, gave increasing methadone dosages, did not supervise patients, and did not
provide counseling. Three judges analogized poorly managed methadone clinics to drug dealers.
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For example: “It seems like drug dealing to me too, in terms of what behaviors that we see and
the treatment failures and the people turning to criminal activity when they don’t have the money
to pay for the methadone. (Judge 1).”
Two judges did not believe methadone to be an effective addiction treatment. One
claimed to have seen urine test results where a participant using methadone still has other opiates
in his or her system, such as oxycodone. But the presence of other drugs has other explanations;
participants who fail to remain abstinent while undergoing methadone treatment may be
receiving too low a dosage, causing them to experience cravings after the methadone wears off
and to other seek readily available opioids that would then show up in participants’ urinalysis
results.
Those judges who strongly distrusted methadone may be discouraged from learning
about buprenorphine or Vivitrol. Methadone appeared to be a kind of baseline pharmaceutical to
which judges compared buprenorphine and Vivitrol. One judge explained how members of the
local criminal justice system had a difficult time accepting buprenorphine treatment because they
had seen overdoses involving methadone.
b. Attitudes towards Buprenorphine
Attitudes and policies towards buprenorphine were somewhat less negative than attitudes
towards methadone. Sixteen of twenty courts permitted participants to begin buprenorphine in
the program, but seven courts required participants to wean off of buprenorphine to graduate
from the program. Two judges stated that they accepted new participants undergoing
buprenorphine treatment through a physician into the drug court but then required or strongly
encouraged participants to wean off of buprenorphine after entry. Judges supposedly deferred to
physicians’ decisions about buprenorphine treatment but in fact held pre-existing opinions about
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the treatment and for how long the treatment should be allowed. Distrust of physicians’ roles in
the treatment process was palpable. Rather than perceiving physicians recommendation to
maintain patients on MAT long-term as being based on medical research (which clearly
concludes that long term is better than short term treatment), judges perceived physicians
recommendations as being motivated by financial gain.
So, it’s interesting; our team battles whether or not we feel that medically
assisted treatment is appropriate. I can tell you I think it is, provided you have
the right professional administering it and working to wean them off of it. One
of the problems that we saw was that we didn’t feel like the people
administering them were trying to wean . . . or cut back and slowly get ‘em off
of this medically assisted treatment, and wanted to keep ‘em on it for, I hate to
say it, but basically their financial gain.
Yeah, it’s not a deal where they take it [they can take suboxone] for 90 days, I
mean I don’t pretend to be a doctor, but our theory is you can’t substitute one
drug for another…Well, it’s up to the doctor, but . . . we want them off as soon
as they can get off…I wouldn’t see more than the thirty days at most, typically
it’s two to three weeks.
Even two judges who claimed to look at participants’ situations on a case-by-case basis
expressed a preference for weaning participants off of buprenorphine. One judge only allowed
buprenorphine for detoxification purposes, contrary to best medical practices. That judge’s court
did not allow buprenorphine use for more than two weeks. Courts’ short-term requirements for
buprenorphine are an unfortunate example of judges and treatment teams (usually without
physicians) making medical decisions contrary to best medical practices. Medical studies
demonstrate that short-term buprenorphine use is less effective at preventing relapse and
mortality than long-term use.638 In fact, the ASAM strongly discourages policy makers from
setting treatment term limits for buprenorphine, such as Medicaid coverage limits.639
Access to buprenorphine varied considerably depending on court location. One judge in
a rural area knew of only one buprenorphine provider in the whole county, while a second judge

122

knew of multiple buprenorphine providers in city. A third judge stated that the one
buprenorphine provider in that city had reached maximum patient levels (as delineated under the
Drug Addiction and Treatment Act). A fourth judge said, “It’s readily accessible to addicts and
it’s readily accessible from addicts.”
Even though 16 courts permitted buprenorphine use for at least a short time period, only
one judge spoke overwhelmingly positively of the medication: “The [local] VA Medical Center
has just been hitting the ball outta the ball park. We’ve had soldiers that are on Suboxone in
particular that’re just doing incredibly well” (Judge 9). In contrast, eight judges spoke
overwhelmingly negatively of buprenorphine. Judges most frequently criticized buprenorphine
for its abuse potential. Some judges distrusted buprenorphine-prescribing clinics because they
were allegedly poorly managed or improperly supervised participants:
You know, Suboxone doctors who, you know, they’re doctors, but, you know,
all you have to do is show up at their office and pay them some money and you
could walk away with however much supply of Suboxone they’ll give you.
(Judge 18)
What we’ve found in the past in our community, the people on, on Methadone,
and now Suboxone, is that at the health clinics, or the pain clinics, or the clinics
that’re administering this, we don’t get the monitoring that, that we feel is
needed, and my case workers feel that there’s more abuse, or a, a high, than
there is use for treatment. (Judge 12)
It’s one of those minute clinics, one of those doc in a box type clinics. I don’t
know about you, but as a judge, I’m sitting there from the outside thinking,
“okay. This is a med check clinic. It’s not an addictions treatment program, but
nine doctors in that facility are prescribing, have the ability to prescribe
Suboxone. (Judge 8)
[The local buprenorphine provider] is sitting in jail … for drug dealing, for the
way he was operating his clinic. (Judge 4)
Multiple judges believed participants sometimes purchased buprenorphine illicitly.
Studies suggest, however, that some drug users who purchase buprenorphine illicitly often do so
in an attempt to self-treat when they lack access to a legitimate medical provider, often for
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reasons such as care expenses or because there is no local buprenorphine provider.640
Interestingly, one judge described a participant who purchased buprenorphine illicitly in an
attempt to quit using heroin. According to the judge, the participant no longer used heroin as a
result:
He had actually got [suboxone] illegitimately from somebody and, and he
understands if, if he continues to use heroin, he’s probably not gonna live too
much longer, so he had made this conscious decision that okay, well, I’m gonna
get Suboxone. I can’t afford it [through a physician] so I can get it from other
people. (Judge 16)
Those judges whose primary opposition to buprenorphine was its potential for abuse and
diversion (as opposed to philosophical disagreement with MAT) were optimistic about
Probuphine, a six-month surgical implant of buprenorphine that received FDA approval in May
2016.
c. Attitudes towards Vivitrol
Vivitrol was the form of MAT that drug court judges viewed most positively. In my
research, I found that 16 of 20 courts explicitly permitted Vivitrol; two judges believed their
courts would probably permit Vivitrol but had not yet had to decide what to do about that issue,
and one judge was “unsure” of the court’s policies towards Vivitrol. Judicial attitudes towards
Vivitrol were fairly consistent: either judges knew about the medication and thought it was good,
or else they knew little about it but were very interested in learning more. The three benefits of
Vivitrol judges most often cited were its inability to be abused or diverted and its effectiveness at
preventing relapse. As one judge enthusiastically remarked: “I am all in on Naltrexone!” (Judge
1) When asked whether the judge had seen benefits from Vivitrol among drug court participants,
another judge asserted: “Oh, absolutely!” (Judge 18) That judge liked to ask participants “how
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it’s going on the Vivitrol” during court hearings in front of other participants in the hopes that
others will become interested in the medication.
Some judges voiced criticisms of buprenorphine, however. Cost was the most common
criticism; two courts were currently getting free Vivitrol samples or discounts through a statefunded study and the manufacturer. Some judges reported that few physicians in their areas
prescribed Vivitrol; according to one judge, only a single doctor in the entire county prescribed
the medication. Another judge said, “I’m very interested in Vivitrol, but we haven’t found
anyone yet who has been prescrib[ing] it.” One judge is actively trying to educate other judges
and even physicians about Vivitrol.
Furthermore, four judges reported limited or no knowledge of Vivitrol. After I briefly
described Vivitrol, three of the four judges appeared interested in learning more about the
medication. The interest was always in relation to its lack of an opioid ingredient. For example,
the following exchange occurred with one judge:
Interviewer: Does that fact that [Vivitrol] lacks an opiate ingredient and is not a
controlled substance make it, in your opinion, something that your drug court
would be more willing to refer patients for, than say Suboxone or Methadone,
which have an opiate ingredient?
Judge 13: Just on what you told me, yes, without a doubt. I don’t know what the
downside is; I’m assuming . . . there may be some downside, but no; we would
be very, very interested in using something like that.
Those judges who were informed Vivitrol mentioned a handful of informative sources,
including trainings, particularly at the annual National Association of Drug Court Professionals
conference; direct communication from the pharmaceutical manufacturer; other criminal justice
system administrators; the VA; and medical literature. But two sources of information about
Vivitrol were conspicuously missing from this list: physicians and counselors.
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Strangely, four courts that allow participants to start Vivitrol in court also require participants to
wean off prior to graduation, contrary to best medical practices. One judge said he refused to
permit Vivitrol until he found a Vivitrol provider who promised to actively wean participants off
of the medication:
We have a private doctor that we’re working with that administers the Vivitrol,
monitors our participant, gives us feedback, and works to, to, to wean them off
of the, the medically assisted treatment…It’s interesting, our team battles
whether or not we feel that medically assisted treatment is appropriate. I can tell
you I think it is, provided you have the, the right professional administerin’ it
and workin’ to wean them off of it. One of the problems that we saw was that
we didn’t feel like the, the people administering them were trying to wean the,
or cut back and slowly get ‘em off of this medically assisted treatment, and
wanted to keep ‘em on it for, I hate to say it, but basically their financial gain.
(Judge 12)
Two judges stated that while they do not have bright line rule prohibiting graduation on
Vivitrol, they encourage participants to get off Vivitrol prior to graduation. One judge believes
participants should be off Vivitrol within 18 months, while the other believes participants should
be off Vivitrol within 24 months.
d. Misunderstanding Sobriety
The Matusow et al. study and my own dissertation research reveal that the problemsolving courts’ definition of sobriety often differed from the medical definition. Some judges
explained that sobriety meant both living life without drug abuse and without the assistance of
MAT. For those judges, a participant who tested negative for opiates was not considered “sober”
if treated with MAT. In other words, how one achieved a series of negative urine tests was most
important, not whether the urine tests were negative for opioids in the first place. In contrast,
other judges believe that participants who did not abuse drugs were “sober,” regardless of
whether they were treated with MAT.
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In my study, five judges expressed some version of the view that abstinence while on
MAT was not “complete” sobriety because MAT merely replaced one drug with another.
Fascinatingly, even though studies overwhelmingly show that MAT leads to treatment success
(i.e. lower relapse rates, overdoses, HIV-rates), one judge described MAT as a sign of “defeat” in
treatment, as if success through MAT is worth less than success through abstinence-only
treatment:
Certainly all of these options [methadone, buprenorphine, and Vivitrol] are
better than buying the crack cocaine, methamphetamines, and heroin off the
streets, but as pharmacological responses being, addiction we need to see the
bigger picture of public policy to ultimately get our clients to live drug free, or
we’re simply trying to maintain the population with something other than
heroin. I don’t want to be a defeatist and say that we can’t get our clients
completely drug free. I think we should instruct our clients and have a goal
towards a life, the life that I have, that’s what they’re entitled to, so I think
moderately drugging is not the right answer, except in those, like I said,
exceptions where a physician or a psychiatrist says this person is bipolar. (Judge
11, italics added)
Some judges equated buprenorphine and methadone to other illegal drugs:
What we focus more on, in our treatment is keeping them sober. You know
what I mean? And, and, and keeping them and, and we focus, sobriety-focused,
as opposed to giving them a drug to replace a drug. It’s to try to, try to, try to get
them to where they don’t, that they, they won’t need to use it, like dealing with
underlying issues and things of that nature… Our goal is to rehabilitate people
so that they would be clean and sober. And so we would want them, by the time
they graduate, to be off Jack Daniels, off the heroin, off the Soboxone, off the
Methadone, and leading a completely clean, sober life. (Judge who oversees
prison treatment program)
We don’t want ‘em jackin’ off for three years, you know it’s a drug program,
doesn’t mean you’re supposed to be on drugs, supposed to be off drugs. (Judge
17)
You know, there are drug courts who are, who are happy to have their people on
Methadone, there are drug courts who are happy to have their people on
Suboxone. We just think that’s another form of addiction. (Judge 18)
I mean I don’t pretend to be a doctor, but our theory is, you know, you can’t
substitute one drug for another. (Judge 19).
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Relatedly, many judges assume that MAT “simply substitute[s] one addiction for
another.”641 As Matusow et al.’s study demonstrates, some individuals even believe that MAT is
a “reward” for bad behavior. This belief completely ignores the fact that MAT allows
individuals with drug dependence to function normally and prevents them from “getting high.”
The AMA and other professional scientific and medical organizations have vigorously opposed
the idea that MAT is “just another drug.” Ignoring the medical community’s expertise, many
drug courts force patients to cease MAT as a precondition of participation.642 Such policies may
harm dependent individuals; studies show that when individuals are forced to stop agonist
treatment before they are ready, relapse is extremely likely.
Some judges also incorrectly assume that individuals cannot lead normal, functional lives
while undergoing MAT. For example, one judge stated that individuals on MAT are “zombies.”
Another judge stated that individuals cannot safely drive while being treated with methadone.
However, individuals can drive while undergoing any form of MAT. Even methadone, a full
agonist, does not impair intellectual functioning, reaction-time, or perceptual-motor skills.643
Misconceptions about how participants feel and act while undergoing MAT contribute to the
notion that recipients cannot truly be “sober.”
e. Treating MAT differently from other Mental Health Medications
While some courts discourages MAT for addiction treatment, they encourage medication
for treating other mental health conditions, such as bipolar disorder.644 This discrepancy between
court-approved treatment for addiction and other psychiatric conditions (e.g. bipolar disorder)
can be interpreted in a few ways. First, it suggests that some judges do not view addiction as a
medical condition with a strong biological component, but regards addiction as fundamentally a
psychosocial condition where the biological component is non-existent or minimal. In contrast,
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the same judge believes bipolar disorder is a biopsychosocial condition.645 This perspective
downplays addiction’s biological component but not the biological components of other mental
health conditions. Because MAT addresses addiction’s physical symptoms (e.g. cravings), those
who lack an accurate understanding of addiction’s biological component may regard the
medication as superfluous. The fact that judges hold such beliefs suggests a need for increased
education about addiction’s biological dimensions, in particular the physiological effects of
opiates on receptors in the brain and the dopamine system.
Second, the disparate treatment of addiction and mental illnesses such as bipolar disorder
may signify that some judges are more familiar with using medications to treat mental illness and
less familiar with pharmaceutical treatments for addiction. Judges may be unaware that
medications for treating addiction are effective, even though they know that pharmaceutical
interventions for mental illness are effective. Again, this belief suggests the need for increased
education about the nature of addiction and research on MAT’s efficacy.
Third, the disparate treatment of addiction and bipolar disorder may be based on fear of
participant abuse and diversion of addiction medication, which does not exist for pharmaceutical
mental illness interventions. Even if judges feel that MAT may be useful for treating addiction,
just like medication is useful for treating bipolar disorder, they may believe the risk of abuse or
diversion is simply too great. In this case, a drug court should not restrict MAT but instead
should carefully monitor participants on MAT and develop working relationships with treating
physicians. Even so, however, some courts may feel unable to properly monitor participants
using MAT due to funding constraints and limited staffing.
Due to the discrepancy in attitudes towards MAT and other mental health medications,
the court may be less likely to refer participants suffering from addiction without other co-
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occurring mental illness to a psychiatrist than participants battling both addiction and mental
illness. One judge explicitly stated that participants without co-occurring mental disorders are
never referred to psychiatrists, and that only those with co-occurring mental disorders would be
referred.
f. MAT is more accessible in Veterans Courts
Throughout the interviews it became evident that the Veterans Administration (VA)
views MAT favorably and recommends it in cases of opiate addiction. The pro-MAT attitude of
the VA seems to infiltrate veterans’ courts. When I asked one judge who oversees both a drug
court and a veterans’ court whether the VA is open to MAT, he responded:
Very, the VA is extremely open. We invited the person that oversees the
program [locally], I can’t think of her name, but she came and spoke to all of
our community corrections and probation officers, kind of explaining how it
works, so they’re, they’re proponents for it. They don’t force it, obviously, but
they’ll educate the participant as to, here are the pros and cons, you know, but I
would say they’re very pro. (Judge 9)
Perhaps equally importantly, the VA covers the cost of MAT for qualified veterans, and the VA
provides relatively easy access to physicians who prescribe MAT within VA facilities. Most, but
not all, veterans’ court participants are VA-eligible and thus have access to MAT through the
VA.
Veterans court’s different because we have the services of [the local] VA
Medical Center. I always call it drug court in heaven because, if you’re a
veteran eligible, you know, benefit eligible, they can provide everything – the,
the medications, psychologists, psychiatrists, housing, transportation, food. I
mean, the VA right now is well funded. (Judge 9)
According to one judge who oversees both a veterans’ court and a regular drug court, a veterans’
court participant will access MAT much faster than a drug court participant. Another judge who
also oversees a veterans court and a drug court stated the participants in the drug court only
obtained access to Vivitrol six months ago due to a state research grant, but participants in the
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veterans’ Court have had access to Vivitrol for years. One judge who oversees both a drug court
and a veterans’ court has two different policies with respect to methadone in the clinics, because
the judge trusts methadone providers in the VA system more than the local non-VA methadone
clinic.
We’re still in a position where we’re not accepting people that’re on Methadone
[in the drug court], although we do in our veterans treatment court…where we
have, what I feel…are physicians that’re properly prescribing it, and monitoring
it. We don’t on the non-veteran side because we didn’t have a trustworthy
relationship in [our county] with the clinic that was prescribing it. (Judge 12)
IV. How are Treatment Decisions Made in Drug Courts?
Very few studies have examined problem solving court MAT treatment policies,
including how courts pick one treatment over another. In my study of 20 Indiana drug and
veterans courts646, every judge stated that the court’s treatment team makes treatment decisions. I
gathered complete team member information for 18 of 20 problem-solving courts. Treatment
teams typically consisted of the following members: the judge (the official head), the prosecutor,
a defense attorney, at least one counselor, and at least one case manager. Additionally, 13 of 18
court treatment teams included a police officer, 12 included a probation officer; and two included
a physician. Veterans’ court teams typically included a Veterans Administration (VA)
representative or outreach officer. One court’s treatment team also included a representative
from a women’s homeless shelter and a representative from a veteran’s charity (non-VA
affiliated). Six court teams included a court director or administrator. Overlap may exist
between some positions; for example, in at least two courts the probation officers also served as
case managers.
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Table 3: Participants on Court Treatment Teams
Court
Defense

Case

Police

Probation

VA

Director

Court

Judge

Prosecutor

Atty.

Counselor

manager

Officer

Officer

Physician

Rep.

(Admin.)

Drug

Y

-

-

Y

-

-

-

-

-

-

Veterans

Y

-

-

Y

-

-

-

-

-

-

Drug

Y

Y

Y

Y

Y

Y

Y

N

n/a

N

Veterans

Y

Y

Y

Y

Y

N

N

N

Y

N

Drug

Y

Y

Y

Y

Y

Y

Y

Y

n/a

N

Drug

Y

Y

Y

Y

Y

Y

Y

N

n/a

N

Drug

Y

Y

Y

Y

Y

Y

N

N

n/a

Y

Drug

Y

Y

Y

Y

Y

Y

Y

N

n/a

N

Drug

Y

Y

Y

Y

Y

Y

Y

N

n/a

N

Veterans

Y

Y

Y

Y

Y

Y

Y

N

Y

N

Veterans

Y

Y

Y

Y

Y

Y

Y

Y

Y

Y

Drug

Y

Y

Y

Y

Y

Y

Y

N

n/a

N

Drug

Y

Y

Y

Y

Y

N

Y

N

n/a

Y

Veterans

Y

Y

Y

Y

Y

N

Y

N

Y

Y

Drug

Y

Y

Y

Y

Y

N

N

Y

n/a

Y

Drug

Y

Y

Y

N

Y

N

N

N

n/a

N

Veterans

Y

Y

Y

Y

Y

Y

N

N

Y

N

Drug

Y

Y

Y

Y

Y

Y

Y

N

n/a

Y

Drug

Y

Y

Y

Y

Y

Y

N

N

n/a

N

Drug

Y

Y

Y

Y

Y

Y

Y

N

n/a

N

Overall
(% Yes)

100%

100%

100%

95%

100%

72.2%

66.7%

16.7%

(100%)

33.3%
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Judges always led the treatment teams, but every judge stated that he or she tended to defer to the
treatment professionals. For example, Judge 11 stated:
When it comes to treatment protocol, that’s actually made by the treatment
professionals, and I suppose, in theory, you know, we have the option as a team
arguing those type things, and then having the judge ultimately say yes or no,
but it’s a practical matter. We let the treatment people do the treatment thing.
(Judge 11)
If there are ten people on the team, oh there are, let’s see, there are eleven
people on the team that have to have a vote, then I have eleven votes I guess, so
yeah, but, you know, I’m not certainly one that has the extensive knowledge of,
of treatment services and, and things like that, so we all, all the non-mentalhealth professionals and non-substance-abuse treatment professionals are
certainly gonna rely on the experts for their recommendations. (Judge 3)
As a judge, it’s not my role to make a decision in terms of appropriate
treatment, but you know, it is my role to be part of the conversation when, you
know, we talk about the all kinds of different needs that the person has in
staffing, one of which is treatment too, and also to share information that I have.
(Judge 1)
Some of these treatment professionals on court treatment teams have private practices.
Most, however, provide counseling through a local health agency to whom the court treatment
team refers participants. Therefore, treatment providers on the team frequently serve as liaisons
between the court and the health agency, sharing information between the two entities. In 18 of
20 courts, the treatment professionals on the treatment team are exclusively counselors, either
psychologists or social workers, and not physicians.
If non-physician treatment professional predominantly make decisions on drug court
treatment teams, then in practice most treatment decisions are made by counselors, who compose
the vast majority of such professionals. Naturally counselors should make decisions regarding
the courts’ use of counseling therapies. But policy makers should consider whether counselors
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are the appropriate decision-makers with respect to MAT policies. Because counselors cannot
legally prescribe MAT, they are unlikely to be extensive educated about such therapies.
Furthermore, approximately 50% of SUD counselors in general in the U.S. are undereducated
about or biased against MAT according to a national study.647 Counselors’ lack of education and
bias against MAT combined with counselor-centered decision-making on treatment teams may
contribute to the widespread underuse of MAT in American drug courts. In a majority of courts,
at least one team counselor was a representative of a local treatment provider (e.g. the local
mental health agency). Interestingly, three treatment team counselors were themselves in
recovery from drug addiction, with one having previously graduated from drug court.
Only two problem-solving court treatment teams included a physician; of the two
physicians, one was an OB-GYN who sometimes counsel drug court participants and the other
was retired and practiced in an unknown area. Physicians’ scarcity on court treatment teams is
unfortunate but unsurprising. Physicians have historically been under-involved in addiction
treatment in the U.S.,648 and few drug courts can afford to compensate physicians in light of their
limited funding. Finally, as one judge stated, most physicians do not have free time to voluntarily
donate to a drug court. One of the two judges whose drug court treatment team included a
physician stated that having a physician was very valuable because that person both assisted with
decision-making and served as a liaison between the court and other physicians who provide
treatment to participants. One judge whose team lacked a physician would “love” to have one
with whom the team could discuss MAT options and provide health assessments.
Even though all problem-solving court judges stated that they have only a small role in
treatment-decision making, subtle comments during the interviews revealed that judges may
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have more persuasive power on treatment teams than they realize. For example, consider the
following statements, in which judges discuss their own views in relation to court policies:
Well, probably up until this year, we’ve had a pretty strong bias against
medication-assisted treatment, and that’s probably been largely because of my
biases… [But] as it stand now, I suppose that if, if the, the treatment folks are
recommending medication-assisted treatment and the participant is open to the
treatment, then I’m probably gonna go along with it. (Judge 10, whose court did
not allow MAT until recently)
I, we, we allow the clients to use [Suboxone] short term to age them from a
more serious drug and addiction process, and kinda bring them down slowly.
But whether it’s Suboxone or whether it’s Methadone, I am not a fan of
marginalizing our clients for life and saying that we’re going to cast them away
as lost souls, and we’re just basically going to drug them for life, that if you’re
going to use Suboxone, or you’re going to use Methadone, you’re going to use
some type of pharmacological response to addiction, it needs to be short term to
bring it down from their level of drug usage with counseling, to have a life of
sobriety, as opposed to a life of moderately, chemically maintained with
Suboxone or Methadone. (Judge 11, whose court only permits short-term use of
MAT)
Many of [the medications] are addictive, that’s, you know, that’s the problem I
have with some of those, they’re addictive themselves. And you’re just
substituting one for another; it can be used for a double weaned it off, but just
like with Methadone. I mean that just it.... There’s this one in Indianapolis and
there’s one in Muncie locally, so I always wonder they go up there and they
come back under the influence, or driving to those clinics, they take their dose
and…I mean, how’s that good for anybody? (Judge 17, whose court does not
permit buprenorphine or methadone)
Nobody’s on Methadone in drug court. I don’t allow that. (Judge 17, whose
court does not permit methadone)
Now I’m willing, personally, as a judge, to have pretty, pretty much an open
mind about, if I can find a provider who will give me good, evidence-based
reasons for using a particular drug-assisted or medicine-assisted kind of
intervention, I’m willing to consider it. (Judge 2, whose court does not ban any
form of MAT)
V. Relationships with Treatment Providers
Most court treatment teams in the study send participants for counseling to outside
agencies, private counselors or physicians. Only one court provides treatment “in house,”
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through court staff members. Even when courts send participants to outside agencies for
counseling, those agencies are represented by one or two treatment providers on the court
treatment team.
Information sharing about participants is an important part of partnering with another
treatment provider. Every court in the study requires participants to sign an information release
form as a condition of court program participation. The extent to which information is shared
about individual participants between the court treatment team and outside providers differs from
court to court. In some courts, information sharing with counselors is fairly minimal, consisting
of a bi-weekly or monthly list of treatments the participant has attended and the counselors’ brief
opinion of whether the participant is making progress. If the counselor tests urine, then urine
results are also included. Such information sharing is typical of veterans’ courts and VA
relationships. However, some drug court judges also described relatively minimal information
sharing with outside counselors.
We get weekly updates on if they made their meetings, and then those agencies
also drug screen, so we find out whether or not they did drug screen, the results.
So drug court team, as a whole, gets updated and we monitor the weekly
activity. (Judge 13)
I don’t think that the case managers who are supervising our participants are
getting, like, weekly progress reports but they do get regular progress reports
and they do, and they do check with the treatment providers regularly to see
how things are going with the treatment, with the particular participant. (Judge
18)
In a few courts, information sharing includes detailed notes of sessions in which the
participant participated, including statements made by the participant to the counselor. Counselor
notes are then reviewed by the court treatment team. One court requires every participant’s
counselor to attend weekly staff meetings at the drug court, a requirement the judge admits is too
onerous for most counselors in the area to want to participate in drug court treatment.
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The

counselor that does attend weekly staff meetings gives the staff a “play-by-play” of what the
participant said and felt during recent counseling sessions. According to that judge, detailed
information sharing keeps the participant honest.
But, these people, in order to hold them accountable, I think it’s only fair that
they recognize that their treatment provider is going to come into court and hold
them accountable in court, just like they would hold them accountable in a
treatment setting, so that they’re not allowed to get away with tellin’ me false
things in court that they, you know, told the, told the counselor something
contrary throughout the week…We’re also getting comments from participants
that said, “Hey, I really like the fact that my treatment provider is there in court
and can confirm the things that I’m telling you.” (Judge 8)
The information sharing goes in the reverse direction as well. For example, during a
weekly staff meeting the case manager (who always works for the court) will tell the team which
participants had positive urine tests and other information acquired by the case manager during
the week. Treatment providers on the team or their representatives use such information to
address problem areas or relapses of which they might otherwise be unaware.
[W]e talk about the, all kinds of different needs that the person has in staffing,
one of which is treatment too, and also to share information that I have that may
make a treatment provider say, “Well, I didn’t know about that”. Maybe, you
know, this thing that came out in, in probation or came out in court might
indicate that this, that we’ve got some trauma here and so we may want to add,
you know, some additional treatment that we didn’t know was necessary at this
time because I didn’t have this information, so that’s really sort of the function
of staffing is that sharing of information so that we can align the treatment and
all the other interventions that we provide most appropriately. (Judge 1)
Information sharing between court treatment team and outside treatment providers
sometimes leads to adjustment in treatment plans by the court treatment team. For example, a
counselor from the treatment agency may discover during the course of counseling that the
participant suffers from post-traumatic stress disorder (PTSD). The counselor, who is also a
member of the court treatment team, will report the diagnosis of PTSD to the court treatment
team the following week during the weekly staff meeting. The court treatment team will then
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decide whether or not to require or recommend that the participant attends a self-help group for
PTSD in addition to a self-help group for addiction.
Typically, treatment teams defer to recommendations by counselors on the team,
especially recommendations about counseling. On the other hand, court teams are less likely to
defer to physicians prescribing MAT, at least not without careful consideration of the physician’s
practice and recommendations. For example, in an interview one judge disagreed with the
physicians’ prescribed dosages at the local methadone clinic:
Just from our local experience, a lot of our clients, they don’t try to wean off,
matter of fact, they go up in dosage. That’s true. They’ve been on it for six
months and . . . they increase it, it’s like, this is crazy. In fact, . . . it’s a lack of
trust, on the client’s part and on the clinic…We try very hard to rely on the
experts in the field, but at the same time, I mean, I have to tell you that we have
not had success with methadone, so no matter what the experts are telling you,
just through our personal results, we definitely wean. Now the other two
[Suboxone and Vivitrol], I’m sure because we have zero familiarity with it, we
would do whatever the experts tell us to do. (Judge 13)
Significantly, too low a methadone dosage can lead to relapse; as cravings and
withdrawal symptoms will appear prior to the next methadone dosing. Another judge described
clear expectations for physicians who prescribe buprenorphine: “What I expect to see is a plan
where they will be weaned off the Suboxone at some point.” Fortunately, multiple judges state
that they defer to physician recommendations when designing MAT policies or applying policies
to a participant’s particular situation:
We haven’t named [weaning off MAT] specific criteria for graduation, but I
think for as long as our program’s gonna be, and, and maybe, maybe this is
naïve, or just uninformed, I think it’s reasonable for them to be drug-free by the
time they graduate. Now if a medical or treatment professional comes in and
says that that’s not feasible for this person, that this is the best we’re gonna get,
then, and, and if they’ve shown that they can manage that, then maybe not, but I
would hope that they would be off of all the substances by the time they
graduate. But I can’t say; . . . I might be naïve. (Judge 16)
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Information sharing with physicians seems to be tinged with distrust in some cases as
compared to information sharing with counselors. In information sharing with counselors, the
focus is on monitoring the patient, not the counselor. But when sharing information with
physicians, judges frequently discuss the need to know if the physician is doing an adequate
job—which entails monitoring the physician along with the participant:
I never want to take the place of a doctor, but I have to be assertive enough in
dealing with a doctor who[], I believe, understands what the person’s actually
going through and making a medical decision to prescribe that medication
consistent with someone . . . who’s gonna be held accountable to manage the
environment and is gonna be actually be working with the program, besides just
going to a clinic to take a pill or get an injection. (Judge 8)
That judge also expressed concerns that physicians might not really understand the goals of drug
court and addiction recovery:
If we have a doctor who’s recommending that [MAT] to a participant, . . . we
want to make sure that we’re in communication with that doctor to make sure
that they understand . . . that the person is in a recovery program, and make sure
that they understand what the program requirements are. . . . I just would say in
general, it’s very difficult to establish quality working relationships with doctors
in a drug court setting, and what I mean by that is that I think I have found
challenges in finding doctors who really understand about addiction and
recovery. (Judge 8) (italics added).
This quote suggests that the judge believes many (if not most doctors) fail to understand
addiction or recovery. However, physicians who self-select to treat addiction (especially in light
of how few physicians actually treat addiction) likely have significant understanding of
addiction. At the minimum, those physicians prescribing buprenorphine require eight hours of
training in buprenorphine. Drug court judges, on the other hand, have no addiction education
requirement to maintain their position. It is quite shocking that a treatment team primarily
composed of members without formal medical (or even health-related) backgrounds may require
a physician to conform to the team’s understanding of addiction and recovery. Not surprisingly,
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in this case the team’s understanding of addiction and recovery was based on abstinence-only
philosophy.
When a participant needs a new counselor, such as upon entry into the drug court
program, the court will typically defer to its partnering local health agency to provide a counselor
for that participant. Delegating this task to the local health agency illustrates that the court trusts
that this counselor is “good” in the sense of possessing the requisite credentials and adhering to
the court’s philosophy and policies. In contrast, when a participant needs or wants to begin
MAT, courts are more likely to carefully investigate the physician and his or her methods. For
example, consider the following exchange, which illustrates a court’s distrust of MATprescribing physicians in contrast to deference to a mental health counselor:
Interviewer: If [the participant] were to request the ability to be on one of the
medications…
Judge 13: We haven’t had that issue come up, but I know the answer. We would
allow a consultation, but . . . because this would happen so rarely, we would
probably require that my drug court director, who is the therapist, substance
abuse therapist, to attend.
Interviewer: To attend the consultation with the doctor?
Judge 13: Yeah, I’m sure we would require that, because again, we’ve never
had it happen, but if somebody wanted to do that, we would, to absolutely be
ensured of everyone being on the same page. I would require my drug court
director to attend.
One wonders how exactly the mental health counselor with no medical training will
judge the physician’s medical ability and motivations. Additionally, the involved process
described by the drug court judge may a chilling effect among patients desiring access to MAT.
Not surprisingly, some physicians dislike non-medical professionals interfering in the practice of
medicine, potentially pushing physicians away from treating drug court participants. For
example, according to one judge:
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I don’t think physicians enjoy having their clients be part of our program. I
think they find that . . . it puts them in a [difficulot] position where we ask that
we’re permitted to be able to access all the [participant’s records on] treatment
and monitoring. We require our participants to sign a release, and I’m not sure
that the doctors appreciate us snooping around, or looking at what’s going on.
So . . . we don’t have a real good relationship . . . throughout the community.
(Judge 12)
Distrust of physicians but not counselors is quite pervasive and striking throughout the
interviews, particularly given judges’ non-medical training and the lack of physicians on the
court treatment teams. In light of the egregious actions of doctors who prescribed oxycodone in
“pill-mill” settings over the last two decades, judges’ caution is justified, for example, if the
physician has had DEA action against him or her. However, the distrust appears primarily to
stem not because of “bad doctors” in the area, but because court treatment teams misunderstand
MAT. For example, judges described doctors as bad apples simply because patients were kept on
MAT-long-term (exactly as they should be according to medical literature!) With practically no
physicians on court treatment teams, misunderstandings about MAT are not surprising. For
judges used to an abstinence-only paradigm of SUD treatment, education from a physician may
be critical for dispelling rumors.
Interestingly, veterans’ courts appear to defer to treatment providers, whether counselors
or physicians, more than do drug courts. Specifically, a high level of deference to any treatment
provider in the VA was evident. In veterans courts most participants are VA-eligible, meaning
they can receive health benefits and treatment from the VA. Rather than making treatment
decisions, veterans’ court treatment teams usually focus on monitoring VA-created treatment
plans, for example, by conducting random urine analysis and ensuring that participants attend
counselor and physician appointments. Veterans’ courts also assist VA-eligible participants in
accessing VA treatment services. Court personnel serve as liaisons between the court
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participants and the VA system. Sometimes a VA outreach officer is on the court treatment team.
Trust exists between veterans’ courts and providers in the VA system.
Specifically with the veterans court, then the case manager teams up with [the]
veterans’ justice outreach officer, who works for the Veterans Administration
who basically operates as sort of a case manager on the veterans side of things,
which handles the treatment, medical services, psychiatric services, drug-related
services. So the the participants in the veterans court receive all those services
through the Veterans Administration and are kinda jointly then supervised and
monitored by the Veterans Administration official and our local case manager.
(Judge 3)
Greater deference towards providers in the VA may exist for a number of reasons. Courts
may trust treatment providers within government-led institutions more so than in nongovernment led institutions. After all, problem solving courts are government institutions as
well. Courts may also assume that greater oversight of treatment providers exists in the VA,
making VA treatment providers appear more trustworthy. Additionally, courts may view
veterans with drug dependence more positively than non-veterans with drug dependence, as if
veterans’ problems are truly medical whereas non-veterans problems are more “criminal.” For
example, one judge stated that veterans had earned their medical treatment, while no judge
described drug court participants as deserving treatment.
That’s part of the services we offer, they’re entitled to benefits, and they’re
getting the benefits that they’re entitled to. They go hand-in-hand with, with,
you know, the treatment aspect as well, so, you know, these people have earned
it. (Judge 15)
III. Encouraging Addiction Treatment within Drug Courts
Ultimately, it appears that American drug courts have appropriated the medical rhetoric
about addiction but have ignored medical expertise on appropriate treatments.649 One might say
that American drug courts have not been sufficiently medicalized, even though they term
addiction a medical condition. According to sociologist Peter Conrad, there are three levels of
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medicalization: conceptual, institutional, and interactional.650 The conceptual level is
characterized by medical rhetoric but no medical intervention.651 The institutional level occurs
when institutions adopt medical rhetoric and some medical approaches, but medical experts do
not directly intervene or have control.652 The final level occurs when medical experts, such as
physicians, directly intervene and control the social action.653 Despite professionals’ use of
medical rhetoric in drug court, medicalization remains at the conceptual level.654 Judges and nonmedical staff, rather than physicians, diagnose and decide the appropriate treatment for the
disease. 655 In most drug courts, judges may even override physicians’ advice.656 As a
consequence, treatment staff may have their treatment suggestions second-guessed by judges
with no medical training.657 One might even argue that some judges are practicing medicine
without a license.
Even though both drug court programs and new medication addiction treatments are
revolutionary developments in substance abuse, these spheres remain like oil and water;
according to one journal, “any hope of these two trends building off and complementing each
other continues to go largely unrealized.”658 For example, one author writes that at an annual
drug court conference “several judges looked squarely at the mounting evidence about
medication effectiveness and still professed skepticism.”659 Even after being presented with
evidence that methadone, buprenorphine, and naltrexone were all effective, some judges stated
that their drug courts would continue to bar defendants currently using methadone from
participating in the drug court “in keeping with the judicial system’s drug-free bent.”660 Mark
Parrino, president of the American Association for the Treatment of Opioid Dependence,
reported, “[t]here are judges who say, ‘I don’t believe in it.’” Parrino retorts, “This is not a belief
system.”661 Some judges fail to acknowledge MAT’s existence. In one recently published
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overview of drug courts written by a former drug court judge, the author discussed multiple
methods for treating drug dependence but failed to mention MAT’s existence at all, despite the
existence of such medication for over 30 years.662 Fortunately, my study of Indiana courts
revealed signs of shifting attitudes in favor of MAT (at least in some courts), largely due to
education about MAT received from physicians or training courses. Additionally, the federal and
some state governments are enacting legal and policy changes to encourage MAT. However,
more state-led MAT initiatives are needed.
A.

Changing attitudes towards MAT in Indiana

Five judges stated that their attitudes towards MAT have changed fairly recently. In each
of these cases, the changing attitude was attributable to greater understanding of the science
behind MAT and awareness of scientific studies about MAT’s effectiveness. Understanding the
reasons for attitude changes in problem-solving courts may help the government design more
effective policies for promoting MAT. The reasons for these attitude changes are described
below.
For one judge, the turning point was education through a “very confident” psychiatrist
sent by the VA who explained the dynamics of MAT and its value.
Well, probably up until this year, we’ve had a pretty strong bias against
medication-assisted treatment, and that’s probably been largely because of my
biases…However, some folks at the VA felt equally strongly that medicationassisted treatment is worthwhile, in some cases, not in every one, and a very
confident psychiatrist came and visited us, spent about three hours explaining
the dynamics of medication-assisted treatment and why it does have value, so
I’ve come about a hundred eighty degrees this year on medication-assisted
treatment, and we, we do use it now, on a very much a case-by-case basis, just
kind of based upon the individual’s perceived needs. (Judge 5)
Interestingly, another judge who is currently “on the fence” about MAT admitted that a good
discussion with a physician might persuade him:
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Now I’m willing, personally, as a judge, to have pretty, pretty much an open
mind about, if I can find a provider who will give me good, evidence-based
reasons for using a particular drug-assisted or medicine-assisted kind of
intervention, I’m willing to consider it. That’s fine. (Judge 2)
Physicians, unsurprisingly, can be persuasive proponents of MAT. After all, they are often the
most knowledgeable about MAT and have the ability to prescribe it. However, as discussed in
Section III, court treatment teams virtually never include physicians due to funding constraints.
For another judge, education provided at the National Association of Drug Court Professionals
(NADCP) annual conference changed his mind about MAT.
The National Association for Drug Court Professionals have come out, and
they, they, they have taken the stand that it’s essential, it’s an essential part of
treatment, to, for your best practices in drug courts, okay so, our national
association, our national leaders have, have come to the conclusion that it
should be, it should be done. So, we have to look at their leadership and, and
say, hey, we need to look into this because it’s been proven that it’s successful.
(Judge 13)
The NADCP is one of the most important sources of addiction treatment information for
judges in problem-solving courts. Its potential to change values, attitudes, and behaviors of
judges should not be underestimated. When I asked judges how they learned about the latest
addiction treatment methods, almost every judge described the NADCP annual conference as
being either their primary source of information about addiction treatment or an extremely
persuasive source of information about addiction treatment. However, attendance at the NADCP
annual conference is voluntary, neither the federal government nor the state government requires
attendance for drug court certification. Additionally, even within the conference, attendance at
information sessions about MAT is voluntary.
Training about MAT, whether from a physician or through a national conference appears
to be a viable way of changing attitudes about MAT. As one judge said,
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I think the teams came a long way through training, you know, they put up the
charge that substitute therapy versus no substitute therapy, and I think the team
has come a long way with understanding, hey, this isn’t just tradin’ a drug for a
drug, this is evidence-based and it’s working. (Judge 10)
One drug court treatment team has changed its philosophy towards buprenorphine after seeing it
work in their “sister” veterans’ court (run by the same judge), suggesting that courts learn from
each other:
I’ve always been more on board than a lot of the team, with the replacement
drug, seein’ some success, so they’re startin’ to kinda warm up with, hey, you
know, maybe this is better than the cold turkey, cause there’s so many
overdoses when, when you do the cold turkey, they may make it, you know, a
month, six months, a year, whatever, but then when they relapse, the overdoses
are so horrific because their tolerances are low. Anyways, we do allow that in
all of our programs, and I think the team is warmin’ up to seein’ some of these
successes that people are just doin’ great, you know, if they take it as
prescribed, and they’re getting’ counseling on top of just eatin’ the pill, you
know. (Judge 9)
In some cases, finding a reputable provider of MAT is the missing ingredient to allowing
MAT in court. Two judges who had previously prohibited MAT now allow MAT after finding
providers with whom they are comfortable. One judge believes that courts are becoming more
open to MAT, because the opiate abuse crisis has reached such extreme proportions. With a
large percentage of court participants addicted to opiates, judges are starting to think critically
about what works for opiate addiction, rather than what works for treating addiction generally:
I think it’s becoming so much more common just because of how opiate addicts
are so much more common, that people are startin’ to see [MAT] work. So I
think it’s an improving trend. I still think there’s a stigma, but I think it’s an
improving trend that people are starting to become more educated on the
benefits. (Judge 10)
Finally, for some judges and their teams what makes a difference is knowing a participant
who has been helped by MAT. Many judges and team members have only seen the effects of
abstinence-only treatment. Sometimes team members are in recovery themselves having used
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abstinence-only methods. If abstinence-only methods worked for them, why try something else
on others? Seeing MAT work in one participant makes it more likely that MAT will be allowed
for other participants. As one judge said,
I think over time, [court treatment team members are] startin’ to see, you know,
people use Suboxone appropriately with counseling, and I think they’re like
hey! This actually does work! You know, so… I think that’s kinda the evolution
is that, you know, they can finally put their hand on someone. Like, you know,
there’s people in my mind vividly right now that I can say, hey, it worked for
him, you know, he’s back with his wife and children, and it’s okay, you know
so… It’s kind of an evolution of goin’ from overdose deaths to seein’ it work.”
(Judge 10)
B.

Educating Drug Court Professionals

Former chair of the NADCP, West Huddleson, says that acceptance of MAT is increasing
in drug courts, and that some of the progress is attributed to educating judges and other drug
court professionals.663 Misinformation is still rampant. Few studies exist regarding the effects of
education about MAT on referral practices within the criminal justice system. However, one
experimental study of attitudes within correctional facility administrations found that a threehour MAT education course combined with an institutional linkage intervention (involving
interagency planning and implementation) significantly improved administrators’ perceptions of
MAT and improved their stated intentions to refer clients to MAT.664
Part of existing federal and state drug court funding should be directed towards
developing an educational program for drug court professionals using evidence-based principles
and the latest scientific and medical data. Such a program should be updated regularly as new
medications and scientific study results become available. Acceptance of federal or state funding
for drug courts could be made contingent on the drug court’s administrators completing such an
educational course. Additionally, problem-solving courts should be accredited (as described
below), and accreditation should require an education component.
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C.

National Accreditation of Drug Courts

The NADCP does not track the use of MAT or other treatment methods used in drug
courts. According to a former NADCP director, “I can’t tell you what’s happening in all 2,800
drug courts…[t]hat’s not our role. We don’t track drug court operations to that level.”665 Neither
is the federal government systematically tracking treatment provided in individual drug courts.
Instead, the federal government merely requires drug courts receiving a federal grant to complete
an “outcome evaluation,” in which the court describes whether or not participants are benefiting
from the drug court.666 While better than nothing, this system fails to promote best practices.
Furthermore, even though drug court participants are being benefitted under a current drug court
program, they may experience more benefits under another program. By tracking eligibility
criteria, treatment methods, and results for each drug court, the federal government could
establish a more accurate list of best practices and improve the quality of drug courts.667
Considering that the federal government provides funding for drug courts, the establishment of
empirically-based best practices is in its best interests.
Douglas Marlowe, an expert on drug courts, recommends the formation of a national
court accreditation system to standardize drug court practice across jurisdictions. He says,
“[T]he responsibility now falls to the drug court field to establish performance benchmarks and
best practices for drug court programs and to develop accreditation procedures that can be used
to document whether a particular program is in compliance with professionally accepted
standards of practice.” Accreditation is also supported by John Roman of the Urban Institute,
who says that accreditation would lead to the best practices becoming institutionalized.668 While
some states, such as Pennsylvania, have a state-wide accreditation program in place, this is not
the case in all states. Additionally, there is no reason to believe that the best practices of drug
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courts in one state should not apply to other states, suggesting that national accreditation is just
as important as state accreditation.
Finally, scholars must become more interested in not only whether drug courts work in
general, but specifically what within drug courts works. Discussing the lack of critical
evaluation of drug courts to date, Judge John Bozza writes, “[t]he overall concern [currently] is
with assuring access to treatment, apparently with little consideration for the nature or the quality
of the change strategy undertaken.”669
D.

Funding Incentives

According to the director of the NADCP, the economic recession has incentivized
decision-makers to think about treatment rather than incarceration, because it is cheaper.670
Hopefully, economic concern will also cause policy-makers to focus on funding evidence-based,
effective treatment methods. So far, the signs are hopeful. Drug courts are also feeling more
pressure to increase access to MAT and to change policies that ban MAT.
Michael Botticelli, the acting director of the Office of National Drug Control Policy, has
been described as “a stalwart supporter of MAT.”671 In February 2015, Botticelli announced that
the White House planned to strip state drug courts of federal funding if they prohibit the use of
MAT. This policy would be implemented through coordination with SAMHSA. Pamela Hyde, a
SAMHSA administrator, said “We are trying to make it clear that medication assisted treatment
is an appropriate approach to opioids.”672 She adds, “Abstinence only ideology often obstructs
appropriate treatment placement, particularly with respect to opioid addiction.”673 At the
minimum, State governments should follow in the federal government’s footsteps and only
provide funding to drug courts that permit MAT.
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I asked judges (including veterans’ court judges) about their views of the federal
government’s new policy of tying federal funding to MAT in drug courts. Only one judge
expressed pre-existing knowledge of the policy. For that judge, the new federal policy is
evidence of the fact that MAT is an effective treatment:
We’re all a little skeptical of [MAT] around here. But I know from, from going
to the NADCP meetings and a, a lot of a, and not that we get any federal
funding, but federal funding is, is tied to, I guess they, they don’t allow it if, if,
the, the federal government will not fund anything if we don’t allow medically
assisted treatment. And I don’t mean that for the funding, it just means that,
well, there’s somebody that thinks that it’s pretty important…” (Judge 16)
Judges’ responses to the new policy (after I explained the policy) were mixed, but tended to be
more negative than positive. According to one judge, the policy does not leave enough room for
judges to make individualized decisions:
I think it’s too fine-grained. That’s probably well-intentioned, but I think that’s
something that needs examined almost case by case…I don’t really have a
blanket restriction on the use of drug-assisted treatment, but I’d want it very
individualized. I don’t want them to just use liberally because it’s available. I
mean, frankly, I’m a cynic. I mean, that sounds to me like the drug industry’s
gotten to the regulators and have them impose something that’s gonna benefit
them. (Judge 2)
Another judge believes the policy is too much too soon:
I don’t think it’s a good policy. I think they should…I’m in agreement that we
should be using medically assisted treatment, and, and I’m in agreement that
they should, they should push that on drug courts, and ask the drug courts use it,
but I, I think they need to be little more patient, and, and forgiving, and work
with programs and educate ‘em on why, and what the benefits are, as opposed
to just defunding them. (Judge 12)
Three judges expressed concern about policy makers interfering in treatment decisions-making:
I think its bad public policy to tie money to treatment of any kind. Treatment
should be stand-alone. (Judge 7)
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Well, I, I think that for a national agency to, to take that approach is not prudent.
I think there is a tremendous variation across the nation in clientele, in
communities and in resources. And I think that absolutes in terms of dealing
with people are probably a bad public policy. I, you know I, it’s, I think you can
encourage it. I think you can do all kinds of things to, to try to, to foster, you
know, the ends of a policy, but blanket prohibitions, or blanket requirements,
either way, I think are short sighted…I think it’s unwise to simply sit in
Washington and mandate this, that, or the other thing. (Judge 10)
I don’t think it’s necessarily a good idea for politicians to make treatment
decisions…I think it’s probably best to keep politicians out of treatment
decisions…But, on the other hand, I also don’t want to give the money out to
people who aren’t producing some sort of results that are demonstrable. (Judge
6)
One judge does not necessarily oppose the policy but wants more public debate about it,
especially since he allows some medications for short-term use but not others.
I guess it would be something that needs to be more fleshed out and have a
whole discussion as to exactly what the policy is, because our drug court
program does not prohibit it, but my philosophy is that we should not medicate
people for life, except when, anytime you start saying we should do this for
everybody is always. (Judge 11)
Only two judges explicitly agreed with federal funding policy:
I agree with that policy. I don’t think you should ever, as a drug court say that
something is totally gonna be banned. I mean, I just, I think you have to take a
look at each individual person and what your alternatives are, so I would not
support a ban. (Judge 13)
Two judges explicitly stated that the policy is irrelevant to them, because their courts
receive very little federal funding. One of those two judges believes that most drug courts receive
little federal funding. That judge is probably correct, because most judges in the study stated that
the bulk of their funding comes from the state and local governments.
Therefore, states must also change their drug court policies to prohibit drug court from
banning MAT. In March 2015, Kentucky began allowing drug court participants to access MAT
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after banning their access for decades.674

Interestingly, Kentucky changed its rules after two

law firms initiated a lawsuit on behalf of a nurse who claimed that Kentucky’s ban on MAT
violated the Americans with Disabilities Act, a claim rendered moot by the policy change.675
Shortly afterwards, New Jersey changed its drug court policy and now also allows drug court
participants to access MAT.676 The New York Senate passed a similar bill in June 2015.677
E.

Incentivizing Physician Involvement

Lack of physician involvement on problem solving courts’ treatment teams may largely
explain misconceptions about MAT. In light of limited or no MAT education received by most
mental health therapists, judges should not base court treatment policies based solely on the
advice of mental health therapist. Of course, basing counseling policies on the advice of mental
health therapists is logical. If governments want more physicians on court treatment teams, then
funding should be allocated specifically to reimburse physicians for their time. If lower
reincarnation rates and lower court program dropout rates result from physicians providing
accurate medical advice, then such funding may be budget neutral.
Additionally, judges should be required to follow physicians’ advice with regards to
MAT unless the judge has a reason based on medical best-practices for disagreeing with a
physician. For example, a notarized statement from another physician or reference to medical
literature could be used to describe the best-practices on which the judge is basing his or her
decision. States should require judges who refer patients to a physician to follow the advice of
the physician unless the judge submits, in writing, a reason for disagreeing and points to a
medical best-practice standard or disciplinary issue (e.g. the physician previously had his or her
license suspended). Otherwise, judges who tell drug court participants to not follow physicians’
advice may be practicing medicine without a license. The mere process of explaining in writing
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why the judge is asking the patient to disregard physician advice may be enough to encourage
deference to physicians.
VI. The Ethics of Providing Access to MAT in the Criminal Justice System
Ludwig and Peters identify three primary ethical considerations for criminal justice
administrators with regards to substance abuse treatment: beneficence, distributive justice, and
autonomy. The authors derive these principles from the influential and widely read Belmont
Report, an ethics report authored by the National Commission for the Protection of Human
Subjects of Biomedical and Behavioral Research that has been codified in professional
healthcare standards.
The ethical principles of beneficence, distributive justice and autonomy suggest that
MAT should be more widely available within criminal justice systems. Beneficence requires
doing good. It is related to non-maleficence, which means doing no harm. Beneficence requires
providing dependent individuals with MAT, because it (especially in combination with
counseling) is proven to decrease mortality, risk of relapse, and re-incarceration more than other
treatment modalities. Non-maleficence requires criminal justice administrators to permit
continuation of previously started MAT rather than force withdrawal, as studies show that forced
discontinuation may increase future relapse risk and overdose upon release from prison. For
example, the relapse rate after discontinuing methadone treatment is approximately 80%.678
According to the Drug Policy Alliance, “[t]he denial of this highly successful treatment [MAT]
for opioid dependence nearly guarantees that most opioid-dependent individuals will fail in drug
court.”679 In my study, some judges assumed that permitting MAT was harmful to participants as
it prevents them from being truly sober, but this assumption misconstrued the meaning of
sobriety.
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Failure to allow MAT also harms participants if inadequate treatment indirectly leads to
their failure in drug court. Without effective treatment, participants face a greater likelihood of
relapse and eventually failing out of the drug court program after repeated relapses. When
participants fail out of drug court, they return to the original court for sentencing. The National
Association of Criminal Defense Lawyers has reported that individuals who fail drug court often
have longer sentences imposed than if they bypassed drug court in the first place.680 Sometimes
these harsher sentences are meant to “set an example” for others who remain in drug court.681
Unfortunately, drug courts usually lack appeal procedures, which theoretically might allow the
participant to dispute reasons for receiving a sanction or failing out of drug court.682 Moreover,
persons convicted of drug possession (including marijuana) lose significant welfare benefits by
becoming ineligible for food stamps, public cash assistance, student educational loans, and (in
some states) the use of a driver’s license.683 Therefore, failing out of drug court can have
extensive and significant repercussions for defendants and their families.
The ethical principle of distributive justice means equitable access to a resource (in this
case, effective health care). The principle of equivalence-of-care derives from distributive
justice; it requires correctional facilities to provide health care that meets the community
standard of care. In the 1976 case Estelle v. Gamble, the U.S. Supreme Court determined that
equivalence-of-care is required under the Eighth Amendment to the Constitution. The Supreme
Court ruled that “deliberate indifference” to a prisoner’s serious medical needs violates the
Eighth Amendment. In the 1979 case Bell v. Wolfish, the Court applied the same standard to preadjudication settings, including jails, under the Fourteenth Amendment. Even a well-intentioned
denial of MAT in prison or drug court would fail the equivalence-of-care standard, because
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MAT (in combination with counseling) is the medical standard of care for treating opioid
addiction.
Finally, the ethical principle of autonomy means that individual rights prevail over the
clinical standard of care. For example, autonomy means that, even if the medical standard of care
for HIV is anti-retroviral therapy, a patient cannot be forced to use this therapy if he prefers an
alternative one. In practice, autonomy is applied through the process of informed consent to
medical treatments. True informed consent requires capacity, disclosure, understanding,
voluntariness and access.684 In the past, some scholars have argued that prisoners cannot give
informed consent to MAT because they lack the capacity to voluntarily agree to undergo that
therapy. According to these scholars, drug cravings destroy prisoners’ physical and
psychological capacity for voluntary assent to treatment. However, as Ludwig and Peters state,
this argument “relies on a false dichotomy by suggesting that treatment without medication does
not require the same degree of capacity.”685 For example, lack of capacity arguments are rarely
(if ever) applied to counseling for drug-dependence or forced detoxification in prison.
Additionally, this argument falsely presumes that drug-addicted individuals are constantly
incapacitated. But even if drug-addicted individuals have diminished capacity, this capacity is
not wholly destroyed.686
Some bioethicists argue that offering agonist medications (like methadone or
buprenorphine) to individuals with opioid dependence is de facto coercive, because the
medication is the “next best thing” to their abused substance, so they cannot resist the option.
However, when offered a choice between alternative treatment options, many individuals with
opioid dependence choose to engage in multiple types of treatment, including those without
opioids (e.g. counseling, and support groups); some choose not to undergo MAT at all.687 At the
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minimum, providing information about MAT may bolster autonomy for inmates’ and drug court
participants, especially if they lack knowledge about MAT.688 One cannot make a truly
autonomous treatment choice without being informed about and understanding all options.
VII.

Summary
Problem-solving routinely design medication policies contrary to the best standard of

medical care. According to Matusow et al. (2013), approximately half of drug courts nationwide
prevent participants from engaging in agonist MAT. My study of Indiana drug and veterans
courts found policies encouraging short-term MAT even though medical studies suggest longterm MAT is most effective.
Problem-solving court treatment decisions are made in treatment teams composed of
criminal justice professionals and counselors, but rarely physicians. Judges head the team and
defer to counselors, but sometimes appear to impose their own treatment beliefs on the treatment
team. The lack of physicians on treatment teams is likely related to misinformation about MAT
within courts. Such misinformation also breeds distrust of MAT-prescribing physicians.
Fortunately, my study suggests that education provided by physicians and conference could
encourage more accurate understandings of MAT. Because judges are not medically trained, they
should refer to physicians’ decisions with respect to MAT. Therefore, more physicians should be
included on treatment teams; the government could encourage their inclusion through funding
mechanisms or accreditation standards. More MAT-prescribing physicians are also needed in the
community. Matusow et al. found that even among courts that allow MAT, many failed to refer
patients due to a lack of local providers. Unfortunately, an undersupply of MAT-prescribing
physicians exists nationwide.
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CHAPTER 4: WHY ARE SO FEW PHYSICIANS TREATING ADDICTION &
PRESCRIBING MAT?
I. Introduction
Demand for addiction treatment services in the U.S. increased under the Affordable Care
Act (ACA), which extended insurance to many previously uninsured individuals and made
substance abuse dependency treatment a mandatory (“essential”) insurance health benefit.
However, the numbers of physicians treating addiction has not kept up with demand and remains
woefully inadequate.689 Relatedly, medical professionals’ knowledge of and training in effective
addiction treatments remains low, signifying an information diffusion problem. According to
Saxon and McCarty (2005), “[m]any areas of medicine adopt new therapies slowly, but barriers
to adoption of addiction therapies may be particularly high.”690
This chapter will discuss the many reasons so few physicians treat addiction and have
been slow to adopt MAT. Historically, physicians have largely been excluded from the field of
addiction treatment, and until recently have not pushed for admission. This has contributed to
limited physician education in addiction medicine and concerns about treatment of co-occurring
conditions, which in turn has allowed several misrepresentations to continue, including the
stigmatization of addiction patients and the providers who treat them, the idea that addiction is a
choice rather than a disease and the belief that primary care physicians should not treat addiction.
Moreover, significant regulatory and institutional barriers have been erected, leading to limited
institutional support for addiction treatment, insurance and reimbursement barriers, and a lack of
support from mental health counselors.
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II. Physicians’ Exclusion from Addiction Treatment
Physicians’ exclusion from addiction treatment has its roots in social and legal
developments dating back over 100 years. In the late 1800s and early 1900s, many Americans
suffered from opioid dependence. Dependence developed in part from the use of morphine to
treat soldiers during the Civil War, opioids’ inclusion in over-the-counter cough syrup and other
products, and the medical practice of prescribing morphine to women for menstrual cramps and
anxiety.691 At the time, some physicians were treating individuals with opioid dependence in
office-based practices by prescribing maintenance doses of morphine (note: methadone,
buprenorphine and naltrexone had not yet been discovered.) In fact, many physicians viewed
maintenance doses as a useful tool for preventing morphine theft and overdoses from selfinduction.
Then, in 1915, Congress passed the Harrison Anti-Narcotics Tax Act (Harrison Act),
making distribution of morphine illegal unless it was for a valid medical purpose. Many
physicians initially interpreted the Harrison Act as allowing morphine maintenance therapy
However, the federal government disagreed with this interpretation and the Supreme Court ruled
that the Act prohibited maintenance treatment for individuals with opioid dependence.692
In response, the newly created DEA began targeting physicians known to prescribe
maintenance therapy, leading to the largest DEA raids on physicians in U.S. history. These raids
were not always conducted pursuant to a valid search warrant, and many physicians’ professional
reputations were irrevocably harmed. Between 1919 and 1935, approximately 25,000 physicians
were indicted, with 10% being convicted and imprisoned”693 As a result, even those physicians
who had not engaged in maintenance treatment began to fear the legal repercussions of treating
opioid addiction—after all, the best self-protection was avoiding treatment of addiction
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altogether.
Thereafter, a dramatic split occurred in addiction treatment: physicians largely ceased to
practice in the field of addiction treatment, leaving a void that would be filled by mental health
counselors and support groups. Physicians not only feared DEA raids but found that it was
difficult to assess whether medical treatment for addiction was efficacious in the first place. Few
methodologically valid studies had been conducted on medical treatments for addiction,
rendering uncertain the value of physicians’ contributions. Some physicians referred dependent
patients to psychiatric hospitals, but to no avail. Historian William White notes that psychiatrists
and their staff frequently resisted integrating addiction patients with other psychiatric patients out
of fears that the addiction patients would spread “immoral behaviors” and drugs to other patients.
This separation of psychiatric patients from addiction patients reinforced some physicians’
perceptions that addiction was a moral failing, not a disease requiring medical treatment. These
perceptions were reinforced by the fact that wealthier opiate-dependent individuals would
segregate themselves, and would sometimes attend rehabilitation centers that essentially
functioned as luxurious spas where they could detox while hiding themselves from society.
In the time period between the passage of the Harrison Act and the widespread
availability of support groups such as AA, middle-class individuals with opioid dependence had
essentially two options: quitting “cold turkey” (which rarely worked) or trying “quack”
treatments. Quack treatments could be bought in catalogs and in stores. Many bore the names of
celebrities who had supposedly been “cured” of their addiction. Ingredients were dubious at best
and harmful at worst. One popular cure consisted primarily of alcohol; another incorporated tiny
amounts of gold that individuals with drug dependence swallowed. Sellers of supposedly
miraculous cures preyed on individuals desperate to reclaim their lives and families. With
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regulatory agencies in their infancy and no active consumer protection movement, federal and
state governments intervened very rarely. Physicians may have interpreted the widespread
availability of quack cures to mean that there was no possibility of any medically sound
addiction treatment.
Approximately 11 years after the Harrison Act was passed, dependent individuals had a
newer, far better treatment option: support groups. While support groups had existed in the late
1800s, namely the Washingtonian Houses, they became widely accessible in the 1930s with the
emergence of AA. AA became the dominant support group, with chapters spreading throughout
the U.S. like wildfire. Decades later, NA would form specifically for individuals with drug
dependence.) The reasons why AA rose to prominence so quickly include the fact that it was
free, anonymous, and was an ideal philosophical fit with American cultural norms. But as any
practicing physician knew, AA and NA were not medical treatments and did not require
professional involvement from physicians. Support groups’ popularity as an addiction treatment
and their widely-perceived efficacy further reinforced physicians’ perceptions that addiction was
not a disease requiring medical treatment.
As the counseling field grew more sophisticated over the next few decades, practitioners
developed new counseling methods that were empirically proven to be effective, including
motivational interviewing, cognitive behavioral therapy, and contingency management.
Although individual counseling was only available to those who could afford it, it began to be
used in combination with support groups. This combination of treatment modalities helped many
dependent individuals; but a large percentage continued to relapse.
Until the early 1970s, then, physicians’ role in addiction treatment was largely one of
referral, encouraging patients to seek help from counseling and/or support groups. Any further
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physician involvement, other than prescribing medication to ease painful detoxification
symptoms, seemed superfluous and not medically necessary. Then in 1972, the FDA approved
methadone for treating opioid dependence. This opened the door to increased physician
involvement, for methadone treatment required physicians to prescribe and manage the
medication. For the first time since before the Harrison Act, physicians played a prominent role
in addiction treatment.
Physician entry into addiction treatment, however, occurred at a snail’s pace. The federal
regulatory structure requiring methadone to be provided within OTPs rather than regular
physicians’ offices, yet most physicians had never visited an OTP or to their knowledge
encountered methadone patients. As a result, the majority perceived they had no reason to
become involved in methadone treatment and, lacking sufficient knowledge about the
medication, even failed to refer patients. Even physicians who would otherwise have referred
patients for methadone treatment were sometimes prevented from doing so by the lack of local
OTPs, especially in rural and suburban areas). Thus, despite the availability of an effective
pharmacological treatment, physicians continued to simply refer patients to counseling and
support groups without further involvement in the treatment process.
This perception that addiction treatment is the exclusive realm of counselors and support
groups continues today among medical professionals. According to one recent study of medical
students’ attitudes when confronted with addiction patients, “[t]hey rarely mentioned addiction
treatment, and when they did, they perceived it as something that was done by specialized
counselors out in the community. At most, they perceived that the physicians’ role was to
identify and refer.”694 Unlike in the 1970s, however, physicians can now prescribe in-office two
pharmacological treatments for opioid dependence: buprenorphine and extended release-
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naltrexone.
In my interviews with physicians, a few stated that they expected more physicians will
enter the addiction treatment field as the number of pharmacological treatments increase. The
increasing availability of pharmacological treatments for addiction may suggest to physicians
that they have an important role to play other merely providing referrals. Furthermore, for those
physicians who view addiction as a choice rather than as a disease, the availability of
pharmacological treatments is persuasive evidence that addiction is a disease similar to other
chronic health conditions. But without widespread physician education about addiction treatment
and effective treatment methods, physicians will continue to remain disengaged from this field of
practice.
III. Limited Education in Addiction Medicine
Many physicians feel unprepared to treat addiction, and a large minority have never heard
of MAT, primarily due to a lack of education.695 Addiction medicine is rarely taught in medical
schools, residency programs, or in continuing education courses.696 When addiction medicine is
taught, it typically comprises only a very small part of the curriculum or an elective course.
These minimal educational offerings in addiction medicine are disproportionate to the significant
numbers of dependent patients and to the fact that addiction is a public health crisis that is still
intensifying. For example, although the percentage of hospitalized patients with addiction is
approximately the same as that with diabetes—25%--medical school and residency curricula
devote significantly more attention to the latter.697
In a survey of internal medicine residents, 37% reported that they had not received any
instruction related to addiction in medical school. Of the 63% who had received some addiction
training in medical school, only 47% received more than a single lecture and only 25% were
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exposed to an addiction patient.698 Such minimal education is shocking in light of the opioid
overdose epidemic. In an interview with the New York Times, Dr. Seitz, from Boston University,
stated, “[t]here's no word for educational malpractice, but not to train people in drug abuse when
you're training them for H.I.V. or Hep C reduction is ridiculous."699
Even when physicians are provided with addiction medicine education, its quality may be
woefully inadequate. In a study of internal medicine residents, 55% rated overall addiction
medicine instruction in their residency programs as “poor” or “fair.” 700 Physician 16, director of
a medical school addiction medicine fellowship program at a medical school told me that, until a
few years ago, psychiatry residents’ training in addiction medicine consisted of observing 12step groups and a brief lecture. Strongly disagreeing with this minimalist approach, the director
pressured the psychiatry residency program to incorporate education about MAT, counseling,
and more medicalized approaches to addiction treatment. According to the director, this prior
observational approach reinforced residents’ presumptions that addiction treatment is not a
professional medical endeavor.
The limited addiction education in medical schools and residency programs is strongly
related to the low percentage of medical school faculty who are trained in addiction medicine.701
Curriculum instruction and instruction from attending physicians are both positively related to a
physician’s self-perceived efficacy in treating addiction.702 Moreover, addiction medicine faculty
could serve as role models for students and residents, helping them to understand negative
patient-physician interactions in light of addiction symptoms.
Just as medical students and residents feel underprepared to treat addiction in general, the
majority of physicians have limited knowledge about MAT specifically. In a study that provided
questionnaires to 101 medical residents, no resident answered all six questions about addiction
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medicine correctly, almost half failed to correctly identify the mechanism of buprenorphine
treatment, and 81% failed a question regarding naltrexone treatment. Only 6% of residents
answered all three questions about MAT correctly.703
Limited education in medical school and residency programs also translates into
physicians’ minimal comfort treating addiction once they are in practice, including low selfefficacy implementing MAT.704 In one study of medical residents, 25% felt unprepared to
diagnose addiction and 62% felt unprepared to treat addiction. No residents reported feeling
“very prepared” to treat addiction. Another study of primary care residents undergoing training
in a public hospital found that the majority had low self-efficacy in addiction management.705
Shockingly, such discomfort extends to psychiatrists, the physician specialty with the most
training in addiction medicine (though it is still inadequate), as well as relatively high levels of
contact with patients suffering from substance abuse disorder.706 A 2004 survey of 1,203
practicing psychiatrists found that 80% felt uncomfortable prescribing buprenorphine for
addiction.707 Even among those psychiatrists specializing in addiction psychiatry (i.e. having
completed a fellowship in addiction psychiatry), 43% felt uncomfortable prescribing
buprenorphine.708
Fortunately, implementing addiction treatment curricula in medical school or residency
programs is correlated with increased physician preparedness to diagnose and manage
addiction.709 Even brief educational interventions increase medical students’ knowledge,
attitudes and clinical skills.710 A meta-analysis of addiction training found that the several
features are especially helpful: exposure to patients in treatment and long-term recovery; clinical
work supervised by a physician experienced in treating addiction; and integrating education
interventions into the general medical school or residency curriculum.711 Taking time in the
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curriculum for student reflection (through journaling, for example), de-briefing sessions and
discussions of their feelings towards drug dependent patients can also assist in learning and
empathy-building.712
Effective training for students and residents can also be provided through innovative
online modules. In one study, nursing students and medical students were provided access to an
online educational platform that included case vignettes, online chat sessions with individuals
pretending to be patients that allowed students to practice drug history screenings and brief
interventions, and “choose your own adventure”-style case scenarios. The training led to a
dramatic rise in participants’ perceived self-efficacy in addiction treatment; prior to the training,
only 10% of students rated their self-efficacy as “good” or “great;” while 60% did after the
training.713
The federal and state governments have historically heavily subsidized medical schools,
thus playing a key financial role in curriculum expansion. In previous decades, university
presidents and planners could move forward with medical expansion under expectation of federal
subsidies. For example, in the mid-1960s, Federal subsidies accounted for approximately 50% of
medical school revenue; medical schools also received subsidies from states. As a result, the
number of medical school graduates doubled in that era.714 In contrast, in recent years federal
funding to medical schools has been slashed. In 2010, over 50% of American Association of
Colleges of Medicine schools reported concern with economic conditions for maintaining and
increasing enrollment. At the same time, the cost of medical school has increased significantly,
growing at twice the rate of inflation in recent years. Even though some states are providing onetime start-up funds for medical school expansion, ongoing funding is limited. Some medical
schools are able to obtain lucrative private donations, but such donations frequently come with
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strings attached and rarely target psychiatry or addiction medicine. One psychiatrist told me that
fundraisers for the psychiatry department at his university are some of the most difficult to get
people to attend and donate to, because psychiatric issues (including addiction) are stigmatized.
In light of the U.S.’s public health needs, medical schools must expand enrollment,
especially in psychiatry, primary care, and other areas of medicine with physician shortages.
Likewise, medical schools must expand curricula to include more classes about addiction
medicine, as well as hire more faculty members trained in addiction medicine. However, in order
for such expansion to take place, the federal and state governments must increase funding for
medical schools.
For physicians already in practice, online or in-person courses are shown to improve selfefficacy and desire to treat addiction. In one study, after four hours of online buprenorphine
training and 3.5 hours of in-person buprenorphine training, 67% of participants intended to
prescribe buprenorphine.715 Prior to the training, only 2% had experience in prescribing
buprenorphine.716 In another study which combined four hours of online buprenorphine
treatment education and a few hours of in-person training, 85% of physicians wanted to learn
more about buprenorphine and observe buprenorphine treatment firsthand. In particular, meeting
with patients undergoing buprenorphine treatment was shown to improve physician confidence
in prescribing the medication.717 During patient meetings, physicians learned about transitioning
patients to buprenorphine and strategies for monitoring and relapse prevention.718
Physician mentorship programs may also aid physicians beginning to treat addiction for
the first time. The Physician Clinician Support System, established by SAMHSA, is a national
mentoring network to assist physicians with buprenorphine treatment. In the Support System,
mentors experienced in buprenorphine treatment provide assistance via phone, email or by
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visiting the less experienced physician’s clinic.719 In-person assistance is particularly helpful for
physicians who cite hesitancy with buprenorphine induction as a barrier to treatment—according
to one study, approximately a quarter of physicians.720
Experts’ educational outreach to physicians may also increase buprenorphine treatment
adoption.721 In 1998, NIDA organized a six-state educational outreach program in which
physician experts in addiction medicine recruited local less-experienced physicians to attend a
free regional training. After the training, recruited physicians began treating patients with
buprenorphine in their offices (in what was essentially a clinical trial). Recruited physicians had
access to experts in case they had questions or concerns. Ultimately, physicians only initiated
expert consultations on isolated occasions, and both physicians and patients expressed high
degrees of satisfaction with buprenorphine treatment.722
Federal and state departments of health should expand funding and grant opportunities
for outreach programs targeting practicing physicians. Programs could be modeled on the NIDA
program described above. As an additional incentive for addiction treatment, states could fund
participation in the online certification courses necessary for physicians to begin prescribing
buprenorphine (under DATA). States could require physicians who obtain such funding to
practice addiction medicine in the state for a specified number of years and to accept Medicaid.
IV. Not Understanding Addiction as a Disease
Even though the AMA has called addiction a disease since the 1930s, some medical
students hold biases towards individuals with drug dependence that mirror biases held by the
American public. One survey found that medical students tended to view addiction as a
dependent individual’s personal choice, causing them to feel angry towards patients who
continued to harm themselves with drugs.723 Medical students frequently believed that patients
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suffering from addiction continued to abuse drugs because they enjoyed drugs, did not know
better, or did not care about the harms that addiction could cause.724 These erroneous opinions
prompted some medical students to express disinterest in treating addiction; as one medical
student responded, “I think it will be difficult to deal with people who don’t want to take an
active role in improving their health.” Medical students’ failure to view addiction as a disease
translates into poor quality physician-patient interactions. Alarmingly, the study authors stated,
“[medical] students did not appear to react as physicians when confronted with addiction
patients. They did not discuss clinical features, diagnosis, medical treatment, or advice. . . . They
did not convey a sense of therapeutic optimism and pride in their acquisition of clinical skills
needed to help addicted patients.”725
Medical students likely carry these biases into their practice careers. Even a group as
well-educated and motivated to help others is not immune to the negative sociocultural
depictions of dependent individuals that appear in movies, music, and the news. Fortunately, one
study found that recent medical school graduates are less likely than older graduates to hold
biased views towards addiction patients, suggesting that positive changes are occurring.
Primary care (family medicine) physicians have also expressed apathy towards treating drug
dependence.726 This apathy is probably a cover for personal bias or other factors underlying their
reluctance to treat addiction that they are hesitant to discuss. It is difficult to imagine a physician
being genuinely disinterested in treating diabetes, asthma, or another serious chronic condition
for which effective medication is available. Primary care physicians may be concerned that,
once word gets around that they prescribe buprenorphine, individuals with opioid dependence
will be lining up at their doors, especially given the undersupply of DATA-qualified physicians.
Such a supposition appears especially likely since some physicians whom I interviewed stated
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that the stigma surrounding SUD patients rubs off on their treating physicians, so that the public
begins to stigmatize the doctor as well. The stigma of addiction is deeply engrained in American
culture and will take a long time to eliminate. If more physicians begin treating dependent
patients, however, then the public may increasingly view addiction as a disease rather than a
personal choice.
A similar process of re-education and de-stigmatization occurred with professional and
public perceptions of depression and depression treatment. As physicians began treating
depression with effective pharmaceuticals, the public increasingly began to view it as a disease
resulting from a neurological chemical imbalance rather than a personal or moral shortcoming.
Even though depression is still stigmatized, this stigma has decreased since the disease has come
to more commonly be perceived as an illness meriting medical treatment.
V. The Perception of Addiction Patients as “Difficult”
Some research suggests that physicians also do not wish to treat patients suffering from
addiction because such patients are rumored to be “difficult,” meaning that they act in
undesirable and antisocial ways such as being manipulative and dishonest.727 According to
physicians whom I have interviewed, many dependent patients do exhibit such negative social
behaviors during appointments in order to obtain prescription drugs. However, these physicians
also explained that these negative behaviors are symptomatic of the addiction disease, not as
inherent and immutable personality traits. Once physicians recognize that such negative
behaviors are symptoms, they can focus on treating the disease.
Understanding addiction behaviors as disease symptoms require empathy for the
patient—the willingness to put themselves in the patient’s shoes and to imagine how they
experience the world. Studies suggest that empathy is a critical factor in treatment relationships
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and enhances treatment success. According to Wakeman et al., increased exposure in residency
to dependent patients may itself increase empathy.728 Additionally, empathy training may help
physicians understand the reasons for negative interactions between dependent patients and
treating physicians and learn not take them personally.729 Additionally, physicians should be
taught communication skills to use with dependent patients so they can more readily facilitate
discussions rather than being confrontational and angry.730 Otherwise, patients confronted with a
physician who seems annoyed or hostile may feel that they are being intentionally mistreated.
These modest educational innovations, including training in evidence-based addiction treatment,
empathy, and communication skills, may help physicians to realize that treating addiction
patients is not significantly more difficult than treating patients with other chronic illnesses.731
Like other chronic relapsing diseases (e.g. hypertension), drug dependence can be effectively
managed with monitoring, medication, continuity of care, and re-intervention when needed.732 In
fact, when effectively managed drug dependence has lower relapse rates than both asthma and
hypertension.733
VI. Negative Interactions With the Criminal Justice System
A large percentage of individuals with opioid dependence are involved in some way with
the criminal justice system, through mechanisms such as probation, parole, or incarceration.
Individuals in drug court, on parole, or on probation may seek medical treatment in the
community. When these individuals seek treatment from a physician, the physician is essentially
forced to interact and coordinate care with criminal justice administrators, such as probation
officers and drug court case managers. Some physicians may not wish to treat patients this extra
baggage with them, which not only carries the potential of stigmatization but also means more
time-intensive administrative work to complete on top of an already demanding schedule.
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But physician communication with criminal justice system administrators may not only
be time-consuming; it may be fraught with discord as well. Within the criminal justice system,
MAT is underused and often misunderstood with abstinence-only treatment philosophy being the
norm. Thus, relationships between criminal justice administrators and physicians prescribing
MAT may be tinged with distrust. This discord may be compounded if physicians and criminal
justice administrators approach information-sharing differently, as is often the case.
Drug court case managers and probation officers commonly want physicians to provide
them with detailed treatment information about patients. Physicians I have interviewed report
that such information often includes urine screening results, notes of patient-physician
conversations, and appointment attendance information. However, physicians usually are averse
to sharing any information besides appointment attendance records—and will share that
information only after a patient signs an information release.
Physicians highly value patient data confidentiality for two reasons. First, encouraging
patients to be open and honest allows physicians to obtain more information, and the more
information the physician has, the better quality treatment she can provide. For example,
physician 4 explained how a patient in drug court attended a medical appointment with his case
manager. During the appointment, the patient answered the physician’s questions in a curt and
evasive manner. A few minutes after the appointment ended and the patient and case manager
left, the patient reappeared alone and explained that he wanted to provide different answers to the
physician’s questions now that the case manager was gone. The patient’s initial set of answers
had been influenced by fears that the case manager would share certain details with the drug
court judge, who in turn would use it to impose sanctions.
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Second, physicians fear that sharing patient information with criminal justice
administrators will lead to the imposition of additional punishment as opposed to improved
medical treatment. For example, physician 4 is very frustrated when probation officers request
urine screening results since such screening serves medical purposes such as assisting her in
determining proper dosages and ascertaining whether she should try a new treatment. In the
criminal justice system, however, urine screening serves very different purposes, namely the
disciplinary aims of detecting and punishing violations. The psychiatrist described a situation
where a coworker accidently revealed a patient’s urine screening results in which he tested
positive for drug use to his probation officer; this evidence of drug use allowed the drug court to
penalize him by jailing him for one week. Because the psychiatrist could not treat the patient
while he was incarcerated, this jail time was a step backward in the addiction recovery process.
But not all physicians view interactions with the criminal justice system negatively.
Although no physician I interviewed ever agreed that imprisonment was an appropriate
consequence of relapse, a few have remarked that requiring a patient to be accountable to
someone else, whether a relative or a probation officer, can encourage treatment adherence—as a
result, medical and penal goals are aligned. Thus, physician and criminal justice system
interactions can be positive and mutually beneficial so long as their goals are clear: providing
evidence-based treatment and encouraging treatment adherence. Additionally, such interactions
should have clearly defined rules: physicians should be able to provide MAT if they feel it is
medically advisable, and should not be required to share any information they feel could hurt the
treatment process. Describing her annoyance at probation officer requests for urine test results,
one physician quipped, “I don’t work for the criminal justice system! I’m a physician!” For their
part, criminal justice administrators should understand that physicians’ resistance to information
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sharing does not represent distrust or dislike of the criminal justice system, but rather reflects
physicians’ desires to safeguard patient health and adhere to their professional ethics.
VII.

Concerns about Treating Co-Occurring Conditions
Opioid dependence co-occurs frequently with other medical conditions, including chronic

pain and other mental health conditions (such as depression, post-traumatic stress disorder, or
bipolar disorder). According to one study, 22% of primary care patients suffer from chronic
pain734; another study estimates that 4-25% of primary care patients suffering from chronic are
also opioid dependent. Moreover, some studies estimate that up to 80% of individuals suffering
from addiction also suffer from a serious mental health condition, including depression, bipolar
disorder, schizophrenia, and generalized anxiety disorder. Patients suffering from non-sports
related trauma (e.g. sexual abuse, child abuse, domestic violence, physical abuse) are at
significantly higher risk of substance abuse disorder.735
Opioid dependence and chronic pain patient populations often overlap. Up to 20% of
primary care patients treated with opioids for chronic pain also suffer from opioid dependence.
Physicians treating patients suffering from both chronic pain and opioid dependence may face
particularly significant challenges; physicians report low self-efficacy for treating both addiction
and for managing chronic pain (a problem particularly common for primary care physicians). 736
These perceptions of low self-efficacy may derive from the fact that medical school and
residency program curricula include only limited (if any) education about the interaction between
pain management and substance abuse treatment.737
Physicians also face challenges when treating patients suffering from both SUD and a cooccurring mental health condition. Medical professionals, particularly those who are not
psychiatrists and who lack extensive training in treating patients with co-occurring mental health
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conditions, may also feel discouraged when treating patients with SUD. It is not enough for
medical school, residency, and continuing education curricula to address addiction treatment,
chronic pain management, and mental health conditions individually; rather, such courses must
prepare physicians to treat patients suffering from combinations of these illnesses.
VIII. Regulatory Concerns
Buprenorphine and Vivitrol are the only two addiction treatment medications that may be
prescribed in a physician’s office rather than an OTP. Of the two medications, buprenorphine is
arguably more accessible to patients because of its lower cost, its greater likelihood of being
covered by commercial health insurance or Medicaid, and its shorter detoxification requirements
(patients must detox for three days versus detoxifying completely under Vivitrol).
Buprenorphine is also more readily available than methadone, which can only be prescribed in
an OTP. Many cities (and, unbelievably, some states) lack OTPs. Additionally, methadone is
heavily stigmatized and not always covered by Medicaid or commercial health insurance. Some
studies have found that, given the choice between buprenorphine and methadone, more patients
prefer buprenorphine.738 Therefore, while physicians should be trained to administer all of forms
of MAT, it is especially crucial to prioritize buprenorphine treatment.
Unfortunately, the Drug Addiction and Treatment Act of 2000 (DATA) imposes severe
restrictions on buprenorphine treatment such as 100-patient limits and physician certification
requirements that do not exist for any other FDA-approved medication, including oxycodone and
other pain killers.739
Merely knowing of these patient limits may deter medical students or residents from
entering the addiction treatment field, prompting fears of profound government intrusion and low
salaries due to limited patient populations. These patient limits directly interfere with physicians’
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ability to meet demands for addiction treatment. In early 2016, ASAM surveyed over 1,300
addiction specialists to assess the severity of waiting lists; 66% of participants stated that they
had patient demand exceeding the 100-patient limit. This means that more than half of
physicians are forced to turn away patients seeking buprenorphine treatment.
Some physicians may also be deterred from prescribing buprenorphine because they
assume that obtaining a DATA waiver will be too time-consuming or labor intensive.740
However, there are few ongoing, time-consuming requirements for a doctor to comply with
under DATA after obtaining a DATA waiver other than an eight-hour training course,
Nevertheless, the waiver requirement may filter out those physicians who are not highly
motivated to treat addiction.741 In an ideal world, such filtering would be a distinct advantage.
But given the current realities of limited numbers of addiction treatment providers and high
patient demand, such filtering harms patients by limiting provider access.
For years, professional medical associations such as the AMA and ASAM, have
supported looser patient limits and allowing highly trained physician assistants and nurse
practitioners to prescribe buprenorphine. In remarks to Congress, a representative of the AMA
stated,
The advantages of reducing the regulatory burdens to prescribing suboxone
would not only increase the availability of suboxone treatment, but would also
increase clinical identification, awareness, and acceptance of opiate addiction as
a disease and reduce stigma associated with opiate addiction.742
If the patient limit is increased, more physicians may consider entering the addiction
treatment field. However, some physicians fear that increasing the patient limit will encourage
so-called “suboxone mills” to spring up, wherein greedy physicians will dole out buprenorphine
like candy without properly managing patients. Anecdotal evidence suggests that the few
physicians operating “suboxone mills” tend to operate on a “cash only” basis, and do not accept
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Medicaid or even commercial insurance. Most physicians are highly skeptical of “cash only”
practices; not only do “cash only” physicians price themselves out of the market for most
addiction patients, they may indirectly encourage addiction patients to sell some of their
medication for cash to pay for appointments. I have spoken with a few “cash only” addiction
treatment physicians, and they argue that insurance reimbursement is too low to cover their
appointment costs. Rather than accepting insurance, therefore, they charge patients
approximately $200 per month for a buprenorphine treatment appointment. Once the patient
obtains a prescription, she then pays for the medication with Medicaid or commercial insurance
at a local pharmacy.
Assuming that “suboxone mill” physicians tend to adopt “cash only” policies, the
government could limit suboxone mills by only increasing patient limits for physicians who
accept insurance, including Medicaid. Medicaid involvement would increase oversight of
physicians’ practices, and patient access would improve due to Medicaid coverage.

IX. Presuming that Few Patients Suffer from Drug Dependence
A surprising number of physicians believe that drug dependence is not widespread within
their patient populations. A study of primary care physicians revealed that a significant minority
stated that they do not treat addiction using MAT because they think only a few of their patients
are drug dependent.743 Not surprisingly, physicians who believe that this crisis has affected only
a few of their patients also have limited motivation to seek a DATA waiver to prescribe
buprenorphine. Most physicians, however, are likely naïve in believing that so few of their
patients are opioid dependent, given the recent epidemic of opioid dependence and overdoses.744
Studies have shown, for instance, that up to 25% of primary care patients prescribed opioids for
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chronic pain also suffer from opioid dependence.745 In outpatient settings, an estimated 10-16%
of patients suffer from a substance abuse disorder, including patients without chronic pain).746 In
inpatient settings, 25 to 40% of admissions are related to substance use.747 Drug use disorders are
common in persons of all ages, sexes, ethnicities and socioeconomic backgrounds.748
Patients with SUD may feel uncomfortable discussing their condition with their doctors,
especially if they have not received any signal from them suggesting that treatment is available
or that such a conversation would be welcomed. When physicians a priori believe that few
patients suffer from drug use disorders, they may fail to screen patients from drug use. A failure
to screen patients may be due to a lack of training or simply physicians’ discomfort discussing
addiction with patients. Unfortunately, the SUD screening rate is currently low. A 2010 study of
family physicians found that only 50% screened for tobacco use and less than 1/3 screened for
alcohol use.749 Although not reported, screening for other drug use is likely even less common.
Screening refers to the combination of a carefully elicited verbal history and a urine test,
the most effective process for detecting SUD.750 A urine screen alone is not enough because the
patient may suffer from drug dependence but any drugs may have already left the patient’s body.
Additionally, if a urine test is positive for drugs, there may be a reason for the drug’s presence
other than an SUD. Therefore, the patient’s verbal history is a particularly important part of the
screening process.
In order to elicit the patient’s verbal history, however, the healthcare provider must feel
comfortable discussing addiction. Substance dependence is so stigmatized in American culture
that some medical practitioners feel uncomfortable broaching the subject during medical
appointments. In an anecdote from my own health care experiences, I remember once attending
an annual primary care visit during which the nurse asked routine questions about alcohol and
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drug use while laughing, which gave me the impression that she thought it ridiculous to be
asking me these questions when I appeared to be a successful professional.

Although I could

not read the exact reason for the nurse’s laughter—whether she genuinely thought drug addiction
was funny or whether she was laughing to indicate her nervousness about asking me these
questions for fear I would take offense – I interpreted this interaction as indicative of a judgment
that certain groups of people were more likely to suffer from drug dependence than others, a lack
of training in drug screening and a lack of knowledge about the full extent of drug dependence in
the U.S. But such an interaction may make persons with dependency too embarrassed to disclose
their drug use. Patients might not only might patients feel uncomfortable disclosing drug use in
that nurse’s office, but might carry the experience with them into future medical settings,
convinced that all health practitioners would have such judgments.
I later recounted this story to one physician who interpreted the nurse’s behavior as
discomfort discussing drug use. In her opinion, nurses and physicians want to help patients with
addiction, but fear that screening will initiate an uncomfortable or embarrassing interaction. As a
result, they prefer to skim through screening questions or to laugh. If a patient appears to be a
professional or a wealthy, powerful individual, then the nurse or physician may feel even more
uncomfortable asking about drug use. Making drug screening a routine part of patients’
examinations regardless of whether or not they presenting symptoms of an SUD will make
patients and physicians more comfortable with the screening process.751 Therefore, routine SUD
screening should be encouraged as a medical best practice, especially in the fields of primary
care, psychiatry, emergency care, and pain management, all of which have relatively high rates
of patients with SUD).
X. Presuming that only Psychiatrists are “Qualified Physicians” to Treat Addiction
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Under DATA, any physician who obtains a DATA waiver from SAMHSA, registers with
the DEA, and follows patient limits may prescribe buprenorphine. However, in practice, most
physicians who prescribe buprenorphine are psychiatrists. Because psychiatrists undergo
significant training in neuroscience and co-occurring mental health diseases, they may receive
the ideal training to prescribe buprenorphine. Many psychiatrists I have interviewed have
articulated this viewpoint. But the opioid epidemic has forced practitioners and patients into an
untenable position. The U.S. is facing a severe shortage of psychiatrists in combination with
rising rates of opioid dependence. For this reason, we cannot rely on psychiatrists being the
primary prescribers of MAT. Other more accessible providers should be involved, especially
primary care physicians. Ideally, physician assistants and nurse practitioners should also be
permitted to prescribe MAT.
Primary care physicians are usually the first physicians whom patients see for addiction
treatment. Because commercial insurance providers such as HMOs often require a referral from a
primary care doctor before a patient sees a specialist, primary care physicians are the “gateway”
to medical treatment.752 Even if referral to a specialist is not required, primary care physicians
may have more appointments available. Additionally, some individuals do not know what type
of specialist they should see, so they schedule an appointment with a primary care physician to
obtain guidance through the maze of options. In some towns, only primary care doctors are
available because the population size is too small to support specialists. One study of
psychiatrists’ distribution concluded that “[t]hey are rare or nonexistent in rural America.”753
Primary doctors also typically have lower appointment fees than specialists,754 and so
may be more affordable for individuals in the low-income brackets to which SUD is correlated.
755

Moreover, patients may have seen their primary care physicians as “family doctors” for
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years,756 so that they might be more familiar with a patient’s background, health history, and
needs than a specialist whom the patient has never seen before. For example, a primary care
physician may notice that a patient is behaving differently, perhaps suggesting a SUD. 757 In
contrast, physicians without long-term knowledge of the patient may fail to notice t addiction
symptoms. Lastly, an appointment with a primary care physician provides anonymity for patients
suffering from drug dependence, because primary care physicians also treat a wide variety of less
stigmatized conditions. Thus, seeing a psychiatrist is more stigmatizing than seeing a primary
care physician.758
The reason for low DATA waiver rates among primary care doctors is not fully
understood, but published studies point to a few possible explanations.759 First, many primary
care doctors feel that they know too little about drug dependence to provide adequate treatment
or believe that they are otherwise underqualified.760 Some primary care physicians may assume
that only psychiatrists are knowledgeable enough to prescribe buprenorphine, even after an
eight-hour training course (as required by DATA). This view, however, has no empirical
support. According to an article published in the Annals of Family Medicine, 54% of patients
were sober following six months of buprenorphine treatment from a primary care doctor, with no
difference in settings.761 Primary care physicians already prescribe the majority of psychoactive
substances nationally.762 Additionally, primary care physicians may feel that they lack time to
treat patients with addiction, given that these patients are more time-consuming and many
primary care physicians already work late hours. They may also fear inadequate reimbursement
or other patient barriers (see below).
XI. Lack of an Integrated Counselor-Physician Relationships
MAT is most effective when provided in conjunction with counseling,763 though the two
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services need not be provided by the same individual or within the same institution. Some
insurers will not reimburse physicians for MAT until they document that the patient is
undergoing counseling. Furthermore, DATA requires that a physician have the capacity to refer a
patient for counseling in order for to obtain a DATA waiver. Unfortunately, many physicians
feel both unable able to provide counseling and unable to refer patients for counseling due not
knowing the qualified counselors in their area.
Lack of support from behavioral care professionals, especially mental health counselors,
is a common barrier to primary care physicians prescribing buprenorphine.764 In one study of
primary care physicians, the physicians noted that a lack of support from mental health
counselors was the primary reason they did not prescribe buprenorphine treatment.765 All
physicians whom I have interviewed believed that buprenorphine treatment should be provided
in conjunction with counseling, but many felt undertrained to provide counseling themselves.
Even psychiatrists who have received training in counseling typically prefer to refer patients to
another therapist for counseling.
Numerous studies have proven the efficacy of treating opioid dependence through a
combination of physician-prescribed MAT and counseling provided by a mental health
professional such as a psychologist or social worker. If a physician providing MAT can refer
their patients to counselors, in theory this treatment should pose no problems. In some cities,
however, there are not enough counselors who are experienced and/or willing to treat addiction.
Even if sufficient numbers of counselors are available, they may not accept commercial health
insurance or Medicaid. A primary care physician who provides buprenorphine treatment told me
that he is trying to encourage other physicians in town to do so as well, but the physicians cannot
find a qualified counselor who accepts Medicaid to whom they can refer patients. As a result,
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these other physicians are not providing buprenorphine treatment. In response, the primary care
physicians has personally called every counselor in his town and the surrounding area to create a
database of counselor information to distribute to other physicians, including whether they are
accepting new patients, what types of insurance they accept, whether they are willing to treat
addiction, and whether they are experienced in this field
Physician No. 14 began treating addiction in Southern treatment facility that provided
three services: MAT, counseling, and non-twelve-step support groups. She described this
setting as an ideal “one-stop-shop” for patients. When the physician moved from the South to the
Midwest, she stopped treating addiction because she no longer worked in a facility that provided
patients with access to all three services, and currently only treats pain. When I asked her why
she did not simply refer patients to an outside counselor, she replied that she only knew of a
handful of counselors who were both willing and experienced in treating addiction but they were
not accepting new patients.
In addition to increasing physician education about MAT, we must make more
educational and training opportunities available to counselors and social workers as well because
these mental health professionals must coordinate their addiction treatment efforts with
physicians.766 These programs should be targeted towards students as well as practicing
professionals, and must address the “abstinence-only” resistance to MAT that is pervasive
among many mental health professionals.767
XII.

Lack of Institutional Support
Even physicians who would like to begin treating addiction patients may find that their

institutions or co-workers disapprove and prefer to refer patients outside to other programs. In a
study of the barriers to buprenorphine treatment that Washington state primary care physicians
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had encountered, 42% cited resistance from practice partners and 36% cited institutional
resistance.768
Co-workers and administrators may fear personal stigmatization for treating addiction,
just as physicians who practice addiction medicine face stigma from the public and even their
colleagues in the medical community.769 This stigma is a corollary of the popular cultural
phenomenon of labeling individuals with dependency as immoral and those who help them—
including medical professionals--as enablers. Co-workers and administrators may also fear that
“difficult” addiction treatment patients will be lining up at their doors, prompting patients
without dependency to seek care elsewhere.
Staff and structural characteristics both influence whether an institution is more or less
likely to adopt MAT. Ducharme and Roman (2009) found that structural factors are even more
predictive of MAT adoption than staff structures.770 In particular, institutions were more likely to
adopt MAT if the possessed accreditation, were affiliated with a hospital, provided inpatient
care, and provided detoxification services.771 Not surprisingly, institutions practicing abstinenceonly treatment are particularly resistant to adopting MAT. Likewise, institutions that are
unaffiliated with hospitals or other medical practices are more likely to resist MAT, possibly due
to less physician involvement.
When organizations accept MAT, this frequently motivates practitioners to adopt such
treatment options.772 D. Simpson, an expert on knowledge diffusion in medicine, argues that topdown, institutional change in practices requires exposure to a new practice and a perceived need
to change, a decision to adopt that practice (which requires that individuals believe the practice
has utility, a consensus that the product has utility, and effective organizational leadership); the
implementation of the practice (including resource allocation and training); and the
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institutionalization of the change.773 The entire process may take years from start to finish.
Staff attributes may also affect whether an institution adopts MAT. Younger individuals
with more professional training are more likely to accept changes in practice than older
individuals without professional training.774 A physician working in an SUD recovery center
likely is part of a team of other treatment providers, including counselors. In team work settings,
all members need to support MAT implementation. However, counselors who are
philosophically inclined aligned with self-help or abstinence-only methods may be averse to
institutionalizing MAT, even if they support the use of medications for treating other
conditions.775 In organizations where staff is resistant to MAT, all staff members, including nonphysicians, should receive continual MAT education and training. Education about
buprenorphine, for example, has been shown to change even resistant health care providers’
attitudes.776
In contrast, primary care physicians typically work in an individual clinical practice
where pharmacotherapy is central to disease treatment, and thus may experience less resistance
from staff regarding MAT. But staff may resist other consequences that are may be associated
with MAT, including low insurance reimbursements, stigma, and bureaucratic hurdles. Smaller
physician practices may worry that they lack adequate staffing to manage addiction treatment.
Physician 1, a primary care physician, cited limited staffing for urine screenings as a primary
point of resistance. This resistance seems odd, however, considering the frequency with which
urine screenings are used in diagnosing and treating other conditions in primary care practices,
such as pregnancy and urinary tract infections. Other physicians I interviewed noted concerns
about the increased staff time needed to complete insurance pre-authorizations and other
insurance matters. Administrators may dislike hiring additional billing staff to complete pre-
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authorizations. When these hurdles are combined with other concerns such as lower
reimbursement, increased governmental oversight, and potential stigma, it is easy to see how
well-meaning physicians and their administrators may be reluctant to implement MAT. Many of
these fears, however, are arguably unsubstantiated and may never come to pass. If physicians
and administrators visit other offices that offer addiction treatment, they may learn that it is not
as difficult as it may appear.
Sometimes institutional change begins at the bottom, at the provider level. Physician 4
works for a large SUD and mental health treatment organization serving thousands of patients.
Until two years ago, this institution not only did not provide MAT, it was a classic “abstinenceonly” institution that explicitly banned patients undergoing agonist treatment from participation.
When the psychiatrist joined this organization, she brought with her extensive experience in
MAT from prior employment at a methadone clinic and in an office-based practice providing
buprenorphine and Vivitrol treatment. Despite her lack of a formal leadership role within this
organization, within one year she had dramatically changed institutional beliefs about MAT. She
organized educational seminars about MAT for all staff members including counselors,
physicians, and administrators. After she successfully petitioned the administration to permit her
to provide MAT, she became the first physician to prescribe buprenorphine and Vivitrol. Coworkers and administrators saw positive results from MAT, yielding increased cultural
acceptance of MAT. The psychiatrist observed, however, that there are still lingering pockets of
resistance, particularly from “recovery coaches,” who are counselors serving as case managers
instead of providing mental health therapy. These recovery coaches tend to lack a graduate
degree, are likely in recovery themselves using “abstinence only” methods, and directly interact
with criminal justice administrators. Sometimes counselors improperly tell patients that they
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should try to wean off MAT as quickly as possible. Thus, the psychiatrist must continually
remind her co-workers that long-term use of MAT is more effective than short-term use. She
stressed the importance of providing regular, ongoing education about MAT to all staff
members.
State mental health authorities can also influence an organization’s culture, particularly at
organizations with state contracts. One study of information diffusion in 50 states and the
District of Columbia found that state contracts mandating MAT use were strongly predictive of
MAT implementation.777 State authorities can also encourage institutional adoption of MAT
through “softer” means, such as educational outreach. The study also found, however, that state
authorities sometimes fail to clearly convey their priorities to institutions, including whether or
not MAT should be implemented.778 Finally, state Medicaid coverage of MAT is a significant
predictor of MAT adoption among institutions and individual providers.779
XIII. Insurance Barriers
The Affordable Care Act (ACA) incorporates requirements under the Mental Health &
Addiction Parity & Equity Act of 2008 (MHAPEA). The MHAPEA prohibits differences in
treatment limits, cost sharing, and in-network/out-of-network coverage between treatment for
physical illness and treatment for mental health or SUD treatment. Under the ACA, MHAPEA
now applies to Medicaid managed care organizations, the Children’s Health Insurance Program,
small and large employer funded plans, commercial health insurance sold on the Marketplace,
and Medicaid Alternative Benefit Plans.780 The MHAPEA does not apply to traditional fee-forservice Medicaid; however, less than 20% of Medicaid enrollees nationwide participate in feefor-service plans.781
Despite the parity required under the ACA and MHPAEA, many health insurers continue
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to place onerous burdens on addiction treatment policy holders and their physicians. In
interviews with 16 physicians, whenever I asked whether they believe such parity actually exists,
the answer has been unanimous: no. Some physicians’ responses have been tinged with anger or
sarcasm, such as “Absolutely not!” and “Oh, is there supposed to be parity? I’ve never seen it!”
When I attended an annual ASAM conference, I heard frustrated physicians from around the
country airing their grievances about the lack of insurance parity and the burdens it imposed.
Foremost among these burdens were time-consuming preauthorization requirements applied only
to addiction treatment that struck many physicians as being medically unsound.782
For example, multiple physicians explained that, when completing pre-authorizations for
buprenorphine, they must tell the insurance company how soon they plan to wean the patient off
of the medication. Some insurance companies require physicians to promise in writing to wean
the patient off after six months or one year. Medical studies clearly conclude, however, that longterm buprenorphine treatment is more effective than short-term treatment. Many frustrated
physicians reported that they have informed insurance companies that they would wean off
patients, but then also attach a prewritten disclaimer describing how long-term treatment is more
effective than short-term treatment. After six months or one year, these physicians must once
again seek preauthorization and provide these same responses. Yet, according to these
physicians, insurers never ask for provider promises to wean patients off of other medications,
only buprenorphine—not even prescription pain killers such as oxycodone. Therefore, these
“weaning off” requirements appear to violate federal parity law.
To compound these issues, pre-authorizations are fiendishly difficult and frustrating to
obtain. Although completing a preauthorization form may sound simple, they are very timeconsuming in the aggregate and are rarely required for other mental health medications. The time
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commitments required to obtain pre-authorizations may deter practices from providing
buprenorphine and Vivitrol treatment. According to one psychiatrist, his office hired an
additional billing specialist whose only task is to complete pre-authorizations and argue with
insurance companies in the event of denials. He does not know how a solo practitioner without a
large staff could successfully surmount this preauthorization hurdle.
Because addiction is a chronic disease, physicians must regularly renew preauthorizations for each MAT patient. Almost every physician I interviewed was annoyed that
insurers do not accept preauthorization renewals until the renewal deadline has passed. In other
words, the physician cannot complete and submit the preauthorization form ahead of time. But
for some patients, any delay in accessing treatment can prove deadly. If a prior authorization
expires January 1st and the patient runs out of buprenorphine that same day, then he may be
unable to receive a buprenorphine prescription by January 3rd unless the prior authorization is
submitted immediately. Buprenorphine only remains in a patient’s system for two to three days;
after that, the patient begins undergoing withdrawal and cravings return. At that moment, the
patient is at serious risk for relapse and overdose, which ironically are very expensive for
insurance companies to treat because they commonly require emergency room treatment,
ambulatory care, or in-patient hospitalization. Therefore, the insurer has little to no financial
incentive to delay buprenorphine treatment and every incentive to provide renewals in a timely
manner.
In 11 states, Medicaid programs impose “life-time” limits per patient for buprenorphine
treatment.783 Such limits are heavily criticized in both medical and public health scholarship. A
recent study published in Health Affairs found that “life-time” limits for buprenorphine treatment
are dangerous to patients because they often leading to relapse once the limit is met and
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moreover are financially unsound for states because relapse or overdose often require expensive
medical treatment.784 Physicians working in states with life-time limits may be wary to prescribe
buprenorphine to patients, not only because the state legislature is intervening so intrusively in
their medical care but also because they fear patients will relapse once they reach their limit.
Other medications do not have “life-time” limits under Medicaid programs.785 Therefore, many
some Medicaid Managed Care Organizations (MCOs) may be violating federal parity law (which
applies to Medicaid MCOs but not traditional fee for service Medicaid).
Commercial insurance providers and Medicaid programs may put other barriers in place
as well, the most obvious of which is refusing to cover these medications at all. 786 For example,
in multiple states, including Indiana, Medicaid does not cover methadone when prescribed for
addiction treatment purposes even though it covers it when prescribed for pain management. 787
A 2013 study found that only 13 state Medicaid programs currently cover all three MAT options:
methadone, buprenorphine, and Vivitrol.788 But because some medications work better for
different patients, limited insurance coverage artificially restricts many physicians’ treatment
options if they know that their patients cannot afford medications without coverage.
Multiple physicians have also reported that their state Medicaid programs will not pay for
buprenorphine or Vivitrol stored in the physicians’ office, even if it is provided pursuant to a
valid prescription. Instead, the patient must pick up the medication from a pharmacy. In states
that impose this Medicaid barrier, new addiction treatment patients must undergo an extremely
time-consuming process to receive MAT medication. First, they must attend an office
appointment, where they receive a diagnosis and a written prescription for buprenorphine or
Vivitrol. Then, they must leave the physician’s office and pick up the medication from a
pharmacy. Finally, they must return to the physician’s office, ideally that same day, where they
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must give the medication to their physician who then “induces” the patient. For patients on
Vivitrol, induction requires that the drug is administered via injection followed by an observation
period. Significantly, Vivitrol patients must always receive their injection from a physician’s
office and hey cannot legally self-inject Vivitrol at home. For patients taking Buprenorphine,
induction means that the patient swallows a pill or places a dissolving sublingual film under their
tongues in the physician’s office, again followed by two to four hours of observation. After the
first dose, buprenorphine patients take the medication daily at home daily.
Unfortunately, requiring patients to leave the physician’s office, go the pharmacy and
then return, many patients will never return. The nature of addiction is such that a patient with
severe cravings may leave the office but instead decide to visit a drug dealer or go home on the
way to the pharmacy. Even a simple trigger, such as seeing a building where the patient has
previously “gotten high,” may overwhelm the patient’s motivation to go to the pharmacy. In
other words, addiction as a disease gives patients only a short and critical window of time during
which they are willing and able to undergo treatment. If that window disappears, then it may be a
long time until a new opportunity appears. In the meantime, the patient is at risk for overdose.
One physician described how his office used to provide the first Vivitrol injection
immediately after it was first prescribed so long as the patient had fully detoxed) because the
office stored Vivitrol. At that time, so long as a patient had a valid Vivitrol prescription in place,
Medicaid covered the medication’s cost. Then the state’s Medicaid policy changed, and the new
policy required patients to pick up Vivitrol from the local pharmacy and then return for the
injection. The office saw a 50% drop in the number of patients who actually received the
injection (rather than just the prescription)—meaning that 50% of the patients left the office
without returning. According to the physician, this tedious Medicaid requirement would be less
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problematic during a patient’s second or third Vivitrol treatment, when the patient might be
stabilized enough to not mind the extra trip to the pharmacy. The first Vivitrol treatment in
contrast is a “golden opportunity” that cannot be delayed since another opportunity may never
arise. In light of the 50% drop in Vivitrol injections, the physician and his partners decided to
altruistically cover the cost of each patient’s first Vivitrol injection in their office, Rather than
having patients pay for the injections out-of-pocket, which most could not afford. Though very
admirable, this altruistic option is not practical for most physicians’ offices as few would be so
selfish or could afford it.
Another of the greatest barriers is limited insurance reimbursement for addiction
treatment, especially low Medicaid reimbursement levels. Medicaid pays for the majority of
SUD treatment in the U.S. because individuals with dependence tend to have limited incomes;
thus, individuals covered by Medicaid are more likely to suffer from opioid dependence relative
to those covered by commercial health insurance.789 However, Medicaid reimbursement rates are
significantly lower than those from commercial health insurance and even Medicare. In a study
of practicing physicians who completed buprenorphine training, 67% intended to begin
prescribing buprenorphine after the training was completed.790 Of those who completed training
but did not wish to begin prescribing buprenorphine, approximately one-quarter cited low
reimbursement rates as the primary barrier.791 Other studies have also found low reimbursement
to be one of the most frequently mentioned barriers to buprenorphine treatment.792
Even within commercial health insurance, addiction treatment tends to be reimbursed at a
lower rate than other covered procedures. Moreover, the type of appointment that addiction
medicine requires is not highly reimbursed. Procedures requiring surgery or expensive
machinery (e.g. magnetic resonance imaging machines) tend to be reimbursed at higher rates
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than appointments (like those utilized in addiction medicine) consisting primarily of physicianpatient counseling and pharmacological prescription. Additionally, capitation payments, a
common commercial insurance payment method, dissuades primary care physicians from
treating patients for addiction. Capitated payment mean that physicians are reimbursed the same
amount of money per patient according to a rate negotiated with the insurance company,
regardless of how much time they spend with each patient. Capitation incentivizes physicians to
see as many patients as possible in one day, and time-consuming patients are barriers to this goal.
But addiction treatment appointments tend to be more time-consuming than others because
physicians need to take patients’ complete drug use history and provide basic counseling, as well
as prescribe MAT and perform urine screenings. If the patient also suffers from co-occurring
mental health conditions or chronic pain, then addiction treatment appointments may last even
longer, often thirty minutes to an hour. Ideally, insurers should “carve out” behavioral health
treatment as an exception to regular capitation rules and reimburse physicians for the extra time
they must spend with addiction patients.
Commercial insurance providers also commonly require step-therapy, in which a patient
must try a cheaper medication for a period of time before trying a more expensive medication or
must begin with a low dosage. For example, insurance providers may require patients to begin on
a low dosage of buprenorphine, which may fail to prevent cravings and euphoria from other
opioids, before covering higher dosages of buprenorphine.793 Although step-therapy is an
important cost-saving tool, in the case of addiction it may result in increased costs if the patient
overdoses due to inadequate medication. Additionally, according to the ASAM, virtually no
commercial health insurance companies cover methadone in IOPs, possibly fearing adverse
selection (wherein patients with SUD specifically choose that insurance) if other commercial
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insurance providers do not cover IOPs.794 However, if all commercial insurance providers
covered methadone in IOPs, then adverse selection would be far less of a concern.795
Some insurance barriers clearly violate federal parity laws, such as requiring physicians
to commit to weaning patients off buprenorphine, limiting buprenorphine coverage time, and
Medicaid Managed Care Organizations’ failure to cover Methadone addiction treatment while
covering it for pain treatment. These insurance policies are also contrary to best medical
practices. However, because individuals with dependence have limited political power, these
practices are allowed to continue as regulators maintain a hands-off approach despite the opioid
epidemic. Many physicians believe that such policies would not exist if the addiction patient
population were wealthier and attracted more public sympathy—and in fact these barriers do not
exist for other conditions and diseases for which these wealthier patient populations may need
treatment. This, of course, reinforces both the stereotype that wealth individuals do not suffer
from drug dependence, and the actuality that patients with financial resources or insurance
coverage can afford to evade these barriers through seeking other treatment options. Other
barriers, such as prohibitions on reimbursement for medication stored in the physician’s office
and low Medicaid reimbursement rates, disproportionately harm addiction patients. Unlike most
patients, addiction patients have a limited window of time during which they are both willing and
able to seek treatment, and are also particularly likely to have Medicaid rather than commercial
health insurance.
Incentivizing more physicians to treat addiction will require raising Medicaid
reimbursement rates, especially in light of the opioid overdose epidemic. Likewise, Congress and
state legislatures should fund studies of insurance barriers in their states affecting mental health
and SUD patients. Enforcement authority depends on the type of insurance plan. In most states,
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MHPAEA enforcement is delegated to the state insurance commissioner for insurance plans with
less than 51 employees; the Department of Labor and the Internal Revenue Service have
enforcement authority with respect to plans subject to the Employee Retirement Income Security
Act; and DHHSA enforces self-funded non-governmental plans, as well as small group plans in
some states. MHPAEA must be rigorously enforced to discourage insurance providers from
violating parity. Furthermore, the Center for Medicaid and Medicare Services should adopt a rule
that would apply MHPAEA to fee-for-service Medicaid, an existing loophole in parity law.796
VIII. Summary
More physicians are needed in addiction treatment; within addiction treatment, more
physicians should prescribe MAT. While psychiatrists (especially those trained in both addiction
and MHDs) are likely the ideal prescribers of MAT, the U.S. is facing a severe shortage of
psychiatrists. Therefore, primary care physicians should become involved in addiction treatment
as well.
Yet, without addiction education in medical school and residency, physicians are unlikely
to begin treating addiction or to seek out addiction-related courses. Addiction treatment patients
are frequently perceived as difficult and often bring co-existing health conditions (such as pain or
other MHDs). Without adequate training in these diseases and evidence-based treatments,
physicians may feel too intimidated to treat addiction and prescribe MAT.
The structure of the health care system and health care financing also prevents physician
involvement in addiction. Insurance companies violate mental health parity; Medicaid provides
insufficient reimbursement rates and, in some states, lifetime buprenorphine limits. Mental health
counselors and physicians rarely collaborate, largely due to the historical separation of
physicians from addiction treatment after the passage of the Harrison Act. This separation
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prevents MAT from diffusing into addiction treatment centers, the majority of which follow an
abstinence-only philosophy. Diffusion of MAT into addiction treatment is critically important in
light of the existing opioid overdose crisis and opioid dependence epidemic.
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CONCLUSION: DIFFUSION OF MAT
I. Introduction
Innovation diffusion is the process by which an innovation is communicated through
social channels and adopted into practices. An innovation is simply an idea perceived as “new,”
meaning the individual or organization has never heard of the innovation or has not used the
innovation. MAT is an innovation in the sense that it is not yet widely adopted within SUD
treatment in the U.S., due to lack of knowledge about MAT, practical barriers (such as costa and
few prescribing physicians) and cultural stigma. Diffusion of MAT into SUD treatment would
move SUD treatment much closer to mainstream medical treatment.797 Addiction treatment
historian William White predicts that “the conceptual and practice silos of medication-assisted
treatment and “drug free” treatment will progressively dissipate within the addiction treatment
field.”798 He expects that drug dependent patients will soon be able to choose from a menu of
services offered at treatment centers, including MAT.
However, other scholars are more skeptical about what future the SUD treatment field
will have in the U.S., given that abstinence-only treatment is still the norm. According to
scholars, innovation diffusion is slow in all medical fields; but in substance abuse treatment,
innovation diffusion appears to be particularly slow.799 MAT innovations seem to have hardly
diffused at all. Unfortunately, just because researchers identified an evidence-based treatment
does not mean that it will be implemented in medical practice.800
A synthesis of the literature on dissemination and implementation theory found that
innovative treatment methods are most likely to be successfully adopted under the following
conditions: practitioners receive coordinated training, supervision and assessments; organizations
provide supervision, training, and evaluations of practitioners; communities and consumers
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participate in selection and implementation of the innovation; and state and federal funding,
regulations and policies “create a hospitable environment for implementation and program
operations.”801
Receipt of information about an innovation alone is rarely sufficient to lead to its
sustained implementation.802 Studies have found that health practitioners frequently disregard
novel information about a treatment method. A randomized controlled study compared what
happened when a managed-care organization mailed new practice guidelines to an experimental
group of counselors; a control group of other counselors received no such information. Only
64% of clinicians received the guidelines, and less than 50% of recipients actually read the
mailing.803 Researchers found no difference in practice implementation between the control and
experimental groups.804 Similar studies have found minimal or no effect on practice
implementation when physicians receive treatment guidelines by mail.805
Fortunately, scholars have developed theories of innovation diffusion, and empirical
researchers have identified factors conducive to innovation implementation. The chapter begins
by examining innovation diffusion theory and problems of innovation diffusion in the SUD
treatment field. The chapter then discusses how SUD treatment organizations and individual
practitioners can integrate MAT into their practices, as well as motivational factors for doing so.
The chapter concludes by proffering a solution: government-level intervention in MAT
diffusion.
I. Effective Implementation and Organizational Change
A. Innovation Diffusion and Organizational Change Theory
Some studies suggest that individuals with greater knowledge of organizational change
processes find it easier to successfully implement innovations, which suggests that diffusion
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theories can aid government policy makers and treatment center administrators in MAT
implementation.806 Scholarly literature describes a number of widely-used theories of
organizational “practice” change, including Rogers’ Diffusion Theory, the Transtheoretical
Model (applied both to individuals and organizations), and Simpson’s Stages of Change Model
(applied to organizations).
Everett Roger’s Diffusion Theory is the most influential innovation diffusion theory in
SUD treatment. Diffusion Theory seeks to explain how organizations (which incorporate
“collective attitudes, actions and relationships” of individuals in the organization) adopt
change.807 Diffusion Theory posits that organizations (meaning administrators and staff) adopt
innovations by consciously or unconsciously following five steps: 1) they identify problems,
creating a perceived need for innovation, and adopt an agenda; 2) they match an innovation to
the relevant problem; 3) they modify the innovation and organization to ensure a better “fit”; 4)
they clarify the relationship between the innovation and organization, addressing
misunderstandings about the innovation; and 5) they make the innovation a regular part of
practice. During the final practice stage, the innovation is no longer considered novel but
becomes “treatment as usual.” At that point, the innovation’s effectiveness in real world settings
should approximate its effectiveness in research settings.808
Another influential model is the Transtheoretical Model (also known as the Stages of
Change Model) developed by Prochaska et al. According to this model, change requires
assessing actors’ readiness for change and then matching interventions to these stages of
readiness. The model can be applied to organizations, practitioners or patients. The authors have
identified five stages of readiness for change: 1) pre-contemplation, where actors think
everything is working well and no need for change exists; 2) contemplation, where actors think
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change might be a good idea, but wonder whether it is really necessary; 3) preparation, where
actors want to make the change but are not yet ready to do so; 4) action (actual implementation
of the change); and 5) maintenance, where actors ask whether the change is working and whether
improvements could be made.809 During the initial stages, actors rely primarily on cognitive,
affective and evaluative process; in later stages, they rely on conditioning and environmental
support.810 Interestingly, counselors often use the Transtheoretical Model to decide whether SUD
clients are ready for change (e.g. beginning psychotherapy), but treatment organizations can use
the same model to determine whether counselors are ready to adopt and implement new
treatment methodologies in their practices.811 This model also explains how individuals and
organizations can relapse and regress from a later to an earlier stage of change.
Simpson’s Stages of Change Model (which differs from the Transtheoretical Model)
include four steps: 1) exposure; 2) adoption; 3) implementation; and 4) practice.812 Exposure
involves training in the new innovation; staff motivation and organizational resources are
necessary for such training to “stick,” however. The adoption stage requires that staff perceive a
need for the change and receive training, that the change has ease of use, and has “fit” with both
the accepted treatment scheme and treatment ideology. For example, if counselors adhere to a
strict abstinence-only ideology and assume that MAT hinders sobriety, they will be unlikely to
adopt MAT. A study by Berwick found that staff perceptions of the innovation explained 49% to
87% of the variation in innovation dissemination813; therefore, organizations that want to
successfully adopt an innovation must first increase staff members’ perceptions that the
innovation is useful. Issuing a top-down mandate requiring staff members to implement an
innovative method without first addressing their perceptions of this innovation is likely to fail.814
The implementation stage includes a usage trial, allowing for staff members to develop and share
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testimonies of the innovation’s usefulness. This stage requires that the organization commit
sufficient resources and create a climate conducive to change. For example, an addiction
treatment organization may need to fund staff travel to MAT training conferences. Creating an
ideal climate for change includes clarifying goals, promoting staff cohesion, and allowing space
for communication of concerns and resolving misunderstandings.815 At this stage, administrators
should also provide formal and informal incentives for adopting a change. In the practice stage,
the innovation is used regularly and is sometimes modified to better fit organizational dynamics.
Maintenance of the change requires ongoing organizational supervision and support; otherwise,
practitioners will likely return to formerly used methodologies with which they are still more
familiar.816 Even if administrator turnover occurs or political and funding climates shift, the
organization must continually monitor and support practitioners’ use of the new innovation.817
Unfortunately, while some researchers have studied dissemination’s beginning stages, few
studies have examined how to sustain newly-adopted practices long-term.818
According to Simpson, organizational readiness for change is critical at each step.
Resistance to change is not necessarily a bad thing, however, if it helps the organization identify
steps that are necessary to make the change viable.819 For example, counselors who resist the
adoption of MAT in a treatment facility may be basing their resistance on the organization’s
failure to accept Medicaid, which is an important source of coverage for MAT, leading the
facility to expand its insurance acceptance policies. Or counselor resistance could be based the
assumption that adopting MAT will lead to a lack of buy-in from criminal justice administrators
referring patients to the treatment organization, indicating that the treatment organization should
consider new, more effective means of communicating MAT’s advantages and the procedures
surrounding its implementation.
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Organizations may require significant financial resources to advance through these stages
of change. Trainings should be repeated frequently, and in-person training is more effective than
general workshop training, which is more effective than training from a manual alone.820 But inperson training and general workshop training can be expensive, and treatment centers may lack
sufficient resources for intensive training, especially if they primarily serve low-income
individuals. Therefore, they may need to partner with universities or apply for government
grants. Unfortunately, while grants may be available for initial stages of change, they are rarely
sufficient to cover shifts in practice over a longer term, including continued trainings and
evaluations.821
B. Factors Associated with Successful Innovation Adoption
Certain factors can predict whether an organization’s adoption of an innovation will be
successful. They can be divided into two categories: innovation-specific factors and
organizational factors.
Diffusion Theory suggests that there are five innovation-specific factors associated with
successful innovation adoption: a) the innovation’s perceived advantage; b) its compatibility
with existing program procedures; c) low innovation complexity; d) gradual implementation
(“baby steps”); and e) observability of results of the innovation. The easier it is for other
practitioners to see the results of an innovation, the more likely they are to adopt the innovation
and spread information about the innovation. These factors partially explain MAT’s slow
adoption. Staff and administrators in abstinence-only treatment centers do not perceive MAT as
advantageous; they regard it as a barrier rather than a facilitator to recovery.
Studies have also examined organizational-level characteristics associated with MAT
adoption, including for-profit status, large organizational size, association with a hospital,
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organizational use of other types of medications (e.g. SSRIs for depression), receiving a higher
percentage of revenue from private or commercial insurance, and Joint Commission
accreditation.822 Some of these factors also characteristic of organizations that are integrated with
mainstream medicine, which suggest that MAT has a greater “fit” within a medicalized program
philosophy (e.g. being associated with a hospital, using other medications, and Joint Commission
accreditation).
Conversely, an organizational emphasis on twelve-step programming (i.e. NA or AA)
predicts MAT resistance, as does practitioners’ allegiance to such a platform.823 MAT is unlikely
to fit within twelve-step programs. The percentage of organizational referrals from the criminal
justice system is also predictive of MAT resistance.824 In light of abstinence-only treatment’s
dominance within the criminal justice system, such resistance can and should be expected.
Finally, programs without access to a physician are less likely to adopt MAT.825 Such a lack of
access may indicate limited organizational resources, an undersupply of local physicians, or
organizational adherence to abstinence-only principles. Public programs (i.e. programs receiving
at least 50% of their revenue from government grants) are less likely to have access to a
physician than private programs.826
C. Expanding Treatment Options Within Organizations
SUD treatment organizations need not eliminate other types of evidence-based treatment
when contemplating MAT implementation. Ideally, SUD treatment organizations should offer a
“menu” of services, including MAT. Professionals might misconstrue the treatment role of
MAT, believing that it is meant to replace other treatment modalities rather than supplement
them. For example, during my interviews with counselors, some expressed concern that patients
would stop attending counseling as a result of MAT. After I mentioned that studies recommend a
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combination of MAT and counseling, they seemed less concerned. Other studies have also found
that counselors resist adopting new mental health treatments when they feel they may be forced
to abandon previous treatment methods.827 Additionally, counselors are more likely to resist new
treatment methodologies if they feel that administrators have not listened to their concerns or
have been insufficiently addressed. Inviting counselor participation in the planning stages of
innovation adoption can prevent such feelings.828
Policymakers should promote MAT as an expansion rather than a narrowing of available
treatments and should clarify that this expansion of treatment options is good for patients. First,
patients who have not been responsive to psychosocial treatments may be responsive to MAT,
decreasing relapse rates. In fact, treatment centers may find patients to be more responsive to
counseling and support groups when used in conjunction with MAT. Second, new patients may
enter the treatment center, especially those who have been resistant to psychosocial treatment.
Third, by integrating SUD treatment with MAT, SUD treatment will appear more similar to
“mainstream” medical treatment, potentially decreasing its stigma.829 Incorporating SUD will
send a clear message to patients and local communities that addiction is a medical illness that can
be treated like other diseases, without morality or spirituality as a foundation of treatment. 830
As potential treatment options increases, staff members will need to understand what
types of treatments work best for what types of patients. Those who lack sufficient training may
feel overwhelmed. Ideally, counselors should easily be able to consult with a physician about
such matters, and vice versa. Treatment centers without a physician on staff will either need to
hire one or form an association with an outside physician.
The Addiction Technology Transfer Network (ATTN) is an important resource for
treatment centers contemplating adding MAT to their service options. Funded by SAMHSA, the
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ATTN provides web-based and in-person trainings, publications, and conferences about
evidence-based SUD treatment methods. ATTN also facilitates alliances between researchers,
counselors, physicians, policy makers, and patients in an attempt to unify the SUD treatment
field. ATTN resources appear effective at promoting adoption of evidence-based treatments. For
example, a study of ATTN-facilitated trainings for rural primary care physicians found that
participants reported high levels of satisfaction, largely due to the trainings’ interdisciplinary
nature.831 Importantly, primary care physicians “became more confident of their capacity to work
with local drug abuse treatment centers and to care for their patients more effectively.”832
Furthermore, counselors developed relationships with primary care physicians in their
community.833
More specifically, ATTN has published The Change Book: A Blueprint for Technology
Transfer (now in its second edition and available online for free) to help treatment centers
implement evidence-based innovations.834 The Change Book distinguishes between training and
technology transfer. Training is a tool of technology transfer that tends to have short-term
results; technology transfer is a broader concept that includes a desire for change, acceptance of
the change, implementation, and reinforcement.835 Simply training counselors in a new treatment
method is not sufficient to promote the use of this method long-term since individuals naturally
prefer to return to more familiar methods. Therefore, treatment centers must also induce or
increase staff motivation for the change and explore organizational-level issues in its adoption.836
D. Motivating MAT as a sound business practice
Although MAT adoption and implementation does not appear to have been economically
driven, the practice is likely economically sound for treatment institutions.837 In a study of
naltrexone adoption within 450 SUD treatment centers nationwide, organizations led by an
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administrator with a medical degree or business degree were significantly more likely to adopt
naltrexone, perhaps signifying a preference for practical and cost-effective results, as well as
openness to medications in general.838 The authors reported that statistically significant variables
were “consistent around the idea that a greater use of naltrexone is a sound business practice.”839
The fact that MAT is cost- may partially explain why for-profit treatment programs are more
likely to adopt it than non-profit treatment programs.840 While an important treatment method,
counseling is more time consuming than providing medication, so institutions may be more costeffective if they provide a combination of counseling and MAT.841
Interestingly, policymakers appear to rarely use economic arguments in persuading
organizations to adopt MAT, even though advocates routinely point to its positive health
benefits. However, treatment centers trying to compete in a turbulent business environment may
be more swayed by economic arguments than by arguments about adopting an effective
treatment method or enhancing the societal good.
II. Change at the Practitioner (Counselor) Level
Counselors are the primary providers of professional SUD treatment in the U.S. Their
knowledge and beliefs about MAT matter because they may affect organizational practices and
policies. Unfortunately, SUD counselors are divided regarding knowledge of MAT and support
for its use in SUD treatment.842 For example, a large minority counselors involved in SUD
treatment have either never heard of buprenorphine or oppose the use of buprenorphine.843 A
study in 2008 by Herbeck et al. found that SUD program directors and staff (the majority of
whom were counselors) viewed MAT as significantly less effective than psychological
interventions for opioid dependence treatment.844 According to the study, many of the surveyed
participants were unaware that buprenorphine was an effective treatment for opioid
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dependence.845 In a 2005 study by Knudsen et al., more than two-thirds of counselors answered
“I don’t know” when asked if buprenorphine was an effective treatment for opioid
dependence.846 A study of SUD counselors in Massachusetts found that 55% had never
recommended naltrexone to either opioid or alcohol dependent individuals, either due to
perceived cost or lack of knowledge.847
The diversity of types of SUD counselors may also explain the heterogeneity of attitudes
towards MAT. Licensed counselors with graduate degrees routinely work alongside those
without college degrees. State law typically only permits certain counselors to provide individual
mental health counseling without supervision: licensed clinical social workers (who by definition
have graduate degrees) and Ph.D.-level psychologists. However, SUD counselors without a
license or college degree can provide patient support, coaching, and lead group meetings.
Nationally, approximately 50% of SUD counselors lack college degrees.848 Diversity is both a
strength and a weakness. It is a strength when it promotes holistic and patient-centered care; but
it is a weakness when it prevents innovation diffusion due to differences in professional beliefs,
attitudes, and norms.
Counselors’ knowledge and beliefs about MAT are related to their formal education.
Roman and Johnson (2002) found that the percentage of counselors with a master’s degree or
higher within an institution significantly increases the likelihood of naltrexone.849 Counselors
who oppose the use of buprenorphine are unlikely to educate patients about buprenorphine’s
availability and benefits.850 Yet counselors have an important role to play in educating patients
about effective drug dependence treatment.851 Even though counselors cannot legally prescribe
buprenorphine, they can refer clients to psychiatrists or other physicians for MAT. Counselors
are already comfortable with referring patients for other medication, such as anti-depressants.
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For example, a survey by the American Psychological Association found that 98% of
psychologists have referred patients to physicians for some kind of mental health medication. 852
SUD counselors without graduate education or licensing are more likely to resist MAT,
often due to burnout and low wages, which create little incentive to learn new treatment
methods. Less-educated SUD counselors are also more likely to be in recovery themselves. As
far back as the early 20th century, SUD treatment programs recruited their own recovered
patients as staff. Some patients may also prefer to receive counseling from a “peer” with shared
experiences. But counselors in recovery themselves are likely to have been through a twelve-step
program and thus to prefer such methods, and studies show that counselors philosophically
aligned with twelve-step programs are particularly likely to resist MAT adoption. Counselors
without college degrees are also less likely to have been exposed to accurate information about
MAT.
Unfortunately, even counselors with graduate education have low knowledge of MAT.
Social workers and psychologists receive minimal (or no) MAT training in graduate school, even
if they specialize in addiction treatment. For example, one licensed clinical social worker whom I
interviewed specialized in addiction treatment while earning an M.S.W. degree, but had only
heard of methadone and naltrexone in one lecture. This counselor had never heard of
buprenorphine and acknowledged having a “very low” level of knowledge about methadone and
naltrexone.”
Social work and counseling education programs on the levels of undergraduate, graduate,
and continuing education should offer courses about MAT and widely encourage professional
attendance. MAT courses should be required for social workers and counselors intending to
specialize in addiction treatment. It seems absurd for a health professional to specialize in SUD
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treatment without knowledge of and training in the most effective treatment for opioid
dependence. Even after counselors are exposed to information about MAT, continued training
and review opportunities must be made available in person or online. Equally important,
managed care organizations, government agencies, professional health organizations, and other
employers should provide incentives for counselors to attend these courses.
In addition to educational background, other thoughts and unconscious feelings about
MAT may prevent individual mental health counselors from accepting MAT for opioid
dependence. One personal concern may be that MAT is diametrically opposed to counseling, so
that patients undergoing MAT will cease attending counseling. I have heard this mentioned a
few times in my interviews with psychologists and social workers. However, such a fear is
unfounded. Professional health organizations, the DHHS and the WHO all recommend that MAT
be combined with counseling, especially cognitive behavioral therapy. 853 Additionally, DATA
explicitly recognizes the concurrent roles of MAT and counseling in dependence treatment,
because DATA requires a buprenorphine-prescribing physician to be able to refer a patient to
ancillary mental health services.854 Likewise, methadone clinics are required to provide
counseling and rehabilitative services.855 When Vivitrol was approved by the FDA, its labelling
required counseling recommendations.856 Every physician I interviewed discussed the
importance of both MAT and counseling together.
The Theory of Reasoned Action and Planned Behavior (TRAPB)857 can be used to
understand counselors’ referrals (or lack of referrals) of patients for MAT. According to TRAPB,
one’s behavior is dependent upon intentions; and intentions are dependent upon attitudes, norms,
and perceived control.858 For adoption of an innovation, counselors’ attitudes toward the
innovation should be positive, counselors’ should feel that their peers support the use of the
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innovation, and counselors should feel that they have the ability to use the innovation.859
Multiple studies have verified that counselors’ personal attitudes and assumptions about
professional norms affect their intentions to inform patients about MAT. For example, in a study
by Rickman et al., attitudes and norms explained 40% to 71% of intentions of counselors to tell
patients about MAT.860 Another study by Kelly, Deane, and Lovett (2012) found that attitudes,
norms, and perceived behavioral control explained 41% the variance between psychologists’
intention to use evidence-based treatment.861 According to Roberto et al., some counselors may
not be referring clients to MAT because they do not feel they have the ability to refer clients to
MAT.862 Clearly, counselors’ personal attitudes, assumptions about norms, and perceived control
matter. In order for institutional leaders to affect counselors’ behavior (in this case, referral of
patients for MAT), they must address counselors’ attitudes, norms and perceived control of
MAT.
Institutional factors play an important role in whether or not a counselor is likely to
recommend MAT. Various studies have examined institutional factors conducive to counselor
support of MAT. Therapists who work in institutions with staff that already prescribe MAT or
referring clients to MAT are more likely themselves to refer clients for MAT.863 Some
institutions actively seek out evidence-based research and the latest studies more than others.
Knudsen et al. refer to this practice as “screening.” Screening is correlated with a higher
acceptance of MAT. Other institutions are less likely to screen for new treatment methods and
prefer to rely on the experience of their own staff. If an institution believes that experience is
more important that research findings, then the institution may be less likely to adopt MAT
(because most SUD counselors have experience in abstinence-only treatment methods but not
MAT referral). One study found that 40% of administrators (the majority of whom were
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counselors) believed that experience was a more important factor than research findings in
guiding clinical practice.864 Such a belief may hinder counselors from seeking information about
newly validated evidence-based psychological treatments and medications. The study also found
that only 51% agreed or strongly agreed that the clinical staff understood the importance of
evidence-based treatment.865
Though counselors cannot legally prescribe medication, their MAT education is very
important; increased education about MAT may make counselors more likely to refer patients to
physicians for medication. In fact, an American Psychology Association survey of counselors
found that 98% of clinical psychologists routinely refer patients to physicians for medications to
treat mental illness (e.g. depression or bipolar disorder). Counselors with knowledge of MAT can
also better coordinate SUD treatment with a physician. Ideally, counselors and physicians would
share information about patients’ treatment progress and reinforce each other’s methodologies.
MAT-trained counselors may also be less likely to consciously or unconsciously discourage
patients from participating in MAT. Finally, such counselors can influence policies within large
treatment organizations, such as supporting the hiring of a staff physician or offer MAT referrals.
III. Government Initiatives
A.

The “Blending Initiative”

According to Everett Rodgers’ Diffusion of Innovations Theory, information diffusion
flows through interpersonal networks, where it is strongly influenced by opinion leaders. End
users of the innovation actively adopt and change the innovation to suit their needs.866
Publications and conferences are the traditional methods for disseminating scientific innovations,
but these are typically designed to serve researchers’ needs rather than practitioners, treatment
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organizations or patients,867 and so they rarely allow for information to diffuse through networks
of patients and practitioners quickly.
In response to limited information diffusion in addiction treatment, the National Institute
on Drug Abuse (NIDA) created the “Blending Initiative” in 2001. The Blending Initiative
attempts to integrate various addiction stakeholders’ (e.g. patients, physicians, counselors,
administrators) knowledge, skill, and resources through a variety of approaches. A key
component of the Blending Initiative is the NIDA Clinical Trials Network, which leads clinical
trials on existing and novel SUD treatments at practitioners’ treatment sites (e.g. physician
offices), allowing them to gain first-hand experience with innovations. Clinicians who see
improved patient outcomes during a clinical trial are more likely to adopt an innovation and to
become “ambassadors” to other clinicians.868 Additionally, because the Clinical Trials Network
examines treatment effectiveness in “real world” settings, it provides important empirical data
for health practitioners and researchers.869
Through the Blending Initiative, NIDA organizes conferences designed for researchers,
treatment providers and policy makers. NIDA representatives also attend conferences with statelevel policymakers.870 NIDA has used these approaches to diffuse information about MAT, but
the number of MAT programs should increase (and be adequately funded), especially in states
hit hardest by the opioid crisis.
B.

Government as Opinion Leader

Opinion leaders play an important role in diffusion of evidence-based treatment. Riskaverse treatment centers wait to try a new treatment method until they have seen encouraging
results or until opinion leaders or risk takers persuade them to do so.871 According to Everett
Rogers, 15% of organizations are “early adopters of innovation”; 34% of organizations adopt the
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innovation shortly thereafter (referred to as “the early majority”), and 51% tend to be slow
adopters. About 16% of organizations are particularly slow at adopting innovations, either
because they are “reactionaries” (i.e. whose business model is premised around attracting
consumers who disagree with mainstream treatments) or have few resources for change.
Building on Rogers’ work, Berwick found that innovations in mental health treatment
have a “tipping point” after which they acquires their own momentum. The tipping point occurs
after approximately 20% of adoption occurs; at that time, communication typically exists
between early adopters typically communicate information about the innovation with subsequent
adopters. Community practitioners are more likely to look to peers for information about
innovations, and learn about them through professional organizations’ publications, newsletters
or continuing education course rather than peer-reviewed research.872 A 1993 study found that
only 35% of practicing counselors read peer-reviewed literature.873 However, widespread
availability of the Internet may have led to higher rates of reading peer reviewed literature since
1993. MAT advocates should encourage information diffusion through all available sources.
NIDA should serve as “the opinion leader” for treatment centers. As a well-respected
government agency, NIDA can offer the widespread education, necessary to combat the many
misconceptions about MAT. Organizations need a credible and authoritative information leader
because they are faced with resistant abstinence-only treatment ideologies and confusing and
sometimes contradictory literature. For example, misunderstandings about naltrexone may exist
because its oral form has low rates of effectiveness for opioid dependence, while its injectable
form (Vivitrol) has high rates of effectiveness. Some treatment program administrators may
know the former fact, but not the latter.874
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NIDA should also create more outreach programs for the general public, as studies
suggest that the public has little knowledge about MAT. A website is unlikely to be enough to
improve consumer demand for MAT; public service announcements on television and radio are
needed as well, particularly in light of the absence of MAT advertisements in the mass media
(television, radio, and magazines).875 Increased patient demand is likely to increase provider
supply, but patients cannot demand MAT from their treatment providers if they do not know that
it exists.
C. Using Government Contracts to Influence Abstinence-Only Treatment
Multiple studies have found that state-level policies influence MAT adoption at the
provider and client level.876 For example, state mental health agencies, known as Single State
Authorities (SSAs) provide grants to treatment centers and contract with treatment centers for
service provision to low-income individuals and criminal justice system organizations.877 SSAs
could impose conditions in grants or contracts that would incentivize MAT; for example, SSAs
could make funding contingent on center accepting patients undergoing MAT. Also, SSAs could
provide “bonus” funding to treatment centers that provide MAT to patients.
Fortunately, a study of 51 SSAs (representing each state and the District of Columbia)
found that SSA prioritization of expanding MAT has increased by an average of 8% between
2007 and 2010, and MAT implementation in public treatment facilities has increased by an
average of 19%.878 States with higher rates of buprenorphine and methadone implementation
also had higher rates of infrastructure implementation such as strategically training physicians in
addiction medication, funding addiction medication, and changes in organizational policies).879
Unfortunately, the study also found that negative attitudes of the public, practitioners, and
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clients/patients served as a barrier to SSA implementation of MAT, especially the idea that MAT
is “just another drug.”880
Most disconcertingly, interviews with SSA directors revealed that many public officials
had negative attitudes towards MAT.881 One SSA director said that his state is a “very strong 12step facilitator” with a “big pocket of resistance to medication-assisted treatment.”882
Policymakers who have little time or incentive to read scientific research publications are
especially likely to defer to local or regional opinion leaders, including those with abstinenceonly philosophies. These policymakers may distrust MAT if they perceive it as a challenge to
established practices and beliefs.883
Some SSAs and municipalities impose an abstinence-only philosophy by not funding
even a single methadone clinic, creating zoning barriers to methadone clinics, or prohibiting
MAT in the criminal justice system.884 Government regulators and legislators who failure to
provide funding for methadone or only provide limited funding for MAT despite funding
abstinence-only treatment centers are likely ignorant of the benefits of MAT.885 Regulators’ and
legislators’ limited knowledge about MAT is also unfortunate because government leaders
educated in evidence-based treatment methods could serve as MAT advocates for the state.
When government policies support MAT, then “core beliefs in the treatment field may shift and
attitudes may become more positive.” For example, legislatures can improve attitudes towards
MAT by funding medications, suggesting to the public that they are effective.886 However, the
federal, state and local agencies responsible for public funding of SUD treatment tend to be
fragmented, making communication and information diffusion between them difficult.
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D. Addressing Biases in AA and NA
NA and AA are self-sustaining, do not receive governmental funding, and strongly
oppose associations with political leaders and the government. Furthermore, NA and AA are
highly decentralized organizations, with most chapters groups making decisions for themselves,
such as whether to accept participants undergoing MAT). The organization’s national
headquarters provide only minimal policy guidance to chapters. The fact that NA and AA have
been self-funded and uninvolved with the government has served them well, helping their
members to maintain anonymity and helping their treatment philosophy survive numerous
government changes. As a result, however, the government has few options for directly
encouraging MAT’s acceptance within NA and AA.
The government could, however, encourage the development of alternative support
groups, such as by increasing grants for development and evaluation of support group
alternatives to NA and AA. These alternative groups could accept MAT as an effective treatment
and not use morality-laden language. The government could also fund online support groups,
which would especially help serve rural areas. Alternative support groups could continue to
maintain the characteristics of NA and AA that scientific studies find most efficacious:
fellowship among like-minded individuals and sponsorship. Neither component directly inhibits
MAT.
Alternative groups would compete with NA and AA, and could potentially cause those in
charge of AA and NA groups to change their attitudes towards MAT to retain members. Or
alternative groups would simply enable more individualized treatment options: abstinence-only
adherents would attend NA and AA, while individuals undergoing MAT could attend alternative
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support groups. Currently, however, some alternative support groups exist, but their availability
is negligible compared to that of NA and AA, especially in rural areas.
D. Educating Criminal Justice Administrators
The criminal justice community’s support is particularly important for MAT
implementation on the state and organizational levels.887 Most individuals enter SUD treatment
through the criminal justice system. Unfortunately, treatment centers with a higher proportion of
criminal justice clients are less likely to adopt MAT. My own study of drug courts—arguably the
most therapeutically-oriented criminal justice institution—found that they exhibited high
resistance to MAT, as did a 2013 study by Matusow et al. Only a small percentage of federal and
state prisons provide prisoners with access to MAT, even though twelve-step groups are widely
available in prison. The abstinence-only philosophy is deeply entrenched within the criminal
justice system.
Criminal justice administrators such as drug court judges and probation officers are not
health practitioners and receive little or no formal education in SUD treatment. They may receive
information about SUD treatment methods from colleagues, employers, and opinion leaders.
According to my study, for instance, drug court judges are most likely to learn about new
treatment methods through professional conferences, in which MAT sessions are unpopular.
Criminal justice administrators play a profound role in addiction treatment despite their
minimal or nonexistent training in SUD treatment methods. Drug court judges lead “treatment
teams” that make SUD treatment referral decisions and design court policies regarding MAT,
such as determining whether a participant can begin buprenorphine while in drug court.
Probation officers communicate regularly with counselors and physicians about clients receiving
SUD treatment. Prison administrators decide whether or not to permit MAT, an important
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predictor of whether prisoners will be treated with MAT upon release or whether they will
relapse.888 Finally, law enforcement administrators make discretionary decisions about whether
to arrest individuals with drug dependence or whether instead to divert them to treatment centers.
Because criminal justice administrators make so many decisions relevant to SUD, they
need greater access to education about SUD treatment. Increased education will require more
local and state funding for training programs and conference travel. Because the criminal justice
system relies on tax payer funding, however, the general public must first be convinced that such
education is a worthwhile investment. But many members of the general public still prefer
punishment without treatment, and view addicts as criminals rather than individuals coping with
a disease. Therefore, decreasing public stigma of addiction and increasing public awareness of
MAT’s efficacy is also necessary.
IV. Summary
Abstinence-only philosophy is so deeply engrained in American culture that many SUD
treatment centers, practitioners, and individuals suffering from opioid dependence assume it is
the only route to recovery. Innovation diffusion models and research on institutional practices
that influence innovation adoption may help policy makers change the status quo.
The time to change SUD practices is now. Skyrocketing rates of opioid dependence are
making media headlines, and many Americans have become sympathetic towards the treatment
of addiction rather than criminalization of drug users. In light of such social concern and the
enormous individual, governmental, and social costs of opioid dependence, policy makers must
prioritize formation of policies that encouraging MAT. Such policies should encourage treatment
centers to approach SUD like other chronic conditions, including provision of medication and
evidence-based behavioral methods. In other words, SUD treatment must be brought into the
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realm of mainstream medical treatment, rather than being relegated to a spiritual disease
requiring spiritual treatment peppered with counseling.
This dissertation suggested options for improving access to MAT, beginning integration
of SUD patients into mainstream medical treatment, which would help debunk the notion that
SUD is caused by immorality or lack of willpower889. If SUD is understood as a medical
condition similar to other medical conditions, then MAT is a natural fit into treatment (after all,
most disorders are treated with some medication). Similarly, individuals with SUD must be
viewed as “normal” individuals suffering from a particular disease, rather than being viewed as
being immoral or willfully contrarian to social norms. Like patients suffering from other chronic
diseases, SUD patients deserve empathy and access to best standards of care.
In order for SUD patients to access MAT, regulatory and statutory barriers must be
changed, namely existing isolation of OTPs, patient limits for buprenorphine, and inability for
physician assistants and NPs to prescribe buprenorphine. For more physicians to enter the field
of addiction treatment and to collaborate with existing SUD treatment centers (who rarely have
an MAT-prescribing physician), medical schools and residency programs must begin widespread
education about addiction medicine. Additionally, policy makers should enforce SUD and
mental health parity law and raise Medicaid reimbursement rates.
Not unlike the era of alcohol prohibition, individuals with SUD today are more likely to
be criminalized than to receive evidence-based medical treatment. Drug and veterans courts are
an important arm of the criminal justice system that has the potential to improve lives by
diverting divert individuals into treatment and away from incarceration. But courts should not
bar individuals from evidence-based treatment. Fortunately, the federal government has taken
notice, with recent DHHS preventing federal funding to courts that ban MAT. State funding rules
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should prohibit bans on MAT as well and incentivize physician involvement in court treatment
teams. National accreditation of drug courts could encourage best-practice standards.
Policy makers should develop public service announcements with messages about
prevention and evidence-based treatment methods. Otherwise, individuals with drug dependence
and their families will be left in a sea of abstinence-only treatment centers without the
knowledge that better treatment exists. If the public demands MAT, then SUD treatment centers
may be more likely to supply it. In the meantime, policy makers must realize that innovative
treatment methods rarely make their way into SUD treatment centers through publication of
research results alone. The Blending Initiative creates an opportunity for collaboration between
researchers, practitioners, and policy makers; similar initiatives should be designed and
implemented by states.
Abstinence-only treatment centers face institutional-level barriers to MAT adoption (such
as limited funding for training and few or no staff physicians) and practitioner-level barriers
(such as lack of education about MAT and attitudes favoring 12-step methodology over
medication). For leaders of abstinence-only treatment centers to change policies and internal
culture, they must provide clear goals, involve counselors in decision-making, provide ongoing
(rather than short-term) training, and encourage valuing research results rather than treatment
experience alone. Additionally, counseling and social work formal education programs should
include information about MAT.
MAT significantly decreases the risk of death for individuals with drug dependence and
saves society money that might otherwise be spent on emergency care and hospitalization.
Therefore, society’s failure to encourage MAT in opioid dependence treatment is unacceptable.
Failure to use MAT is based outdated notions of recovery that stigmatize those individuals who
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seek help despite the many barriers they already face. A national conversation about the meaning
of “recovery” must begin now. Recovery does not mean abstinence from all medication;
recovery means abstinence from drug abuse, often coupled with re-integration into the
community and improvement in overall health. As thousands of patients have known for
decades but are often too stigmatized to voice publically, MAT is literally life-saving.
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APPENDIX A: ACRONYMS
12-Step: Support groups and philosophy centered on the 12 step program of Alcoholics Anonymous
AA: Alcoholics Anonymous
AATOD: American Association for the Treatment of Opioid Dependence
ACA: Affordable Care Act
AMA: American Medical Association
ASAM: American Society of Addiction Medicine
CARA: Comprehensive Addiction Recovery Act of 2016
CSA: Controlled Substances Act
DATA: Drug Addiction & Treatment Act of 2000
DATA-Waiver: a waiver required by a physician in order to prescribe buprenorphine for addiction treatment
DEA: Drug Enforcement Agency
DHHS: U.S. Department of Health & Human Services
FDA: Food & Drug Administration
MAT: Medication-assisted treatment
MHAEA: Mental Health & Addiction Equity Act of 2008
MHD: Mental Health Disorder
NA: Narcotics Anonymous
NADCP: National Association of Drug Court Professionals
NIDA: National Institute on Drug Abuse
NPs: Nurse Practitioners
PAs: Physician Assistants
SAMHSA: U.S. Substance Abuse & Mental Health Services Administration
SUD: Substance Use Disorder
WHO: World Health Organization
VA: Department of Veterans Affairs
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APPENDIX B: INTERVIEW INSTRUMENT - POLICY MAKERS
Thank you for taking the time to speak with me today about this important issue.
May I have your permission to record this interview?
I will ask you several questions related to opiate addiction and medication assisted-treatment. You can choose not
to answer any question, and may stop the interview at any time.
1.

How prevalent do you think opiate addiction is within your geographic locale (city, county, state) or
jurisdiction?

2. Do you feel that opiate addiction is a serious problem within your geographic locale (city, county, state) in
light of factors such as opiate overdose rates, death rates, and emergency room admissions?
3. How do you feel opiate addiction has affected the criminal justice system in your geographic locale
(city/county/state)?
4. What treatment options for opiate addition exist within your geographic locale (city/county/state)?
5. How accessible are these treatment options (geographic access, expense, patient volume limits)
6. What opiate addiction prevention policies/programs exist within your geographic locale (city/county/state)?
7. What opiate overdose prevention policies/programs exist within your geographic locale (city/county/state)?
8. Now I would like to ask a few questions about the perceived effectiveness of these prevention programs.
a. Do you think that these prevention programs are effective? Why or why not?
b. Do you think that other members of your profession think that these prevention programs are
effective? Why or why not?
c. Do you think members of the public feel that these prevention programs are effective? Why or why
not?
d. Do you think patients struggling with opiate addiction feel that these prevention programs are
effective? Why or why not?
9. Are you familiar with other treatment options for opiate addiction such as support groups, 12-step groups,
mental health counseling and in-patient rehabilitation?
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a. Do you feel that these treatment options are safe? (go over each)
b. Do you feel that these treatment options are effective (go over each)
c. Do you feel that these treatment options are accessible (go over each)
10. The White House Office of National Drug Control Policy recently announced that it will be taking steps to
expand access to medication-assisted treatment for opiate addiction. Therefore, these next questions will
be asking you about your opinions, knowledge, and experiences related to medication-assisted treatment.
11. Are you familiar with medication-assisted therapy for opiate addiction?
12. What is your opinion on the safety of medication-assisted therapy for opiate addiction?
13. What is your opinion on the efficacy of medication-assisted therapy for opiate addiction?
14. Do you think it is easy for patients to access medication-assisted treatment for opiate addition within your
geographic locale (city/county/state)?
15. In your geographic location, do you know if medication-assisted therapy is covered by Medicaid? What
about other treatment options—are they covered?
16. Now I would like to ask a few questions about how others perceive the safety and effectiveness of
medication-assisted therapy.
a. Do you think that other members of your profession regard medication-assisted therapy as safe?
What about effective?
b. Do you think that members of the public regard medication-assisted therapy as safe? What about
effective?
c. Do you think that patients struggling with opiate addiction feel that medication-assisted therapy is
safe? What about effective?
17. Do you know of any existing or planned government programs that expand or limit the use of medicationassisted treatment within your geographic locale (city/county/state)?
18. Do you feel that medication-assisted treatment is stigmatized within your geographic locale
(city/county/state)? If so, why?
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19. Do you feel that you would face political difficulties expanding access to medication-assisted treatment
within your geographic locale (city/county/state)? Why or why not?
20. In your opinion, what types of incentives from the federal government could lead to expanded access to
medication-assisted treatment in your geographic locale (city/county/state)?
21. In your opinion, what types of incentives from the state government could lead to expanded access to
medication-assisted treatment in your geographic locale (city/county)?
22. Do you think any of your constituents groups or local institutions (such as professional associations,
churches or for-profit rehabilitations centers) would oppose expansion of medication-assisted treatment in
your geographic locale (city/county/state)?
a. If so, who? Why?
23. Do you believe that medication-assisted treatment should be used within the criminal justice system (e.g.
prisons, drug courts, or parole supervision) in your geographic locale (city/county/state)? Why or why not?
a. If so, what government policies could be used to incentivize its use?
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APPENDIX C: INTERVIEW INSTRUMENT – CRIMINAL JUSTICE ADMINISTRATORS
Thank you for taking the time to speak with me today about this important issue.
May I have your permission to record this interview?
I will ask you several questions related to opiate addiction and medication assisted-treatment. You can choose not
to answer any question, and may stop the interview at any time.
1. What type of criminal justice institution do you work for? (e.g. drug court, prison)
2. What is your role within the institution? (e.g. case manager, administrator)
3. How prevalent do you think opiate addiction is within your geographic locale (city, county, state) or
jurisdiction?
4. Do you feel that opiate addiction is a serious problem within your geographic locale (city, county, state) in
light of factors such as opiate overdose rates, death rates, and emergency room admissions?
5. How do you feel opiate addiction has affected the criminal justice system in your geographic locale
(city/county/state)?
6. What treatment options for opiate addition exist within your geographic locale (city/county/state)?
7. How accessible are these treatment options (geographic access, expense, patient volume limits)
8. What opiate addiction prevention policies/programs exist within your geographic locale (city/county/state)?
9. What opiate overdose prevention policies/programs exist within your geographic locale (city/county/state)?
10. Now I would like to ask a few questions about the perceived effectiveness of these prevention programs.
a. Do you think that these prevention programs are effective? Why or why not?
b. Do you think that other members of your profession think that these prevention programs are
effective? Why or why not?
c. Do you think members of the public feel that these prevention programs are effective? Why or why
not?
d. Do you think patients struggling with opiate addiction feel that these prevention programs are
effective? Why or why not?
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11. Are you familiar with other treatment options for opiate addiction such as support groups, 12-step groups,
mental health counseling and in-patient rehabilitation?
a. Do you feel that these treatment options are safe? (go over each)
b. Do you feel that these treatment options are effective (go over each)
c. Do you feel that these treatment options are accessible (go over each)
12. The White House Office of National Drug Control Policy recently announced that it will be taking steps to
expand access to medication-assisted treatment for opiate addiction. Therefore, these next questions will
be asking you about your opinions, knowledge, and experiences related to medication-assisted treatment.
13. Are you familiar with medication-assisted therapy for opiate addiction?
14. What is your opinion on the safety of medication-assisted therapy for opiate addiction?
15. What is your opinion on the efficacy of medication-assisted therapy for opiate addiction?
16. Do you think it is easy for patients to access medication-assisted treatment for opiate addition within your
geographic locale (city/county/state)?
17. In your geographic location, do you know if medication-assisted therapy is covered by Medicaid? What
about other treatment options—are they covered?
18. Now I would like to ask a few questions about how others perceive the safety and effectiveness of
medication-assisted therapy.
a. Do you think that other members of your profession regard medication-assisted therapy as safe?
What about effective?
b. Do you think that members of the public regard medication-assisted therapy as safe? What about
effective?
c. Do you think that patients struggling with opiate addiction feel that medication-assisted therapy is
safe? What about effective?
19. Do you know of any existing or planned government programs that expand or limit the use of medicationassisted treatment within your geographic locale (city/county/state)?
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20. Do you feel that medication-assisted treatment is stigmatized within your geographic locale
(city/county/state)? If so, why?
21. What type of criminal justice institution do you work within? (e.g. law enforcement, prison, drug court,
parole board)
22. Does your institution provide access to 12 step groups? Why or why not?
23. Does your institution require participants (e.g. drug court participants, inmates) suffering from opiate
dependence to participate in 12 step groups? If yes:
a. How often must participants attend meetings?
b. Where are meetings held?
c. Are participants provided transportation?
d. What happens if participants fail to attend required meetings?
e. Are non-spiritual alternative meetings available for non-religious individuals?
f. How effective is this type of treatment, in your opinion?
24. Does your institution require any participants (e.g. drug court participants, inmates) suffering from opiate
dependence to participate in psychological counseling? If not, why? If yes:
a. How often are participants required to attend appointments?
b. What happens if participants fail to attend required meetings?
c. Where are appointments held?
d. Does your institution cover the cost of such treatment?
e. How does your institution find mental health therapists with whom to collaborate?
f. How many mental health therapists collaborate with your institution?
g. What type of quality check does your institution perform with regards to the therapist who is
chosen?
h. How effective is this type of treatment, in your opinion?
25. Does your institution provide access to medication-assisted treatment? If yes:
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a. What types?
b. How is access provided? (e.g. referrals to physicians)
c. Does your institution cover the cost of such treatment?
d. With how many physicians does your institution collaborate in providing such treatment?
e. How does your institution find physicians with whom to collaborate?
f. Is such treatment supplemented with mental health counseling? With 12-step groups?
g. How effective, in your opinion, is this type of treatment?
h. How safe, in your opinion, is this type of treatment?
26. If your institution does not provide medication-assisted treatment, does your institution ban the use of
medication-assisted treatment (e.g. methadone, buprenorphine, and/or naltrexone)? Why?
27. If your institution bans the use of medication-assisted treatment, are individuals who enter the institution
required to stop using medication-assisted treatment that they were previously prescribed?
28. Does your institution place any individuals within residential treatment centers? If no, why? If yes:
a. How are such rehabilitation centers chosen? (e.g. choice may be based on cost, reputation, location)
b. In your opinion, how effective are the rehabilitation centers?
c. How long is a participant usually required to stay within the rehabilitation center?
d. What types of treatments are provided within the rehabilitation center? E.g. 12-step groups, art
therapy, medication-assisted treatment, psychological counseling?
e. What types of quality checks does your institution perform with regards to the rehabilitation center?
f. How much does residence within the center cost? Who pays? (e.g. criminal justice institution,
insurance of participant)
29. How does your institution match a particular participant to a particular treatment? Who makes the decision
regarding treatment type? Does the participant have a say in the decision?
30. Does your institution provide any mental health medications to participants? (e.g. antipsychotics,
depression medication)
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31. Does your institution view medication assisted treatments for opiate addiction (methadone, buprenorphine,
and naltrexone) differently than mental health medications for depression, schizophrenia, or other mental
health disorders?
32. Do you believe that medication-assisted treatment should be used within the criminal justice system (e.g.
prisons, drug courts, or parole supervision) in your geographic locale (city/county/state)? Why or why not?
33. If you do believe that medication-assisted treatment should be used within the criminal justice system in
your geographic locale (city/county/state), what government policies could be used to incentivize its use?
34. What kind of training does your institution provide to administrators regarding drug addiction treatment?
Does such training include information regarding medication-assisted treatment?
35. If your institution does not provide training regarding medication-assisted treatment, do you think your
institution would be interested in obtaining such training?
36. In your opinion, do you see drug addiction primarily as a moral issue, medical issue, criminal issue, or a
combination of these? Why?
37. Do you believe that your institution sees drug addiction primarily as a moral issue, medical issue, criminal
issue, or a combination of these?
38. Overall, do you believe that your institution provides an adequate level of treatment for opiate dependence?
If not, how could treatment provided be improved?
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APPENDIX D: INTERVIEW INSTRUMENT – HEALTH PRACTITIONERS
Thank you for taking the time to speak with me today about this important issue.
May I have your permission to record this interview?
I will ask you several questions related to opiate addiction and medication assisted-treatment. You can choose not
to answer any question, and may stop the interview at any time.
1. In what institutional setting do you practice?
a. What types of treatment options are available to you?
b. What types of treatment options are not available? Please explain.
2. How prevalent do you think opiate addiction is within your geographic locale (city, county, state) or
jurisdiction?
3. Do you feel that opiate addiction is a serious problem within your geographic locale (city, county, state) in
light of factors such as opiate overdose rates, death rates, and emergency room admissions?
4. Are you familiar with other treatment options for opiate addiction such as support groups, 12-step groups,
mental health counseling and in-patient rehabilitation?
a. Do you feel that these treatment options are safe? (go over each)
b. Do you feel that these treatment options are effective (go over each)
c. Do you feel that these treatment options are accessible?
d. Do you feel that members of the public are aware of these treatment options?
5. Do you receive promotional materials regarding these treatment options? From what sources?
6. To which of these treatment options are you most likely to refer patients struggling with opiate addiction?
Does it depend on different factors? If so, please explain.
7. Approximately how much do each of these treatment options cost (or how would you rank them from most
to least expensive)? Do you accept Medicaid for these expenses?
8. What is the role of 12-step groups in your community in treatment opiate addiction? Are they a
predominant treatment method? Do they influence community treatment policymaking?
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9. Do you collaborate with the criminal justice system to provide treatment for prisoners or paroled
individuals struggling with opiate addiction? (This includes drug courts).
a. If so, what treatment methods are commonly used in these settings?
10. The White House Office of National Drug Control Policy recently announced that it will be taking steps to
expand access to medication-assisted treatment for opiate addiction. Therefore, these next questions will
be asking you about your opinions, knowledge, and experiences related to medication-assisted treatment.
11. Are you familiar with medication-assisted therapy for opiate addiction?
12. (IF PROVIDE MAT) How expensive is medication-assisted treatment? In comparison with other treatment
options?
13. What is your opinion on the safety of medication-assisted treatment for opiate addiction?
14. What is your opinion on the efficacy of medication-assisted treatment for opiate addiction?
15. Do you think that medication-assisted treatment is stigmatized in your professional community? If so,
why?
16. Do you think that members of the public are familiar with medication-assisted treatment for opiate
addiction? Why or why not? What about other treatment methods?
17. Do you receive promotional materials from pharmaceutical companies or other entities regarding
medication-assisted treatment? From what sources?
18. Do you think it is easy for patients to access medication-assisted treatment for opiate addiction within your
geographic locale (city/county/state)?
19. Personal use of medication assisted therapy:
a. THERAPISTS: Do you refer patients struggling with opiate addiction to physicians for medicationassisted therapy?
b. PHYSICIANS: Do you prescribe medication-assisted treatment for patients struggling with opiate
addiction or refer them to other specialists for such treatment?
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20. What government policies would effectively incentivize or de-incentivize members of your profession to
provide access medication-assisted treatment?
21. Opinions on educational opportunities for medication-assisted treatment
a. THERAPISTS: How do you feel about the education and training available regarding medicationassisted therapy in graduate school and continuing education programs? Is it extensive enough? Is
it effective?
b. PHYSICIANS: How do you feel about the education and training available regarding medicationassisted therapy in medical school and continuing education programs? Is it extensive enough? Is
it effective?
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